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ABSTRACT 
 
In rheumatoid arthritis (RA), chronic inflammation and destruction of the joint is driven by 
local production of cytokines. My aims were to characterise cytokine mRNA expression in 
multiple synovial fluid cell populations in early and established RA and to study these, in 
addition to whole synovial tissue, in early synovitis patients in relation to disease outcome. 
 
I established a novel method to determine cytokine mRNA expression in synovial fluid CD4 
T cells, CD8 T cells, B cells, macrophages and neutrophils directly ex vivo. I made several 
novel observations, for example RA synovial fluid B cells expressed high levels of RANKL. 
As RANKL drives bone resorption, this suggests a potential role for B cells in bone erosion in 
RA. RANKL protein was expressed by B cells in synovial tissue, and mainly by memory B 
cells in synovial fluid. Furthermore, synovial RANKL levels were reduced after treatment 
with the B cell depleting therapy, rituximab.  
 
Overall, both in whole synovial tissue and in sorted cells, the cytokine mRNA expression 
profile was very similar in early synovitis patients who subsequently developed RA or had 
resolving synovitis, and in patients with early or established RA. In comparison, cytokines 
and chemokines were upregulated in early and established arthritis patients compared to 
uninflamed controls. The finding that cytokine mRNA expression is largely similar in early 
synovitis patients who develop RA or have resolving disease, and in the early and established 
phases of RA, suggests that cytokine expression is reflective of general synovial 
inflammation, rather than being specific for early synovitis outcome or stage of RA. 
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1 INTRODUCTION 
1.1 The role of the immune system 
1.1.1  Introduction 
The primary role of the immune system is to protect the body from danger. The immune 
system thus provides defence against pathogenic organisms and tissue damage, and eliminates 
altered-self cells. The first line of defence against a potentially harmful agent is provided by 
the physical and chemical barriers of the body. However, if these are breached, the body 
responds using specialised cells and effector molecules of the immune system in an attempt to 
eliminate pathogens, limit tissue damage, and stimulate tissue repair. A sign of host response 
to infection or injury is acute inflammation, which is characterised by the classical signs of 
heat, pain, redness and swelling. 
 
The immune system can be divided into two arms: the innate and adaptive. Innate immunity 
provides an immediate line of defence against pathogens and is usually sufficient to eliminate 
potential pathogens encountered in peripheral tissue. While the innate immune system offers 
an immediate non-specific or broadly-specific response in order to deal with a wide range of 
pathogens, the adaptive immune response is highly specific for a given pathogen and provides 
immunological memory which allows an individual to mount a rapid and stronger response 
upon re-exposure. The key players of the innate immune system are macrophages, 
neutrophils, natural killer (NK) cells, mast cells, eosinophils and basophils, while 
lymphocytes are central to the adaptive immune system, and antigen presenting cells such as 
dendritic cells link innate and adaptive immunity. 
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1.1.2 The inflammatory response 
Acute inflammation is a physiological response triggered by infection or tissue damage. The 
innate immune system can respond to various classes of microorganisms by recognising 
highly conserved molecular structures known as Pathogen Associated Molecular Patterns 
(PAMPs). The recognition of PAMPs is facilitated by Pattern Recognition Receptors (PRRs) 
such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs). PRRs are expressed on 
antigen presenting cells, and interaction of a PRR with its ligand results in the internalisation 
of the pathogen expressing the ligand through phagocytosis. Internalisation of the pathogen 
can be enhanced by the surface of the pathogen being coated by opsonins, which may be 
antibodies or proteins involved in the complement cascade. Activation of the complement 
cascade results in the recruitment of phagocytes to sites of infection, and can also kill 
pathogens directly. The immune system can also detect danger signals provided by 
endogenous molecules which are associated with tissue damage or stress, such as heat shock 
proteins, high mobility group box 1 and hyaluronic acid (Gallucci and Matzinger 2001). 
 
An acute inflammatory response is characterised by the infiltration of leukocytes in which 
neutrophils dominate. Neutrophils are the most abundant leukocyte in the body and play a key 
role in the front-line defence against invading pathogens by utilising several mechanisms: (i) 
phagocytosis and destruction of microorganisms; (ii) release of cytoplasmic granules 
containing soluble anti-microbial products such as defensins, myeloperoxidase, elastase, 
proteinase-3 and cathepsin G and properdin; and (iii) release of neutrophil extracellular traps 
(NETs) comprising de-condensed chromatin and antimicrobial proteins which prevent 
spreading of microorganisms.  
 
3 
 
The initial influx of neutrophils is followed by monocytes which migrate from the 
bloodstream into the tissue and rapidly differentiate into tissue macrophages. Macrophages 
are polarised functionally in response to cytokines, being classified as M1 (classically 
activated) if induced by IFN-γ and TNF-α, or M2 (alternatively activated) if induced by IL-4 
or IL-10 (Gordon 2003). Macrophages contribute to phagocytosis of the pathogens, and also 
produce cytokines which activate endothelial cells of local blood vessels, allowing circulating 
leukocytes to migrate into the inflamed tissue. In addition, macrophages produce lipid 
mediators of inflammation such as prostaglandins, leukotrienes and platelet-activating factor. 
 
Normally the acute inflammatory response is followed by resolution of inflammation and 
tissue repair. Elimination or neutralisation of the pathogen halts further production of pro-
inflammatory mediators such as eicosanoids, cytokines, and cell adhesion molecules, and 
leads to their catabolism. Neutrophils and eosinophils that have been recruited to the site of 
injury or infection are cleared by local death followed by phagocytosis by recruited 
macrophages. Macrophages then exit the site of inflammation via the lymphatics, while a 
small population may die locally by apoptosis. 
 
Although traditionally viewed as a passive process, resolution of inflammation is an active 
process that requires activation of endogenous programs to maintain tissue homeostasis. 
These include negative feedback pathways which inhibit TLR and NLR signalling, and anti-
inflammatory cytokine production by regulatory T cells. Stromal cells such as fibroblasts, 
endothelial cells and macrophages also contribute to resolution by reducing leukocyte 
infiltration by withdrawing survival signals, normalising chemokine gradients, and inducing 
resolution programs that result in apoptosis or exit from the inflamed tissue. Molecular 
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mechanisms involved in the resolution of inflammation include the lipid mediators, lipoxins, 
resolvins and protectins (Serhan et al. 2008). Resolution of the acute inflammatory response 
by such mechanisms normally allows the inflamed tissue to return to homeostasis. However, 
if these naturally occurring resolution programs become dysregulated in some way, it is 
possible that inflammation may become chronic. In certain conditions such as rheumatoid 
arthritis, psoriasis, multiple sclerosis, atherosclerosis and inflammatory bowel diseases, this 
chronic state of inflammation may last the lifetime of the individual. 
 
1.1.3 Adaptive immunity 
The functions of the adaptive immune system are primarily mediated by lymphocytes. Both T 
and B cell subsets have diverse repertoires of receptors on their surfaces that enable them to 
recognise specific motifs of any pathogen they may encounter. The diversity of lymphocyte 
receptors arises by somatic recombination of V(D)J segments during development (Tonegawa 
1983). Lymphocytes bearing receptors with high affinity for self molecules are deleted, while 
those with receptors with high affinity for pathogen-associated molecules survive. Naïve 
lymphocytes which have not yet engaged their cognate antigen move continuously between 
the lymph nodes and the blood via the lymphatics to search for antigens. 
 
Naïve T cells continuously search for antigens being presented on the surface of antigen 
presenting cells such as dendritic cells. CD8 T cells recognise endogenous antigen presented 
by class I major histocompatibility complex (MHC) antigens, and thus deal with the removal 
of virally infected or altered self cells. CD4 T cells recognise exogenous antigens that have 
been processed by professional antigen presenting cells such as monocytes, dendritic cells, 
macrophages and B cells, and are presented by MHC class II molecules, and thus deal with 
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bacterial, fungal and parasitic infection. Cross-presentation of antigens may also occur in 
which MHC class I molecules present antigen of exogenous origin, and MHC class II 
molecules present peptides derived from cytoplasmic or nuclear antigens. Phagocytosed or 
endocytosed antigens may leave the vacuole in which they have been engulfed, gain access to 
the cytosol and be presented by MHC class I molecules. Peptide exchange with MHC class I 
molecules recycling from the cell membrane may also result in peptides derived from 
exogenous antigens being presented by MHC class I molecules. Intracellular antigens may be 
presented by MHC class II molecules if cytosolic peptides are engulfed by autophagosomes 
and thereby gain entry into the class II processing and presentation pathway.  
 
Recognition of presented antigen by the T cell receptor (TCR), and a simultaneous co-
stimulatory signal, results in the proliferation and activation of T cells. Induction of IL-2 
stimulates clonal expansion of the engaged T cell. Naïve T cells subsequently differentiate 
into effector T cells with specific functions according to the activating antigen and the local 
cytokine milieu, such as Th1, Th2, Th17, Th9, Th22, T follicular helper (Tfh), or inducible 
regulatory T cell (Treg) subsets. More recently, Th9 and Th22 T helper subsets have also been 
described (Dardalhon et al. 2008; Eyerich et al. 2009; Veldhoen et al. 2008). Transcription 
factors direct the development of T helper cell subsets with distinct cytokine-secreting 
potentials. Th1 cells, which are important in defence against intracellular pathogens, express 
the transcription factor T-bet, a member of the T-box family of transcription factors. Th2 cells 
provide defence against helminths, and express the master regulator for Th2 differentiation, 
GATA-3. Th17 cells contribute to host defence against extracellular bacteria and fungi; the 
retinoic acid-related orphan receptors, ROR-α and ROR-γt, are the key transcription factors in 
Th17 differentiation. Tfh cells help B cells in making antibody responses, and express the 
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master regulator Bcl-6. Inducible Tregs, which exert immunosuppressive functions, express 
the master regulator Foxp3. Th9 cells mediate defence against extracellular parasites; recent 
studies have suggested PU.1, IRF-4 and STAT-6 as transcription factors required for Th9 
differentiation (Chang et al, 2010; Goswami et a. 2011.; Staudt et al. 2010). Th22 cells are 
also important in defence against extracellular parasites; the aryl hydrocarbon receptor (AHR) 
is the master regular of Th22 cell differentiation. Following activation and proliferation, T 
cells migrate to sites of inflammation. After the clearance of the pathogen, some antigen-
specific T cells remain in the body as memory T cells which facilitate a more rapid response 
upon re-exposure than the original response. 
7 
 
 
 
 
 
 
 
 
 
Figure 1.1 CD4 T helper cell subsets. Naïve CD4 T cells differentiate into different subsets 
of effector CD4 T cells which are specialised to deal with different types of pathogens. 
Effector T cells produce certain cytokines that produce distinct and appropriate effects on the 
target cell. Effector T cell subsets described at present include T helper 1 (Th1), T helper 2 
(Th2), T helper 17 (Th17), T helper 9 (Th9), T helper 22 (Th22), T follicular helper (Tfh) and 
regulatory T cells (Treg). Th1 cells are important in defence against intracellular bacteria, 
T-bet 
GATA-3 
Foxp3 
RORγt 
AHR 
? 
Bcl-6 
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viruses and cancer, Th2 cells against helmiths and extracellular pathogens, Th17 cells against 
extracellular bacteria and fungi, and Th22 and Th9 cells against extracellular parasites. Tfh 
promote germinal centre responses, and Tregs maintain tolerance to commensals, innocuous 
antigens and self-antigens. The specific transcription factors required for the differentiation of 
distinct T helper cell subsets are shown in italics. 
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Naïve B cells become activated following an encounter with their cognate antigen, whereupon 
they may adopt one of two fates: (i) differentiation to short-lived plasma cells which produce 
antibody, or (ii) formation of germinal centres (Murphy et al, 2007). Within the germinal 
centre, B cell receptors undergo diversification by the process of somatic hypermutation. 
Lymphocytes bearing receptors with high affinity for antigen are selected for survival and 
further proliferation, whereas cells with receptors which have low affinity die. Selected B 
cells eventually differentiate into memory B cells or antibody-producing plasma cells. In 
addition to their important role in antibody production, B cells also act as antigen presenting 
cells. Antigen presentation by B cells and their recognition by T cells involves activation of 
co-stimulatory pathways and cytokine production, which triggers B cell proliferation and 
antibody secretion. During this process, cytokines are released by activated T helper cells 
which induce further T cell proliferation. In addition, B cells also produce polarising 
cytokines which influence the differentiation of T cells.  
 
1.1.4 Autoimmunity 
While the immune system is clearly essential for protecting the host from disease, it is also 
recognised that excessive activation of the immune system can be detrimental, and may lead 
to autoimmune diseases in which the immune system attacks an individual’s own cells and 
tissues. The gene rearrangement that occurs during lymphocyte development in the central 
lymphoid organs is a random process, and inevitably leads to the formation of some 
lymphocytes with affinity for self antigens. Under normal circumstances, autoimmune attack 
is avoided by several mechanisms which maintain a state of self-tolerance including (i) 
removal of autoreactive lymphocytes during development in the thymus and bone marrow 
(central tolerance); (ii) tolerization of lymphocytes to antigens that are expressed at a high and 
constant concentration and thus correlate to self antigens; and (iii) peripheral tolerance 
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induced by encounter with self antigen in the absence of a co-stimulatory signal, which leads 
to a negative inactivating signal. However, all of these mechanisms are error-prone as none 
distinguishes self from non-self at the molecular level. A breakdown or failure of self-
tolerance mechanisms can thus lead to development of an autoimmune disease and associated 
tissue damage. 
 
1.2 Rheumatoid arthritis 
1.2.1 Introduction 
Rheumatoid arthritis (RA) is a chronic systemic disease of unknown aetiology characterised 
by inflammation and destruction of diarthroidal joints. Patients typically develop a 
symmetrical synovitis involving the small joints of the hands and feet, which over time can 
lead to joint destruction and functional disability. RA is associated with substantial 
comorbidity due to the involvement of multiple organs and systems, and is estimated to 
reduce life expectancy by 3 to 18 years. RA affects approximately 1% of the population in the 
UK and the overall occurrence is approximately two times greater in women than men. The 
peak age of onset is between 40 and 50 years. 
 
1.2.2 Classification 
For the purpose of standardising epidemiologic studies and clinical trials, classification 
criteria for RA were developed by the American College of Rheumatology (ACR) in 1958 
and were revised in 1987 (Arnett et al. 1988) (Table 1.1). In the list version of the 1987 ACR 
criteria, RA is classified based on the presence of four of seven criteria; these include five 
clinical variables and two investigation-based variables: radiographic evidence of erosions 
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and the presence of rheumatoid factor, an antibody directed against IgG. These criteria were 
developed based on data from patients with established disease, and it is widely recognised 
that some of these features are absent during early stages of the disease. In 2010, the ACR and 
the European League Against Rheumatism (EULAR) developed new classification criteria to 
facilitate identification of patients with RA with newly presenting inflammatory arthritis 
(Aletaha et al. 2010) (Table 1.2). In these criteria, classification as “definite RA” is based on 
the presence of synovitis, the number and site of involved joints, the presence of rheumatoid 
factor and anti-citrullinated protein antibodies (ACPA), elevated acute-phase response 
reactants, and symptom duration.  
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Criterion Description 
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour before 
maximal improvement 
2. Arthritis of 3 or more 
joint areas 
At least 3 joint areas simultaneously have had soft tissue swelling or 
fluid (not bony overgrowth alone) observed by a physician. The 14 
possible areas are right or left PIP, MCP, wrist, elbow, knee, ankle, and 
MTP joints 
3. Arthritis of hand 
joints 
At least 1 area swollen (as defined above) in a wrist, MCP, or PIP joint 
4. Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 2) on 
both sides of the body (bilateral involvement of PIPs, MCPs, or MTPs is 
acceptable without absolute symmetry)  
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or extensor surfaces, or 
in juxtaarticular regions, observed by a physician 
6. Serum rheumatoid 
factor 
Demonstration of abnormal amounts of serum rheumatoid factor by any 
method for which the result has been positive in <5% of normal control 
subjects 
7. Radiographic 
changes 
Radiographic changes typical of rheumatoid arthritis on posteroanterior 
hand and wrist radiographs, which must include erosions or unequivocal 
bony decalcification localized in or most marked adjacent to the 
involved joints (osteoarthritis changes alone do not qualify)  
* For classification purposes, a patient shall be said to have rheumatoid arthritis if he/she has 
satisfied at least 4 or these 7 criteria. Criteria 1 through 4 must have been present for at least 6 
weeks. Patients with 2 clinical diagnoses are not excluded.  
Table 1.1 1987 American College of Rheumatology classification criteria.  
 
 
Criterion Score 
A. Joint involvement 
1 large joint 
2-10 large joints 
1-3 small joints (with or without involvement of large joints) 
4-10 small joints (with or without involvement of large joints) 
>10 joints (at least 1 small joint 
 
0 
1 
2 
3 
5 
B. Serology (at least 1 test result is needed for classification) 
Negative RF and negative ACPA 
Low-positive RF or low-positive ACPA 
High-positive RF or high-positive ACPA 
 
0 
2 
3 
C. Acute-phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR 
 
0 
1 
D. Duration of symptoms 
<6 weeks 
≥6 weeks 
 
0 
1 
Table 1.2 2010 ACR/EULAR classification criteria. Classification criteria for RA 
(score-based algorithm: add score of categories A–D; a score of ≥6/10 is needed for 
classification of a patient as having definite RA 
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1.2.3 Pathophysiology of RA 
RA is regarded as a complex disease involving both genetic and environmental factors. 
Despite significant advances in our understanding of the pathogenesis of RA in recent years, 
so far the cause remains unknown. Current models imply an underlying immunologic 
abnormality, which may involve an autoimmune trigger that drives the chronic and 
destructive inflammatory response in the synovium. 
 
The prevalence of RA in the general population is approximately 1%, but among siblings the 
prevalence increases to 2-4% (Seldin et al. 1999). In cross-sectional twin studies, concordance 
rates for RA were found to be between 12.3% and 15.4% for monozygotic twins, and 3.5% 
for dizygotic twins (MacGregor et al. 2000). From these studies it is estimated that the genetic 
contribution to RA is 50% to 60%. The strongest genetic association is the HLA-DRB1 locus 
which encodes the β-chain of MHC class II molecules. HLA-DRB1 alleles associated with 
increased risk of RA contain a common amino acid sequence (QKRAA, QRRAA, or 
RRRAA), known as the “shared epitope”, at positions 70–74 in the third hypervariable region 
of the DRβ1 chain, within the peptide-binding groove (Gregersen et al. 1987). The shared 
epitope hypothesis suggests that presentation of auto-antigenic peptides to T cells drives the 
disease process in RA. Another important genetic risk factor is PTPN22 which encodes the 
protein tyrosine phosphatase, Lyp. A single nucleotide polymorphism in this gene, which 
results in deregulated signalling downstream of the TCR, is associated with increased risk of a 
number of autoimmune diseases including RA (Begovich et al. 2004; Burkhardt et al. 2006; 
Hinks et al. 2005). Genome-wide association studies have identified several single nucleotide 
polymorphisms associated with RA, many of which are linked to T or B cell activation, or 
differentiation and cytokine signalling. 
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Anti-citrullinated protein/peptide antibodies (ACPA) have become associated with RA in 
recent years. ACPA have been found to be pathogenic in experimental murine models of 
arthritis (Lundberg et al, 2005; Kuhn et al., 2006), but it is not clear whether they have a 
directly pathogenic role in human RA. ACPA are present in approximately 70% of RA 
patients and are highly specific for RA (Nishimura et al. 2007; Schellekens et al. 2000). 
ACPA are most commonly measured as anti-cyclic citrullinated peptide (anti-CCP) auto-
antibodies. They can be detected many years before clinical onset of disease and are 
predictive for the development of RA (Avouac et al. 2006; Bos et al. 2010; van der Helm-van 
Mil et al. 2007). ACPA recognise proteins or peptides in which the amino acid arginine is 
deiminated to citrulline through a post-translational modification process (Figure 1.1). 
Citrullination reduces the net charge of the protein by the loss of a positive charge per 
citrulline residue. As arginine residues often play a central role in the structural integrity of a 
protein, conversion into citrulline may result in an altered three-dimensional structure and 
altered protein function. Citrullination is mediated by peptidyl arginine deiminase (PAD) 
enzymes. PAD enzymes are normally present within cells and can be activated by high 
calcium levels when cells undergo apoptosis, for example during inflammation (Gyorgy et al. 
2006). ACPA can recognise several citrullinated proteins such as vimentin, collagen, enolase 
and fibrinogen. ACPA have been shown to be enriched in RA synovial fluid (Snir et al. 2010) 
and citrullinated proteins have been detected in the RA synovium (De Rycke et al. 2005). In 
addition, antibodies against the citrullinating enzyme, peptidyl arginine deiminase type 4 
(PAD4), have been found in the serum prior to clinical onset of RA (Kolfenbach et al. 2010). 
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Figure 1.2 Conversion of peptidylarginine into peptidylcitrulline. This reaction is 
catalyzed by the family of peptidylarginine deiminase (PAD) enzymes. The positively 
charged arginine guanidino group is converted into the neutral citrulline ureido group in the 
presence of water, yielding ammonia and a hydrogen ion as by-products. The loss of a 
positive charge per citrulline residue may alter protein structure as shown schematically. 
Image taken from Wegner et al, Immunological Reviews 2010. 
 
Increasing evidence indicates that ACPA-positive and ACPA–negative RA represent distinct 
disease entities. This notion is mainly based on differences in genetic and environmental risk 
factors between these two groups. The genetic associations of HLA-DRB1 and PTPN22 are 
confined to the ACPA-positive subset of disease, whereas other genes such as HLA-
DRB1*03 are associated only with ACPA-negative disease (Padyukov et al. 2011; van der 
Helm-van Mil et al. 2006; Verpoort et al. 2005). Histological differences of the synovium are 
also apparent, with ACPA-positive RA being characterised by denser lymphocyte infiltrate 
and ACPA-negative RA showing more extensive fibrosis (van Oosterhout et al. 2008). 
Although ACPA-positive and ACPA-negative patients present with similar clinical features, 
they have different disease courses: ACPA-positive patients have a more severe disease 
course characterised by more radiological joint damage and worse disease activity scores 
(Forslind et al. 2004; Kastbom et al. 2004; Kroot et al. 2000; Ronnelid et al. 2005). 
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The best established environmental risk factor for RA is smoking. A genetic-environmental 
interaction between ACPA, shared-epitope alleles and smoking has been well described 
(Lundstrom et al. 2009). Recently, it has been shown that the combination of shared epitope 
alleles and smoking may also be present in autoantibody-negative disease (Bang et al. 2010; 
Mikuls et al. 2010). Another emerging environmental trigger for RA is the oral pathogen, P. 
gingivalis which is associated with periodontitis. P. gingivalis has the unique ability to 
citrullinate proteins using endogeneously produced PAD enzymes. Antibodies to P. gingivalis 
have been found to associate with ACPA in patients with RA and their relatives, suggesting a 
possible involvement in pathogenesis (Hitchon et al. 2010). Diet has also been associated 
with onset and persistence of RA. Dietary factors that may be relevant include vitamin C, β-
cryptoxanthin, zeaxanthin and red meat (Pattison et al. 2005). 
 
1.2.4 Phases of RA 
The processes involved in the initiation and progression of RA remain poorly understood. The 
presence of rheumatoid factor and ACPA in the serum up to 14 years before the disease 
becomes clinically apparent indicates that immunological abnormalities precede the 
development of RA. Recently it has been reported that plasma levels of several cytokines and 
chemokines are increased prior to disease onset (Kokkonen et al. 2010). In addition, increased 
levels of C-reactive protein (CRP) can be detected in the peripheral blood together with 
rheumatoid factor and/or ACPA before clinical onset (Kolfenbach et al. 2009; Nielen et al. 
2004). The observation that synovial inflammation is present in clinically unaffected knee 
joints from patients with established RA suggests that inflammatory changes may also occur 
in the pre-clinical phase (Kraan et al. 1998). In addition, several animal models of RA have 
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demonstrated inflammatory changes in the synovium in the latency phase of arthritis (Kraan 
et al. 1998). 
 
It is not known if the initial immune response leading to the production of autoantibodies 
takes place in the synovium or at other sites in the body. One candidate site is the lung where 
cigarette smoke could trigger citrullination of specific peptides, which in combination with a 
loss of tolerance to these peptides could result in ACPA production. It has been proposed that 
a “second hit” is needed to induce citrullination of proteins in the synovium, such as minor 
trauma or a viral infection. Indeed, it has been reported that citrullination can occur in the 
synovium in any form of arthritis (Vossenaar et al. 2004). On the background of pre-existing 
immunity against citrullinated antigens, this could lead to epitope spreading and progression 
of synovitis, in accordance with the observation that ACPA immunoglobulin isotypes and 
epitopes recognised by ACPA evolve over time (Ioan-Facsinay et al. 2008; Verpoort et al. 
2006). 
 
Figure 1.3 Timeline depicting the different stages of disease of autoantibody-positive 
rheumatoid arthritis. Autoantibody formation may precede the development of clinical 
signs and symptoms of RA by several years. Image taken from van de Sande M G H et al., 
Annnals of Rheumatic Disease 2011. 
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Clinically, RA appears to develop in several stages beginning with swelling and pain in a 
limited number of joints, followed by a subsequent increase in the number of affected joints 
and severity of symptoms, and finally resulting in destruction and deformity. In 1985 
Konttinen and colleagues defined three phases of synovitis based on the predominant cell 
types found at each stage of disease. Phases described were an acute phase (< 3 months’ 
duration in RA patients) in which monocytes and macrophages predominate with little T cell 
infiltration; a subacute phase (recent synovitis in patients with RA of longer than 3 years) in 
which primarily infiltrating T cells were found, and also B cells and plasma cells in addition 
to mononuclear cells seen in the acute phase; and a chronic phase (clinical synovitis and 
disease for longer than 3 years) which demonstrated a shift towards a predominance of T cell 
infiltration and dense plasma cell infiltrates. Other studies have reported that late stages of 
chronic RA are dominated by macrophages and synovial fibroblasts rather than T cells 
(Bromley and Woolley 1984; Kobayashi and Ziff 1975; Matsuno et al. 2002; Muirden 1982; 
Youssef et al. 1998), and NK cell numbers appears to decrease with disease duration (Tak et 
al. 1994). 
 
Other studies which have examined synovial tissue from patients with early and long-standing 
RA reported no significant differences between the two groups in terms of macrophage 
infiltration, synovial thickening, or expression of cytokines, chemokines, granzymes, 
adhesion molecules and matrix metalloproteinases (MMPs) (Kraan et al. 1999; Schumacher 
and Kitridou 1972; Smeets et al. 1998a; Tak 2001). These findings suggest that different 
phases of RA cannot easily be distinguished on the basis of clinical disease duration, although 
there was a wide range in the definitions used for early disease (4 weeks to 12 months after 
symptom onset) and long-standing disease (>1 year to > 5 years in duration). 
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More recent evidence suggests that the pathology of very early RA differs from that of 
established RA. Early RA patients were shown to have a distinct and transient cytokine 
profile in first 12 weeks after symptom onset that was not seen in other early arthritides and 
not present in established RA. Synovial fluid from patients with early RA contained higher 
levels of IL-2, IL-4, IL-15 and GM-CSF compared to patients with established RA (Raza et 
al. 2005). Molecular profiling of synovial biopsies from patients with early and long-standing 
RA has also revealed distinct molecular signatures between the two groups, indicating that 
different biological processes operate at different stages of the disease (Lequerre et al. 2009). 
 
In support of the concept of distinct pathological mechanisms operating in early and 
established RA is the observation that treatment initiated in the early stages of RA reduces 
disease activity to a greater extent than when started later in the disease course (Mottonen et 
al. 2002; Nell et al. 2005). Several trials have shown that institution of disease-modifying 
anti-rheumatic drug (DMARD) therapy is more beneficial in improving the outcome of RA 
when started early in the disease (Lard et al. 2001; Nell et al. 2005; van der Heide et al. 
1996). Evidence suggests that there may a crucial “window of opportunity” within which 
disease course can be altered, and this may be as short as 12 weeks. Understanding this early 
phase of disease remains an important goal in order to facilitate early diagnosis of RA and to 
allow treatment to be targeted to the appropriate patient group. 
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1.3 Cells of the RA synovium  
The synovium is a delicate membrane that encapsulates the joints, offering structural support 
and lubricating the surfaces, and providing nutrients to the cartilage. The synovium is 
composed of an intimal lining layer and a sublining layer. The intimal lining layer, which 
produces synovial fluid, is normally a single-cell layer composed of synovial fibroblasts and 
macrophages. The sublining layer is normally comprised of relatively acellular connective 
tissue and blood vessels. In RA, the synovium transforms into a hyperplastic, invasive tissue. 
The intimal lining layer expands to a depth of up to 10-20 cells due to an increase in synovial 
fibroblasts and macrophages, and the sublining layer becomes infiltrated by multiple cell 
types including T cells, B cells, plasma cells and macrophages, as well as a smaller number of 
mast cells, NK cells, neutrophils and dendritic cells. The organisation of the cellular infiltrate 
varies between patients, ranging from a diffuse infiltrate through to focal lymphoid aggregates 
and development of germinal centre-like structures. In addition, the sub-lining layer becomes 
oedematous and highly vascular. At the cartilage-bone interface, the inflamed synovium 
forms an aggressive pannus lesion formed of macrophages, osteoclasts and fibroblasts, which 
invades the adjacent cartilage and bone and promotes articular destruction by osteoclasts, 
chondrocytes and synovial fibroblasts. Neutrophils are also found at the cartilage-pannus 
junction, suggesting they may play a role in the marginal erosion of the joints (Bromley and 
Woolley 1984). 
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Figure 1.4 Changes in the synovium in RA. In the healthy joint there is a thin synovial 
membrane lining the joint. In RA the synovial lining becomes hyperplastic due to the 
proliferation of synovial fibroblasts, and the synovial membrane becomes infiltrated by 
inflammatory cells including macrophages, T cells, B cells, mast cells, NK cells and dendritic 
cells. Neutrophils accumulate in the synovial fluid. At the cartilage-bone interface, the 
inflamed synovium forms an aggressive pannus lesion which invades the articular cartilage 
and underlying bone.  
 
 
Figure 1.5 Patterns of leukocyte infiltration in the RA synovium. Cellular infiltration of 
the synovial tissue varies between patients, ranging from little infiltration (left), diffuse 
cellular infiltration (centre) to the formation focal lymphocytic aggregates (right). Images 
courtesy of D. Scheel-Toellner. 
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1.3.1 Macrophages 
Macrophages are found in prominent numbers in the rheumatoid synovium and at the 
cartilage-pannus junction. They display an activated phenotype and are important contributors 
to inflammation and joint destruction in RA due to their production of pro-inflammatory 
mediators and tissue-degrading enzymes. The central role of macrophages in RA is supported 
by the fact that conventional therapies, including methotrexate and cytokine inhibitors, act to 
reduce levels of cytokines which are produced predominantly by macrophages (Lavagno et al. 
2004). Furthermore, the number of synovial macrophage has been found to correlate with 
joint erosion in RA (Mulherin et al. 1996). Macrophage-like (type A) synoviocytes present in 
the intimal lining layer are thought to be derived from the CD14+ branch of the monocyte 
lineage, but they share features with dendritic cells, distinguishing them from typical 
monocytes. These cells likely have a phagocytic role in clearing debris from the synovial 
fluid, and animal models of arthritis suggest they have a role in propagating chronic synovitis 
(van Lent et al. 1998). 
 
Macrophages are an important source of many pro-inflammatory cytokines which are 
considered to have a central role in RA, including TNF-α, IL-1 α and IL-6 (Chu et al. 1992; 
Chu et al. 1991). Other pro-inflammatory cytokines produced by synovial macrophages in RA 
include IL-15, IL-18 and IL-27 (McInnes et al. 1996). Synovial macrophages produce several 
chemokines which act as chemoattractants for leukocytes into the inflamed synovium and 
promote angiogenesis. Furthermore, synovial macrophages produce growth factors that 
promote cell survival in the rheumatoid synovium including GM-CSF, G-CSF, M-CSF, 
bFGF, VEGF and TGF-b.  In addition, they produce MMPs which mediate tissue degradation 
and remodelling. Other roles for synovial macrophages in RA include Th1 polarisation via 
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production of IL-12, IL-15 and IL-18, and promoting B cell survival by their expression of 
BAFF, APRIL and LT-β. 
 
1.3.2 Neutrophils 
Neutrophils are often the most abundant cell type in RA synovial fluid, although relatively 
low numbers are found in the synovial tissue. While the primary role of neutrophils in RA 
pathogenesis remains unclear, they are known to release a wide range of inflammatory 
mediators which could support a range of pathological events. Neutrophils release reactive 
oxygen and nitrogen species, proteases, complement and pro-inflammatory cytokines 
including TNF-α, IL-1, IL-18, IL-15, IL-6 and BAFF which could promote synovial 
inflammation and joint destruction (Assi et al. 2007; Edwards and Hallett 1997). Activated 
neutrophils are found at the cartilage-pannus interface where they could have a direct role in 
promoting erosion (Bromley and Woolley 1984). Neutrophils may also be involved in bone 
remodelling through expression of RANKL, RANK and OPG (Poubelle et al. 2007). 
Although the normal lifespan of neutrophils is relatively short, neutrophils in patients with 
early RA have reduced rates of apoptosis compared to patients with other persistent forms of 
arthritis or self-limiting disease (Raza et al. 2006). Neutrophils have an essential role in the 
initiation and progression of joint inflammation in the mouse K/BxN spontaneous arthritis 
model, implicating an important role for this cell type in the pathogenesis of RA (Wipke and 
Allen 2001). 
 
1.3.3 T cells 
T cells are abundant in the rheumatoid synovium, found in close proximity to B cells, 
dendritic cells and synovial fibroblasts. Both CD4 T cells and CD8 T cells are found in the 
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RA synovium. CD4 T cells are often  found clustered in perivascular cuffs, while CD8 T cells 
are found scattered throughout the synovium (Kurosaka and Ziff 1983). Synovial T cells have 
a highly differentiated CD45RO+CD45RBdull phenotype and display markers of activation 
such as CD69, CD28 and CD40L, but are hyporesponsive to antigenic stimulation (Cope et 
al. 1994; Emery et al. 1985; Malone et al. 1984). Although cytokine secretion by synovial T 
cells appears to be suppressed, T cells can promote cytokine production by macrophages and 
synovial fibroblasts via CD40L-CD40 interactions (Aarvak and Natvig 2001; McInnes et al. 
2000). Cytokine production and proliferation of T cells in RA may be impaired by chronic 
exposure to TNF-α in the RA synovium (Cope et al. 1997; Cope et al. 1994). Prolonged 
exposure of T cells to TNF-α downregulates expression of the TCRζ chain which is required 
for sensing and regulating lymphocyte responses (Isomaki et al. 2001). Furthermore, TCRζdim 
lymphocytes accumulate in the RA synovium where they show limited proliferation and 
effector responses (Zhang et al. 2007). 
 
T cells are implicated in the pathogenesis of RA due to the genetic association with MHC 
class II alleles, the abundance of T cells in the rheumatoid synovium, and the requirement for 
T cells in various animal models of arthritis (Rankin et al. 2008; Sakaguchi et al. 2003). 
Therapeutic targeting of T cells in RA using cyclosporin and antibodies specific for CD4 and 
CD52 have been disappointing (Keystone 2003). However, clinical benefit is seen with 
abatacept, a recombinant fusion protein consisting of the extracellular domain of CTLA4 and 
a fragment of the Fc portion of IgG that inhibits co-stimulatory signals required for T-cell 
activation, supporting a role for T cell co-stimulation and activation in RA (Wells et al. 2011). 
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Largely on the basis of animal models, RA has classically been considered a Th1 cell-
mediated disease driven by a population of T cells producing inflammatory cytokines such as 
IFN-γ and TNF-α. However, in mice lacking the Th1-cell-associated genes Ifng, Ifngr or 
IL12p35, collagen-induced arthritis (CIA) is accelerated (Manoury-Schwartz et al. 1997; 
Murphy et al. 2003; Vermeire et al. 1997). In addition, IFN-γ is lacking or present at low 
levels in the RA synovium and is rarely detectable in the synovial fluid (Firestein and Zvaifler 
1987), although some studies support the presence of Th1 cells in the synovium (Kanik et al. 
1998; Ronnelid et al. 1998). The notion of RA being a Th1-mediated disease was originally 
supported by the observation that IL-12, a major stimulator of Th1 development, enhanced 
murine CIA (Germann et al. 1995). However it was subsequently found that the autoimmune 
actions ascribed to IL-12 were in fact attributable to the newly discovered cytokine IL-23 
which is composed of a unique p19 subunit and the p40 subunit component of IL-12. Both 
mice lacking IL-23p19 and mice lacking IL-12p40 were protected from CIA, whereas mice 
lacking IL-12p35 developed more severe diseases (Becher et al. 2002; Cua et al. 2003; 
Murphy et al. 2003). While IL-12 induces development of Th1 cells, IL-23 binds to memory 
T cells and induces the proliferation of Th17 cells. 
 
A new model implicates Th17 cells as a crucial effector subset in RA. The Th17 cell subset 
plays a central role in the pathogenesis of several animal models of autoimmune diseases 
including RA. In the CIA model of arthritis, disease is suppressed in IL-17-deficient mice, 
whereas administration of anti-IL-17 antibodies significantly reduces disease severity 
(reviewed in (Lubberts et al. 2005)). Autoimmune arthritis in SKG mice, a strain of mice that 
spontaneously develops inflammatory arthritis due to a mutation in the T cell signalling 
molecule ZAP-70, is also highly dependent on IL-17 production by CD4 T cells (Hirota et al. 
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2007). In RA, IL-17 has been detected in synovial fluid and synovium (Fossiez et al. 1996; 
Hitchon et al. 2004; Kotake et al. 1999; Ziolkowska et al. 2000). IL-17 expression is 
associated with synovial inflammation and joint destruction mediated by inducing the 
production of pro-inflammatory cytokines and tissue-degrading proteins by stromal cells. 
 
Tregs play an important role in the maintenance of immune tolerance. Human Tregs were 
originally identified by their expression of the IL-2 receptor alpha chain, CD25, and the 
transcription factor Foxp3. However, CD25 and Foxp3 are also upregulated on activated CD4 
T cells which do not have a Treg function, and a CD25-negative subset of regulatory T cells 
has also been described. After in vitro activation, Tregs can suppress proliferation and 
cytokine production of CD4+CD25- T cells, and can also supress monocytes, macrophages, B 
cells and dendritic cells (Misra et al. 2004; Taams et al. 2005; Thornton and Shevach 1998; 
Zhao et al. 2006). Tregs exert their suppressive function via secretion of inhibitory cytokines 
and cytotoxic factors, or by modulating antigen presenting cells. Tregs are present in the 
rheumatoid synovium, but appear to have impaired regulatory function, being unable to 
suppress pro-inflammatory cytokine secretion by activated T cells and monocytes (Ehrenstein 
et al. 2004). Additionally, T responder cells in RA synovial fluid are less susceptible to 
suppression compared with circulating T cells which is consistent with the observation that 
strongly activated CD4 T cells are resistant to suppression by Tregs (Baecher-Allan et al. 
2002; van Amelsfort et al. 2004). The defective regulatory capacity of RA Tregs is associated 
with their reduced expression of the suppressive molecule CTLA-4 (Flores-Borja et al. 2008). 
Their regulatory capacity also appears to be modulated by TNF-α, as TNF-α inhibition in RA 
patients promotes the emergence of functional Foxp3+CD4+CD25+CD62L- Treg population 
(Nadkarni et al. 2007). This is consistent with a recent paper which showed that TNF-α 
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increases localisation of PKCθ to the immune synapse where it acts as a negative regulator of 
Treg function, supporting the notion that TNF-α has an inhibitory effect of Treg function in 
RA (Zanin-Zhorov et al. 2010). 
 
1.3.4 B cells 
The therapeutic success of B cell depletion in RA has revived interest in the role of this cell 
type in RA pathogenesis. In the RA synovium, B cells are found within lymphocyte 
aggregates which are often surrounded by large numbers of plasma cells. In a proportion of 
patients, ectopic germinal-centre like structures can be observed in the synovium, with 
follicles containing T and B cells arranged around a network of follicular dendritic cells 
(Magalhaes et al. 2002; Takemura et al. 2001a). Naïve and memory B cells infiltrate and 
accumulate in the synovial tissue in RA, and there appears to be continuous activation of 
selected B cell clones with a high migratory capacity (Scheel et al. 2011). 
 
For many years, B cells have been regarded as important in RA due to their production of 
autoantibodies. Autoantibodies initiate immune complex formation within the joint, resulting 
in complement activation and recruitment of cells to the synovium. B cells have several other 
functions relevant to the pathogenesis of RA. B cells are able to process and present antigen to 
T cells, and they may represent the predominant population of antigen presenting cells in later 
phases of the immune response (MacLennan et al. 1997). Rheumatoid-factor-producing B 
cells have been shown to be particularly effective in binding immune complexes and 
presenting antigens from the immune complex to T cells, irrespective of the antigen within the 
antigen-antibody complex (Roosnek and Lanzavecchia 1991). B cells can also secrete several 
cytokines including IL-6, IL-10, IFN-γ, TGF-β and LT-α, indicating that they may have a 
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direct inflammatory role and support B cell development (Duddy et al. 2007; Pistoia 1997). 
Studies in mice indicate that IL-10-producing B cells are involved in the suppression of 
autoimmune and inflammatory disease, including RA (Mauri et al. 2003). However, these so-
called “regulatory B cells” have not been described in the RA synovium. In addition, B cells 
can regulate lymphoid tissue organisation and neogenesis (Gonzalez et al. 1998; Tumanov et 
al. 2002), and the transfer of synovial tissue into immunodeficient mice demonstrated that B 
cells were required for germinal centre CD4 T-cell activation (Takemura et al. 2001b; 
Weyand and Goronzy 2003). 
 
B cell depletion in RA patients using rituximab significantly reduces synovial inflammation. 
However, the return of B cells is accompanied by return of the disease, suggesting that 
transient B cell depletion by rituximab is unable to reset the immune system, possibly due to 
the persistence of memory B cells in the bone marrow or synovium (Nakou et al. 2009; Teng 
et al. 2009). 
 
1.3.5 Synovial fibroblasts 
Synovial fibroblasts are a dominant cell type in the hyperplastic rheumatoid synovium where 
they have an important role in amplifying the inflammatory cascade by production of pro-
inflammatory cytokines such as IL-1, IL-6 and TNF-α (Hashizume et al. 2008). Synovial 
fibroblasts also drive joint destruction by production of MMPs and cathepsins, and promote 
osteoclastogenesis by expression of RANKL (Hashizume et al. 2008). 
 
29 
 
Compared to synovial fibroblasts from healthy joints, synovial fibroblasts found in the 
rheumatoid synovium have an altered phenotype in terms of altered morphological features, 
changes in long-term growth and apoptosis, and altered response to extracellular stimuli. RA 
synovial fibroblasts show long-term growth and reduced apoptosis which is associated with 
upregulation of early response genes and proto-oncogenes such as egr-1, c-fos, myc and ras, 
and a corresponding deficiency of tumour-suppressor genes such as p53, p53-upregulated 
modulator of apoptosis (PUMA), mapsin and phosphatase and tensin homolog (PTEN) (Cha 
et al. 2006; Matsumoto et al. 1996; Pap et al. 2000; Pap et al. 2004). Synovial fibroblasts also 
upregulate the anti-apoptotic molecules, FLICE inhibitor protein (FLIP) and sentrin (SUMO-
1), as well as members of the Bcl family such as Bcl-2 and Mcl-1 (Franz et al. 2000; Kataoka 
2005; Palao et al. 2004; Salmon et al. 1997). This imbalance of pro-apoptotic and anti-
apoptotic pathways is thought to contribute to sustaining their long-term survival in the 
rheumatoid synovium. 
Rheumatoid synovial fibroblasts also have invasive properties, facilitating cartilage erosion in 
RA. In addition to the activating effects of cytokines and growth factors, cytokine-
independent pathways appear to be required for induction of an aggressive phenotype.  Such 
triggers could include epigenetic modifications or the galectin-3 system. Galectin-3, which is 
elevated in tumours and metastasis, induces angiogenesis and inhibits apoptosis, and has been 
found at high levels in the serum and synovial fluid of RA patients (Ohshima et al. 2003). A 
recent study showed that when healthy human cartilage and cartilage-invading synovial 
fibroblasts were implanted subcutaneously at distinct sites in SCID mice, the healthy cartilage 
was also invaded by synovial fibroblasts which appeared to have migrated via the vasculature 
(Lefevre et al. 2009). This has led to the suggestion that the migratory properties of synovial 
fibroblasts could participate in the spread of RA to previously unaffected joints. 
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1.4 Cytokines in RA 
Cytokines are a heterogeneous group of low molecular weight proteins which act as 
intercellular mediators. They have pleiotropic effects which include regulation of cell growth, 
development, differentiation and activation, and are thus involved in almost every biological 
process. Most cytokines are soluble, although some remain cell-bound, and others exist in 
both soluble and cell-bound forms. They usually act at short range and are able to produce 
immediate responses in target cells by activating direct signalling pathways that rapidly effect 
changes in gene transcription.  
 
Cytokines act within a complex network to regulate the processes involved in chronic 
inflammation and tissue destruction in RA. In view of the complex cross-talk that exists 
between immune cell pathways, it is important to try to understand the roles of cytokines as 
components of larger networks rather than isolated pathways. Novel cytokine activities are 
being described on an ongoing basis, but it is difficult to understand cytokine interactions and 
define regulatory hierarchies using existing model systems such as animal models of disease 
in which genes for individual cytokines are genetically manipulated. While therapeutic 
targeting of cytokines has been largely successful to date, further targets still need to be 
identified because of partial and non-responders, the loss of effect observed in most 
therapeutic regimes, and an increasing drive to achieve remission. 
 
Bioinformatic analysis of the cytokine network as a whole has demonstrated how immune 
cells function via cytokines in innately integrated and hierarchical collectives. Frankenstein 
and colleagues (Frankenstein et al. 2006) identified a five-tiered system structure of the 
cytokine connectivities between immune cell types in which the macrophage and B cell form 
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a pair in the first tier, being reciprocally connected by cytokines to all other cells of the 
immune system; Th1 and Th2 T cells are paired in a second tier, being mutually connected to 
other cells, but unique in providing one-way cytokine signals to a variety of cell types; the 
cytotoxic lymphocyte is in its own tier, being the only cell type that receives multiple one-
way signals; neutrophils and NK cells form another tier, receiving more limited one-way 
signals; while the remaining immune cells comprise the final tier, receiving and sending one-
way signals. The analysis also revealed a high degree of cytokine connectivity between 
immune cells – macrophages, B cells, dendritic cells and NK cells – and non-immune cells – 
fibroblasts, endothelial cells, epithelial cells, platelets, osteoblasts, osteoclasts, chondrocytes 
and smooth muscle cells. The involvement of these cell types in wound healing, bone repair 
and angiogenesis suggests that cytokines have an important role in regulating the physiology 
of the body as well as its defence. This analysis is interesting in the context of the rheumatoid 
synovium in which abnormal cytokine networks between immune cells and non-immune cells 
are known to exist. 
 
Cytokines can be grouped into families using several strategies. Grouping of cytokines into 
families may be based on structural homology, shared functional properties, or the type of 
receptor that they engage. Cytokine receptors themselves are grouped by structure into several 
families. A brief overview of the major cytokine families is given in this chapter.  
 
1.4.1 IL-1 family 
The IL-1 family is composed of 11 structurally related cytokines. The first members to be 
identified were IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra) and IL-18. Seven additional 
members have been identified on the basis of sequence homology, three-dimensional 
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structure, gene location and receptor binding. A new system of terminology has been 
proposed in which IL-1 α, IL-1β, IL-1Ra and IL-18 become IL-1F1, IL-1F2, IL-1F3 and IL-
1F4 respectively, and newly identified cytokines are termed IL-1F5 through IL-1F11, the 
latter representing IL-33. Although all of the IL-1 family cytokines are extracellular, only IL-
1Ra is secreted by the endoplasmic reticulum and Golgi apparatus. The mechanism of 
secretion of the other IL-1 family members remain unknown. However, IL-1β and IL-18 are 
known to require processing by a protein assembly complex known as the inflammasome to 
generate the biologically active forms and to be secreted. IL-1β and IL-18 have amino-
terminal pro-domains that require cleavage by the inflammasome. IL-1α also has a pro-
domain, but it is not required to be cleaved for its biological activity. IL-1F5, IL-1F6, IL-1F8, 
IL-1F9 and IL-33 are functional as full-length molecules and do not require processing by the 
inflammasome. IL-1 family members signal through a group of closely related receptors. 
 
The term IL-1 is often used to refer to IL-1α and IL-1β, as both proteins signal through the 
same receptor complex and have identical biological activities in vitro. However, IL-1β is 
secreted and circulates systematically, whereas IL-1α is generally associated with plasma 
membrane and acts locally. Their actions can be blocked by IL-1Ra, and by the decoy 
receptor, IL-1RII. IL-1α and IL-1β are mainly produced by stimulated monocytes and 
macrophages, and to a lesser extent by neutrophils, epithelial and endothelial cells, 
lymphocytes and fibroblasts (Dinarello 1994). IL-1 exerts a broad range of pro-inflammatory 
effects, inducing mononuclear and stromal cells to produce pro-inflammatory mediators, 
degradative enzymes, adhesion molecules, cytokines and chemokines. IL-1 also promotes 
articular destruction by stimulating the maturation of osteoclasts and activating chondrocytes. 
IL-1 is also reported to induce Th17 differentiation and IL-17 production in mice and humans 
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(Acosta-Rodriguez et al. 2007; Chung et al. 2009). IL-1α, IL-1β and IL-1Ra are abundant in 
the synovial membrane (Dayer 2003). Targeting IL-1 and the IL-1 receptor in rodent models 
of arthritis effectively reduces inflammation and cartilage and bone damage (Joosten et al. 
1999a; van den Berg et al. 1994). Mice that are deficient in the IL-1Ra develop spontaneous 
arthritis, partly mediated by enhanced Th17-dependent inflammation (Nakae et al. 2003a). 
Evidence thus suggests that blockade of IL-1 in RA would be beneficial, especially in 
reducing bone destruction. Several IL-1-targeting agents have been developed for use in RA, 
but these have shown modest or negative results. The recombinant IL-1R antagonist, 
anakinra, and a fully human monoclonal anti-IL-1RI showed modest benefit, whereas other 
approaches to target IL-1 such as rilonacept (IL-1 trap fusion protein), canakinumab (anti-IL-
1β antibody) and soluble IL-1RI showed no effect.  
 
IL-18 is produced by a range of cells including macrophages, neutrophils, dendritic cells, 
osteoblasts and synovial fibroblasts. IL-18 activity is regulated by binding of the soluble IL-
18-binding protein (IL-18BP) which prevents IL-18 from interacting with its receptor. IL-18 
has diverse functions which include promoting Th1 or Th2 differentiation, depending on other 
cytokines present, and increasing NK cell cytotoxicity and IFN-γ production. IL-18 is 
implicated in the pathogenesis of RA and is found at elevated levels in the serum of RA 
patients and in the RA synovium (Gracie et al. 1999). Blockade of IL-18 using neutralising 
antibody or soluble IL-18 receptor is effective in rodent models of RA, and there is reduced 
incidence and severity of CIA in mice lacking IL-18 (Plater-Zyberk et al. 2001; Wei et al. 
2001).  
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IL-33 is the most recently described member of the IL-1 family. It was originally identified as 
a nuclear protein prominent in high endothelial venules, and its cytokine function was 
described later. IL-33 is predominantly expressed in the nucleus of cells with a barrier 
function such as endothelial and epithelial cells. IL-33 can activate T cells and basophils, 
promote degranulation and pro-inflammatory cytokine production by mast cells and 
eosinphils, and induce Th2 cell and neutrophil migration (Allakhverdi et al. 2007; Alves-
Filho et al. 2010; Komai-Koma et al. 2011; Kurowska-Stolarska et al. 2008; Schmitz et al. 
2005; Smithgall et al. 2008). Expression of IL-33 is detected in RA synovial membrane and is 
produced predominantly by synovial fibroblasts (Xu et al. 2008). In murine models of 
arthritis, administration of IL-33 was found to exacerbate disease, whereas disease was 
reduced in mice lacking the IL-33 receptor and in mice administered sST2, a natural 
antagonist of IL-33 (Xu et al. 2008). The effects of IL-33 appear to be mediated by the 
activation of mast cells (Xu et al. 2008). 
 
1.4.2 Cytokines binding a γc-containing receptor 
Several cytokines are grouped on the basis of their usage of heterodimeric cytokine receptors 
which contain a common gamma chain receptor subunit as a signal-transducing chain, 
together with a cytokine-specific chain. These cytokines have the common structural feature 
of a four-helix bundle motif. Cytokines signalling through γc-containing receptors include IL-
2, IL-4, IL-7, IL-9, IL-15 and IL-21. IL-13 is closely related to IL-4, and the alpha chain and 
gamma chain components of the IL-4 receptor both play a role in the IL-13 receptor complex. 
 
IL-2 was the first cytokine shown to bind a receptor containing the common gamma chain. IL-
2 is produced by activated T cells and drives their proliferation and differentiation following 
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antigen stimulation. IL-2 also stimulates NK cells to proliferate and induces cytolytic activity, 
and stimulates B cells to divide and produce antibody. IL-2 has an important role in 
controlling immune responses through the development and maintenance of Tregs and also 
perhaps by suppression of Th17 differentiation and promotion of Fas-mediated cell death. 
Despite displaying a highly activated phenotype, RA synovial T cells express relatively low 
levels of IL-2, no spontaneous IL-2 production has been observed in freshly isolated RA T 
cells, and peripheral blood cells show reduced IL-2 production in RA compared to healthy 
controls (Combe et al. 1985; Firestein et al. 1988; Kitas et al. 1988; Smeets et al. 1998a). 
 
IL-4 is a Th2-cell derived cytokine whose role in RA is not well understood. IL-4 exerts an 
anti-inflammatory effect by inhibiting the production of pro-inflammatory cytokines by 
macrophages and monocytes, such as IL-1, TNF-α, IL-6 and IL-12. IL-4 can also induce the 
production of several cytokine inhibitors such as IL-1Ra, IL-1RII and TNF receptors. IL-4 is 
the predominant cytokine capable of inducing differentiation of naive T cells into Th2 cells. 
In vitro, IL-4 inhibits MMP and induces tissue inhibitor of metalloproteinase (TIMP) 
production, and can inhibit osteoclast activity and survival, suggesting a protective role in 
bone resorption. Animal models of arthritis have suggested both pathogenic and protective 
roles for IL-4. IL-4 is required for the development of CIA (Ortmann and Shevach 2001). 
However, in mice with established CIA, treatment with IL-4 suppresses disease and bone 
erosion is reduced (Joosten et al. 1999b; Lubberts et al. 2000; Saidenberg-Kermanac'h et al. 
2004). In addition, CIA is attenuated in mice injected with dendritic cells genetically 
engineered to produce IL-4 (Morita et al. 2001), and in rat adjuvant-induced arthritis IL-4 
adenoviral gene therapy reduces disease severity and articular damage (Woods et al. 2001). In 
patients with RA, a polymorphism in the IL-4 receptor that results in reduced responsiveness 
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to IL-4 is associated with rapidly erosive disease (Prots et al. 2006). IL-4 has not been 
detected in RA synovium but IL-4 has been detected in the synovial fluid of early RA patients 
(Raza et al. 2005). 
 
IL-13 is closely related to IL-4, sharing overlapping functions and being encoded by genes on 
the same chromosome. The IL-4 receptor alpha chain plays an important role in IL-13 
signalling, and the common gamma chain also plays a role although it does not bind IL-13. 
Like IL-4, IL-13 is a classical Th2 cytokine and is involved in allergic responses and IgE class 
switching. IL-13 has multiple effects on the differentiation and functions of monocytes and 
macrophages, and is able to suppress their cytotoxic function (McKenzie et al. 1993). In 
addition, IL-13 can suppress the production of pro-inflammatory cytokines. IL-13 has been 
detected in synovial fluid from RA patients and is expressed by synovial fluid macrophages 
(Isomaki et al. 1996b; Raza et al. 2005; Tokayer et al. 2002). Animal models of arthritis 
indicate a protective role for this cytokine in RA. CIA is attenuated in mice treated with 
vector cells engineered to secrete IL-13 (Bessis et al. 1996; Bessis et al. 1999). Similarly, IL-
13 adenoviral gene therapy reduces inflammation, vascularisation and bony destruction in rat 
adjuvant-induced arthritis (Woods et al. 2002). Overexpression of IL-13 in immune-complex-
mediated arthritis reduced chondrocyte death and MMP-mediated cartilage damage, although 
there was increased joint inflammation (Nabbe et al. 2005).  
 
IL-7 is produced by stromal cells at lymphopoietic sites and has a role in T cell and B cell 
development and homeostasis (Fry and Mackall 2005; Link et al. 2007). IL-7 can also induce 
TNF-α production by monocytes in a T-cell dependent manner, modify chondrocyte function 
and promote RANKL-mediated osteoclastogenesis. IL-7 is detected in RA synovial fluid and 
tissue, and its expression in the synovium has been localised to macrophages, endothelial cells 
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and fibroblasts (Harada et al. 1999; Pickens et al. 2011; van Roon et al. 2007). Addition of 
IL-7 to synovial cultures has a pro-inflammatory effect (Harada et al. 1999; van Roon et al. 
2005). In the CIA model of arthritis, blockade of IL-7R ameliorates joint inflammation by 
reducing T cell trafficking and macrophage production of pro-inflammatory mediators 
(Hartgring et al. 2010). 
 
IL-15 is widely expressed in numerous tissues and cell types, including activated monocytes, 
mast cells, dendritic cells and fibroblasts (Grabstein et al. 1994; Waldmann and Tagaya 
1999). It mediates its effects by binding to IL-15R which is found on T and B cells, NK cells, 
monocytes, macrophages, DCs and fibroblasts. IL-15 can also participate in trans-signalling 
in which IL-15-IL-15Rα complexes on one cell can bind to IL-15Rβγ chains on adjacent cells. 
IL-15 has broad pro-inflammatory effects including induction of Th1 and Th17 cell 
proliferation, and activation of neutrophil, macrophage and mast cell effector functions 
(Lodolce et al. 2002; Miranda-Carus et al. 2004; Verri et al. 2007; Waldmann and Tagaya 
1999). IL-15 is present in the RA synovium where it is expressed by macrophages and 
synovial fibroblasts, and is spontaneously produced in RA synovial cultures and isolated 
synovial fibroblasts (McInnes et al., 1996; Harada et al., 1999). In the RA synovium, IL-15 
drives the release of IFN-γ, IL-17, TNF-α and various chemokines, and also promotes the 
survival and migration of synovial T cells and synovial fibroblasts (McInnes et al. 1996; 
McInnes et al. 1997; Miranda-Carus et al. 2004). IL-15 blockade reduces severity of CIA 
(Ferrari-Lacraz et al. 2004; Ruchatz et al. 1998). IL-15 has been targeted in RA using an 
antibody specific for human IL-15, and has showed clinical responses during clinical trial 
(Baslund et al. 2005). 
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IL-21 is a potent inflammatory cytokine which plays an important role in B cell maturation 
and plasma cell development, and is also involved in T cell activation and differentiation, 
including the generation of Th17 cells (Nakae et al. 2003b). IL-21 induces NK-cell and NKT-
cell maturation and activation, and promotes the generation of Tfh cells. It may also suppress 
the generation of Tregs. IL-21 is detected in the synovial fluid and synovial tissue in patients 
with RA (Andersson et al. 2008). Addition of IL-21 to synovial T cell cultures induces 
activation and pro-inflammatory cytokine production (Jungel et al. 2004; Li et al. 2006), 
whereas neutralisation of IL-21 in synovial cultures suppresses release of TNF-α, IL-1 and 
IL-6 (Andersson et al. 2008). Mice deficient in IL-21 receptor are resistant to development of 
spontaneous arthritis, and have fewer homeostatically proliferating and Tfh cells than control 
mice, but more Th17 cells (Jang et al. 2009). In CIA, blockade of IL-21 delays onset and 
progression of disease (Young et al. 2007). In addition, polymorphisms in IL-21 loci have 
been identified as a risk factor for RA (Daha et al. 2009). 
 
1.4.3 Cytokines binding a gp130-containing receptor 
Several cytokines signal through a receptor containing the signal-transducing protein 
glycoprotein 130 (gp130). These cytokines have a four alpha-helix structure. This family 
includes IL-6, IL-11, IL-27, IL-31, ciliary neurotrophic factor, leukemia inhibitory factor, 
oncostatin M, and osteopontin.  
 
IL-6 is predominantly produced by mononuclear phagocytic cells, and is also produced by T 
cells, B cells, fibroblasts, endothelial cells, keratinocytes, hepatocytes and bone marrow cells. 
IL-6 was originally identified as a substance produced by T cells which induced B cells to 
produce antibodies (Hirano et al. 1986). IL-6 is now known to have a wide range of biological 
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effects including the activation of B cells and T cells, macrophages, osteoclasts, chondrocytes 
and endothelial cells. IL-6 also induces and the proliferation of keratinocytes and has effects 
on haematopoiesis. IL-6 shares several activities with IL-1, including the induction of pyrexia 
and production of acute phase proteins. IL-6 exerts its effects by binding to the IL-6 receptor 
(IL-6R) which then associates with gp130 (Taga et al. 1989). IL-6R exists as a membrane-
bound receptor and also in a soluble form (Lust et al. 1992; Matthews et al. 2003). Soluble 
IL-6R and IL-6 are able to stimulate cells which express gp130 but not membrane-bound IL-
6R in a process known as trans-signalling (Mackiewicz et al. 1992). IL-6 is elevated in RA 
synovial fluid and synovial tissue (Houssiau et al. 1988), and IL-6 in synovium correlates 
with disease activity (Cohick et al. 1994; Tak et al. 1997). In CIA, deletion of the IL-6 gene is 
protective, and administration of antibodies specific for IL-6 ameliorates disease (Alonzi et al. 
1998). Using an experimental arthritis model in IL-6-deficient mice, administration of  a 
soluble IL-6R/IL-6 fusion protein restored disease activity, while blockade of soluble IL-6R 
by soluble gp130 ameliorated disease (Nowell et al. 2003). Tocilizumab is a monoclonal 
antibody targeted against the IL-6 receptor which reduces inflammation and erosions in RA, 
and has been approved for clinical use. 
 
IL-11 regulates the growth and development of haematopoietic stem cells and polarises T cell 
differentiation towards a Th2 phenotype (Curti et al. 2001). It mediates anti-inflammatory 
effects by suppressing production of pro-inflammatory cytokines and nitric oxide production 
(Trepicchio et al. 1996).  IL-11 is detected in the serum, synovial fluid and synovium of 
patients with RA (Hermann et al. 1998). IL-11 has immunoregulatory effects on RA synovial 
tissue cultures, inhibiting spontaneous production of TNF-α and MMPs (Hermann et al. 
1998). In animal models of collagen-induced and adjuvant-induced arthritis, treatment with 
recombinant human IL-11 (rhIL-11) reduced the level of synovitis and the histologic lesion 
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scores in the joints, suggesting that IL-11 could have therapeutic activity in RA (Walmsley et 
al. 1998). However, in a phase-I/II randomised trial of recombinant human IL-11, no 
therapeutic benefit was found (Moreland et al. 2001). 
 
1.4.4 IL-12 family 
The IL-12 family comprises a family of structurally related cytokines which are composed of 
two covalently-linked subunits. IL-12 was the first cytokine to be identified as a 
heterodimeric cytokine, and is composed of the IL-12p40 and IL-12p35 subunits. The IL-
23p19 subunit was later identified, which dimerises with IL-12p40 to form IL-23. IL-12 and 
IL-23 signal through receptors which share a common component, IL-12Rβ1. IL-27 is a 
cytokine formed from IL-27p28 and the Epstein-Barr virus (EBV)-induced molecule (EBI3). 
The receptor for IL-27 comprises WSX1 and gp130. The newest family member is IL-35, 
which is composed of EBI3 and IL-12 p35. 
 
The two subunits of IL-12, p35 and p40, are both required for the biological activity of IL-12. 
The p40 subunit can be secreted in the absence of p35, but p35 cannot be secreted without co-
expression of p40. p35 is found at low levels in many cell types, while expression of the p40 
subunit is usually much higher and restricted to cells that produce the biologically active 
dimer. IL-12 is produced by dendritic cells and monocytes and macrophages in response to 
bacterial products and immune signals. IL-12 induces the development of Th1 cells. Some 
studies have demonstrated a correlation between elevated IL-12 in the serum and synovial 
fluid with disease activity in RA (Kim et al. 2000), whereas others have not found IL-12 to be 
increased in RA.  
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IL-23, composed of a unique p19 subunit and an IL-12p40 subunit, also requires expression 
of both subunits for the biologically active cytokine. In vitro experiments have shown that 
activated monocytes and dendritic cells are capable of inducing both subunits required for 
functionally active IL-23, but activated synovial fibroblasts only express the p19 subunit. IL-
23 is produced predominantly by activated dendritic cells and macrophages and can be 
triggered by TLR agonists and CD40/CD40L interaction with T cells. IL-23 binds to its 
receptor on memory T cells, NK cells, macrophages and dendritic cells. IL-23 appears to be 
required for the induction and maintenance of Th17 cells (Veldhoen et al. 2006). IL-23 also 
upregulates RANK on myeloid precursors and induces RANKL on T cells indicating a role in 
osteoclastogenesis and bone erosion. In RA synovial tissue, high levels of IL-23p19 
expression are reported, but only low levels of bioactive IL-23 (Brentano et al. 2009; Kim et 
al. 2007; Liu et al. 2007). In a murine model of CIA, administration of anti-IL-23 produced 
less severe disease (Yago et al. 2007), and in a spontaneous arthritis murine model 
administration of IL-23 increased disease severity (Ju et al. 2008). Furthermore, IL-23p19-
deficient mice are protected against arthritis (Murphy et al. 2003), indicating a pathogenic 
role for IL-23 in disease. Ustekinumab, a human monoclonal antibody against IL-12p40 that 
targets IL-12 and IL-23 is in phase III clinical trials.  
 
Another member of the IL-12 family is IL-27, composed of a specific IL-27p28 subunit and 
the EBI3 subunit. IL-27 is secreted by activated monocytes and macrophages and dendritic 
cells and binds to the IL-27R expressed on naïve CD4 T cells, NK cells, mast cells, 
macrophages and neutrophils. IL-27 induces the proliferation of naïve T cells, promoting Th1 
differentiation (Lucas et al. 2003; Pflanz et al. 2002) and suppressing Th17 development 
(Amadi-Obi et al. 2007; Artis et al. 2004; Batten et al. 2006; Villarino et al. 2003). In 
addition, animal models of infection have demonstrated anti-inflammatory effects of IL-27, as 
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observed by the increased T cell and NK cell responses in the absence of the IL-27 receptor 
component WSX1, and increased mast cell and macrophage responses in the absence of the 
IL-27 receptor (Holscher et al. 2005; Pearl et al. 2004; Villarino et al. 2003). IL-27 has been 
detected in the synovial tissue of patients with RA (Niedbala et al. 2008). In murine models of 
arthritis, IL-27 has been found to have a protective or pathogenic role, depending on the 
model used. IL-27 has a pathogenic effect in adjuvant-induced arthritis and proteoglycan-
induced arthritis, which are considered to be Th1-mediated (Cao et al. 2008; Goldberg et al. 
2004). In contrast, IL-27 has a protective role in CIA, which is thought to be Th17-mediated 
(Niedbala et al. 2008).  
 
1.4.5 IL-10 family 
The IL-10 family comprises a group of cytokines which are structurally related to IL-10. 
Bioinformatics was used to identify molecules with a similar structure to IL-10, which 
contains six alpha helices. This led to the isolation and naming of new family members IL-19, 
IL-20, IL-22, IL-24 and IL-26. 
 
IL-10 is an immunoregulatory cytokine that blocks production of pro-inflammatory cytokines 
and inhibits the antigen presenting capacity of macrophages and dendritic cells. IL-10 also has 
a weak stimulatory effect on B cells. IL-10 is produced by macrophages, T and B cells, 
dendritic cells, mast cells, NK cells and neutrophils. IL-10 is produced by macrophages and T 
cells in the RA synovium (Katsikis et al. 1994), and in RA synovial tissue membrane cultures 
is able to regulate endogenous pro-inflammatory cytokine production (Cohen et al. 1995; 
Katsikis et al. 1994). IL-10 levels have been found to be increased in patients with RA 
(Alanara et al. 2009; Cush et al. 1995; Isomaki et al. 1996a). High IL-10 producer genotypes 
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are increased in patients with a higher rate of joint destruction (Lard et al. 2003), and are 
associated with more severe radiographic damage in seronegative patients (Marinou et al. 
2007). In animal models of arthritis, CIA is exacerbated in IL-10-deficient mice, whereas 
treatment of established CIA with IL-10 suppresses disease (Ortmann and Shevach 2001; 
Walmsley et al. 1996), indicating a protective role for IL-10 in the disease. However, clinical 
studies performed with human recombinant IL-10 in patients with rheumatoid arthritis (RA) 
have shown little efficacy (Maini et al., 1997). 
 
IL-20 is expressed by monocytes, epithelial cells, and endothelial cells and induces 
production of inflammatory mediators. IL-20 has been shown to induce cytokine secretion by 
synovial fibroblasts, and promote neutrophil chemotaxis, synovial fibroblast migration and 
endothelial cell proliferation. IL-20 and its three receptors are expressed in synovial 
membranes and synovial fibroblasts in synovial tissue of RA patients and CIA rats, and levels 
of IL-20 are elevated in RA synovial fluid compared to healthy controls (Hsu et al. 2006). In a 
rodent model of CIA, administration of soluble IL-20 receptor type 1 significantly reduced 
disease (Hsu et al. 2006), supporting a pro-inflammatory role for IL-20 in RA. 
 
IL-22 is known to be produced by Th17 and Th22 cells (Duhen et al. 2009; Liang et al. 2006; 
Trifari et al. 2009). IL-22 has been detected in RA synovial tissue macrophages and 
fibroblasts and synovial fluid mononuclear cells (Ikeuchi et al. 2005). Addition of 
recombinant IL-22 to synovial fibroblasts was found to enhance proliferation and production 
of CCL2. In the CIA model of arthritis, mice deficient in IL-22 have reduced incidence of 
arthritis and pannus formation, and IL-22 was found to promote osteoclastogenesis in vitro, 
indicating a pro-inflammatory role for IL-22 in RA (Geboes et al. 2009). 
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1.4.6 IL-17 family 
The IL-17 family is a group of cytokines which shares little homology with other cytokines. 
Six family members have been identified, designated IL-17A to IL-17F. The first described 
cytokine known as IL-17 has been termed IL-17A. The five related cytokines which have 
since been identified share 20% to 50% sequence homology with IL-17A. The members of 
the IL-17 family bind to a unique class of cytokine receptors. 
 
IL-17 plays a critical role in the defence against extracellular pathogens. IL-17 is able to 
induce production of pro-inflammatory cytokines such as IL-1, IL-6, TNF-α, nitric oxide 
species and MMPs by fibroblasts, macrophages and endothelial cells (Fossiez et al. 1996; 
Parsonage et al. 2008). IL-17 also induces several chemokines that attract T cells and 
macrophages to sites of inflammation. IL-17 promotes osteoclastogenesis by upregulating 
RANKL on osteoblasts (Fossiez et al. 1996; Parsonage et al. 2008; Sato et al. 2006). 
 
Evidence from animal and human studies suggests that IL-17 may be of importance in the 
pathogenesis of RA. In CIA, the incidence and severity of disease is markedly reduced in IL-
17-deficient mice (Nakae et al. 2003a), while administration of IL-17 promotes osteoclastic 
bone destruction (Lubberts et al. 2003). IL-17 is present in RA synovial fluid and Th17 cells 
have been detected in synovial tissue (Fossiez et al. 1996; Hitchon et al. 2004; Kotake et al. 
1999; Ziolkowska et al. 2000). In RA synovial fibroblasts, IL-17 stimulated the production of 
IL-6, CXCL8, leukaemia inhibitory factor and prostaglandin E2, and could synergise with IL-
1 and TNF-α to induce production of cytokines and MMPs (Miossec 2003). IL-17 stimulated 
dendritic cell migration and recruitment of T cells by inducing production of CCL20 by RA 
synoviocytes (Chabaud et al. 2001). In a recent study which assessed the cytokine profile and 
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frequency of IL-17-producing CD4 T cells in RA synovial fluid, synovial fluid mononuclear 
cells were found to have reduced levels of IL-22 (a Th17- and Th1-derived cytokine) and did 
not express IL-23R which is important for Th17 expansion and survival (Church et al. 2010). 
Compared to the peripheral blood and synovium, there was a modest enrichment of IL-17-
producing CD4 T cells in the synovial fluid but the overall proportion of this population was 
low, suggesting that there may be an alternative source of IL-17 in the rheumatoid joint. 
Indeed, expression of IL-17 has been reported by mast cells in the RA synovium (Hueber et 
al.). IL-17 has been investigated as a potential therapeutic target in RA. In two phase I clinical 
trials, a monoclonal anti-IL-17 was reported to show benefit in RA compared to placebo 
(Genovese et al. 2010; Hueber et al. 2010). 
 
1.4.7 TNF family 
Several cytokines have been identified as part of the TNF family on the basis of structural and 
functional homology. TNF family cytokines are trimeric proteins which are membrane-bound, 
with the exception of TL1A which is synthesized as a secreted soluble protein. Some of the 
TNF family members may be cleaved to generate soluble forms. The founding members of 
the TNF family, TNF-α and LT-α were initially identified as proteins that possess tumour 
cytotoxicity; however, it is now recognised that TNF family members have a variety of 
cellular functions including regulating cell differentiation, effector function, survival and 
apoptosis. TNF family members are important in regulating key biological processes 
including inflammation, lymphoid organogenesis, bone homeostasis, and developmental 
processes. TNF family cytokines bind to membrane-bound receptors of the TNF receptor 
family. Members of this receptor family are typically transmembrane proteins, although some 
TNF family receptors exist as soluble proteins. The members of the TNF family are LT-α 
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(TNFSF1), TNF-α (TNFSF2), LT-β (TNFSF3), OX40L (TNFSF4), CD40L (TNFSF5), FASL 
(TNFSF6), CD70 (TNFSF7), CD30L (TNFSF8), 4-1BB-L (TNFSF9), TRAIL (TNFSF10), 
RANKL (TNFSF11), TWEAK (TNFSF12), APRIL (TNFSF13), BAFF (TNFSF13B), LIGHT 
(TNFSF14), TL1A (TNFSF15) and GITRL (TNFSF18).  
 
TNF-α is considered a classical pro-inflammatory cytokine and plays an important role in host 
defence.  TNF-α is mainly produced by activated macrophages but can also be released by 
other leukocytes including T cells, NK cells and neutrophils. During infection, production of 
TNF-α by macrophages triggers local containment of infection by acting on blood vessels to 
increase blood flow and permeability, and to increase the ability of leukocytes and platelets to 
adhere to the endothelial cells. The local release of TNF-α thus allows an influx of cells and 
proteins into the infected tissue where they participate in host defence. TNF-α is recognised 
as a pivotal pro-inflammatory cytokine that mediates inflammation and joint destruction in 
RA, and therapeutic targeting of this molecule has proved to be highly successful (Feldmann 
et al. 1994). Blockade of cytokines produced spontaneously by RA synovial cultures showed 
that blockade of TNF-α downregulated IL-1, and also GM-CSF, IL-6 and IL-8 (Butler et al. 
1995; Haworth et al. 1991). Furthermore, samples from RA patients in clinical trials showed 
that following anti-TNF therapy there was a dramatic and rapid reduction in levels of serum 
IL-6 and many other cytokines in the blood and synovium (Charles et al. 1999). These 
findings support the concept of a TNF-α-dependent cytokine cascade operating in RA. In RA, 
TNF-α induces leukocyte and endothelial cell activation, leading to the production of other 
pro-inflammatory cytokines such as IL-1 and IL-6, and leukocyte accumulation in the 
inflamed synovium. Furthermore, TNF-α stimulates MMP release by fibroblasts leading to 
cartilage destruction, and also has a role in promoting angiogenesis. TNF-blocking agents 
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currently approved for clinical use are infliximab (a chimeric antibody specific for human 
TNF-α), etanercept (a fusion protein comprised of human soluble TNF receptor linked to the 
Fc component of human IgG1), adalimumab (a fully humanised antibody specific for human 
TNF-α), certolizumab pegol (a humanized antigen-binding fragment (Fab') of a monoclonal 
antibody that has been conjugated to polyethylene glycol), and golimumab (a fully humanised 
antibody specific for human TNF-α), all of which act by partly neutralising circulating and 
synovial TNF-α. TNF blockade is effective in reducing leukocyte trafficking to the joints, 
reducing fatigue and improving mood, and reducing pain. Importantly, anti-TNF therapy has 
been shown to reduce joint inflammation and slow radiographic progression of joint damage 
(Maini and Taylor 2000). Therapeutic blockade of TNF-α produces a clinical response in 
approximately 70% of patients with established RA, and is able to induce remission in a 
proportion of these patients (Quinn et al. 2005). 
 
RANKL is a TNF family member which has an important role in bone homeostasis. RANKL 
is expressed at high levels in skeletal tissues and in primary and secondary lymphoid tissues. 
RANKL is produced either as a transmembrane protein or in a soluble form which can be 
derived from proteolytic cleavage or alternative splicing. Binding of surface-bound or soluble 
RANKL to its membrane-bound receptor, RANK, is critical for the terminal differentiation of 
osteoclasts from myeloid lineage precursors. Osteoclasts degrade bone via expression of 
effector molecules such as cathepsins, MMPs and local production of hydrogen ions. RANKL 
signalling can be regulated by osteoprotegerin (OPG), a soluble decoy receptor which is 
produced by bone-forming osteoblasts. 
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High levels of RANKL expression have been described in the RA synovium (Crotti et al. 
2002; Gravallese et al. 2000; Takayanagi et al. 2000), and RANKL is expressed 
predominantly at the pannus-cartilage junction at sites of bone erosion (Pettit et al. 2006). 
Levels of soluble RANKL have also been reported to be elevated in the synovial fluid of RA 
patients (Skoumal et al. 2005; Ziolkowska et al. 2002). Cytokines present in the RA 
synovium such as TNF-α, IL-1β, IL-6 and IL-17 are capable of inducing RANKL expression 
by synovial fibroblasts, osteoblasts and bone marrow stromal cells (Gravallese et al. 2000; 
Hashizume et al. 2008; Kotake et al. 1999; Romas et al. 2002). In addition, RANKL is 
expressed by synovial T cells (Crotti et al. 2002). Anti-RANKL therapies have been shown to 
inhibit bone loss in post-menopausal women (Bone et al. 2008; Cohen et al. 2008; Kearns et 
al. 2008; McClung et al. 2006), and the fully human monoclonal antibody specific for 
RANKL, denosumab, is effective in suppressing erosive progression in RA (Cohen et al. 
2008). 
 
The observation that RANKL-deficient mice have a defect in the development of lymph 
nodes indicates that RANKL also has an important role in the immune system (Kong et al. 
1999b; Theill et al. 2002). An immunoregulatory role for RANKL has been suggested by the 
observation that RANKL is involved in the generation of Tregs in a model of diabetes (Green 
et al. 2002).  
 
BAFF and APRIL are TNF family members which regulate B cell maturation, differentiation 
and activation. BAFF is expressed by various cell types including monocytes, dendritic cells 
and bone marrow stromal cells. Several studies have suggested a role for BAFF in RA. BAFF 
is detected in the RA synovium in macrophages and synovial fibroblasts (Ohata et al. 2005). 
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In animal models of arthritis, silencing of BAFF ameliorates disease and suppresses Th17 cell 
generation (Lai Kwan Lam et al. 2008). In the human-synovium-SCID mouse model, 
disruption of BAFF-BAFF-receptor interaction with the TACI-Ig Fc fusion protein inhibits 
antibody production and cytokine production by B cells (Seyler et al. 2005). A fully 
humanised anti-BAFF antibody, belimumab, has demonstrated modest efficacy in clinical 
trials in RA.  
 
The B cell survival factor, APRIL, is produced predominantly by monocytes and 
macrophages. APRIL has also been implicated in RA, and is found to be highly expressed by 
dendritic cells in RA synovial membranes containing ectopic germinal centres (Seyler et al. 
2005). APRIL levels are elevated in RA synovial fluid and correlate with plasma cells in the 
synovium (Dong et al. 2009). APRIL-deficient mice have a reduced incidence of CIA with 
reduced antibody and IL-17 production (Xiao et al. 2008), whereas APRIL overexpression 
correlates with increased autoantibody production and induces pro-inflammatory production 
by RA synovial fibroblasts (Nagatani 2007). Heterodimeric complexes of BAFF and APRIL 
are found at elevated levels in the serum in RA, and correlate with synovial lymphoid 
architecture and disease severity (Seyler et al. 2005; Vallerskog et al. 2006). Atacicept, a 
fusion protein which prevents binding of both BAFF and APRIL to B cells, has been trialled 
in a phase II study in RA but did not produce significant improvement (van Vollenhoven et 
al. 2011). 
 
LT-α and LT-β are TNF family members which are involved in the development of secondary 
lymphoid organs and germinal centre organisation. LT-α may be secreted as a homotrimer, or 
form a membrane-bound heteromeric complex with LT-β. LT-α is secreted by Th1 cells, 
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whereas LT-β does not appear to function by itself. Cell-surface lymphotoxin heteromers are 
expressed by activated lymphocytes and a subset of resting B cells. The receptor LTβR is 
expressed mainly by non-haematopoietic and myeloid lineage cells. LT-α activates 
macrophages, inhibits B cells and is directly cytotoxic for some cells. The membrane-bound 
form of lymphotoxin can promote production of cytokines, chemokines and MMPs by 
synovial fibroblasts, including IL-1, IL-6, GM-CSF, CCL2, CCL5, MMP1 and MMP3 (Braun 
et al. 2004). The lymphotoxin pathway has been implicated in the development of tertiary 
lymphoid structures in chronically inflamed tissue associated with autoimmune diseases, 
including RA. LT-α and LT-β are found in the RA synovial tissues containing B cell follicles, 
and B cell expression of LT-β is associated with germinal centre formation (Takemura et al. 
2001a). LT-β expression in the RA synovium has also been found to correlate with the degree 
of inflammation (O'Rourke et al. 2008). Blockade of LTβR is beneficial in preventing disease 
in animal models of arthritis (Gommerman 2003, Han 2005), and treatment of mice with an 
LT-α-specific monoclonal antibody ameliorates disease (Chiang 2009). LTβR-Ig has been 
trialled in patients with RA, but failed to meet clinical end points in a Phase IIb clinical trial. 
 
1.4.8 Interferons 
Interferons are widely expressed cytokines with potent anti-viral and growth-inhibitory 
effects. There are three major classes of IFNs, designated type I, type II and type III. Within 
the family of type I IFNs, there are several members, all of which have considerable structural 
homology. The subtypes that exist in humans are IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω. 
IFN-α can be further subdivided into 13 different subtypes. The most highly expressed 
members of the type I IFN family are IFN-α and IFN-β. All type I IFNs bind a common cell-
surface receptor known as the type I IFN receptor. There is only one member of the type II 
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IFN family, IFN-γ. IFN-γ does not have marked structural homology with type I IFNs, and 
binds a different receptor, the type II IFN receptor. IFN-γ was originally classified in the IFN 
family because of its ability to “interfere” with viral infections, consistent with the original 
definition of interferons. The type III IFNs consist of IFN-λ1, IFN-λ2 and IFN-λ3, which are 
also called IL-29, IL-28A, and IL-28B, respectively. Type III IFNs exhibit several features 
common with type I IFNs including activation of the same signalling pathways and anti-viral, 
anti-proliferative and anti-tumour activities. They act through a receptor composed of an IFN-
γ-specific chain and an IL-10R2 chain. 
 
IFN-α and IFN-β are produced by many cell types in response to infection by viruses, and 
induce the transcription of several proteins that help to inhibit viral replication. IFN-α and 
IFN-β also activate NK cells which can kill virus-infected cells. IFN-α and IFN-β activate the 
adaptive immune response by inducing the expression of co-stimulatory molecules on 
macrophages and dendritic cells to enable them to act as antigen presenting cells. IFN-α and 
IFN-β also stimulate increased expression of MHC class I molecules on all cell types, thus 
promoting the killing of virus-infected cells by CD8 T cells. Almost all cell types can produce 
IFN-α and IFN-β if required, although plasmacytoid dendritic cells are capable of expressing 
particularly high levels. 
 
Evidence suggests that type I IFNs play a crucial role in RA. Gene expression profiling 
studies of RA patients have identified a type I IFN signature in a subset of patients (Thurlings 
et al. 2010; van der Pouw Kraan et al. 2007; Vosslamber et al. 2011). Circulating 
lymphocytes from patients with RA have been found to exhibit significantly reduced IFN-α 
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production after stimulation with virus compared to healthy controls (Seitz et al. 1987), and 
RA synoviocytes exposed to IFN-α exhibit increased expression of the anti-inflammatory 
molecules IL-1Ra and soluble TNF receptor (Wong et al. 2003). IFN-α therapy has been 
associated with de novo development of RA in the treatment of malignant melanoma and 
chronic HCV infection (Ionescu et al. 2008; Passos de Souza et al. 2001), but there have also 
been reports of the effectiveness of IFN-α in treating RA (Niewold and Gibofsky 2006; 
Shiozawa et al. 1992).  
 
There has been much interest in the role of IFN-β in RA. IFN-β is involved in suppression of 
the pro-inflammatory cytokines IL-1β and TNF-α, induction of the anti-inflammatory 
cytokines IL-1Ra, IL-10 and TGF-β (Coclet-Ninin et al. 1997; Palmer et al. 2004; van Holten 
et al. 2002; Yong et al. 1998), suppression of MHC Class II expression (Yong et al. 1998), 
inhibition of T cell activation (Noronha et al. 1993), and reduction of adhesion molecule 
expression (Calabresi et al. 1997). IFN-β has also been identified as a stromal cell-derived 
factor that is able to rescue T cells from apoptosis (Pilling et al. 1999). Studies performed in 
animal models of arthritis suggest a protective role for IFN-β in RA. In the collagen-induced 
and adjuvant-induced models of arthritis, administration of IFN-β resulted in reduced disease 
activity and suppressed cartilage and bone destruction, whereas IFN-β deficiency worsened 
disease (Adriaansen et al. 2006; Treschow et al. 2005; van Holten et al. 2004). Systemic 
administration of IFN-β has been trialled for the treatment of RA but did not show clinical 
benefit in a phase II study (van Holten et al. 2005). 
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IFN-γ is the main cytokine released by CD8 effector T cells, which can block viral replication 
by inducing MHC class I and class II expression in somatic cells, and activating NK cells. 
IFN-γ is also produced by Th1 cells, and has potent effects in activating macrophages. IFN-γ 
is detected at relatively low levels in RA synovial T cells (Firestein and Zvaifler 1987; Smeets 
et al. 1998a). In animal models of arthritis, IFN-γ has been reported to have both protective 
and pathogenic effects, which may be explained by its ability to both induce inflammation and 
also inhibit Th17 differentiation. In the CIA model of arthritis, disease is accelerated in IFN-γ-
deficient mice, indicating a protective role. (Cooper et al. 1988; Manoury-Schwartz et al. 
1997; Mauritz et al. 1988; Sarkar et al. 2009; Vermeire et al. 1997). In contrast, proteoglycan-
induced arthritis is dependent on IFN-γ, suggesting a pathogenic role (Doodes et al. 2008; 
Finnegan et al. 1999). 
 
1.4.9 Growth factors  
Growth factors are diverse group of proteins capable of stimulating cell growth, proliferation 
and differentiation. Growth factors can be grouped by structure or function into several 
families. 
 
Colony-stimulating factors were originally identified as growth and differentiation factors for 
haematopoietic precursor cells. Granulocyte/macrophage colony-stimulating factor (GM-
CSF), macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating 
factor (G-CSF) were initially defined by their abilities to generate colonies of mature myeloid 
cells from bone-marrow precursor cells - granulocytic and macrophage colonies in the case of 
GM-CSF, macrophage colonies in the case of M-CSF, and granulocytic colonies in the case 
of G-CSF. 
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M-CSF (CSF1) promotes the survival, proliferation and differentiation of 
monocytes/macrophages, and is also required for osteoclast differentiation. M-CSF can be 
expressed by fibroblasts, macrophages, bone marrow stromal cells and endothelial cells. M-
CSF is detected in RA synovial fluid, and is produced at high levels by synovial fibroblasts 
(Kawaji et al. 1995; Seitz et al. 1994; Williamson et al. 1989). M-CSF is also produced by 
endothelial cells from RA synovium and has been shown to stimulate osteoclastogenesis 
(Nakano et al. 2007). Administration of M-CSF exacerbates disease in murine models of 
arthritis (Abd et al. 1991; Bischof et al. 2000; Campbell et al. 2000), supporting a role in 
promoting disease and joint destruction. 
 
GM-CSF (CSF2) stimulates the growth of cells of the myelomonocytic lineage. GM-CSF is 
produced by a range of cell types including T cells, B cells, macrophages, mast cells, 
endothelial cells, fibroblasts and adipocytes. GM-CSF is detected in RA synovial fluid and is 
spontaneously produced by RA synovial cells (Bell et al. 1995; Haworth et al. 1991). 
Administration of GM-CSF exacerbates murine CIA, indicating a pathogenic effect (Bischof 
et al. 2000). A phase I study using a human monoclonal antibody targeting the GM-CSF 
receptor-alpha in RA has shown preliminary evidence of pharmacodynamic activity 
(Burmester et al. 2011). 
 
G-CSF (CSF3) stimulates the development and differentiation of neutrophils. G-CSF is 
mainly produced by monocytes and macrophages, and can also be secreted by other cell types 
including fibroblasts, endothelial cells and bone marrow stromal cells. G-CSF is used to treat 
neutropenia and mobilise hematopoietic stem cells for transplantation. G-CSF is present in 
RA synovial fluid (Nakamura et al. 2000; Williamson et al. 1989). IL-1 and TNF-α induce the 
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production of G-CSF by human synovial fibroblasts and chondrocytes in vitro (Campbell et 
al. 1991; Leizer et al. 1990). Administration of G-CSF exacerbates murine CIA (Campbell et 
al. 2000), and a passive transfer model of CIA in rats (`Miyahara et al. 1993) whereas G-CSF 
blockade in murine CIA reduces disease activity (Lawlor et al. 2004). Administration of r-Hu-
methionyl G-CSF to patients with RA in a trial for using haematopoietic stem cell 
mobilisation produced flare of RA in a proportion of patients (Snowden et al. 1998). Evidence 
thus suggests a pro-inflammatory role for G-CSF in RA. 
 
Macrophage migration inhibitor factor (MIF) regulates the activation of macrophages and 
lymphocytes. MIF is expressed by several cell types including T cells and macrophages. MIF 
has a pro-inflammatory effect mediated by its ability to induce macrophages to release a range 
of cytokines including TNF-α, IL-1, IL-6 and IL-8, and stimulate synovial fibroblast to 
produce phospholipase A2, cyclooxygenase-2, prostaglandin E2 and MMPs. Elevated levels of 
MIF have been reported in RA synovial fluid (Onodera et al. 1999), and MIF expression in 
the synovium has been localised to macrophages, endothelial cells, synovial fibroblasts and T 
cells (Leech et al. 1999; Onodera et al. 1999). MIF induces RA synovial fibroblasts to 
produce pro-inflammatory mediators and MMPs including IL-1, IL-6, COX2 and PGE2 
(Onodera 2000, Santos 2004). In murine models of arthritis, antagonism of MIF delayed onset 
and decreased frequency of CIA, and inhibited adjuvant-induced arthritis; conversely, 
adjuvant-induced arthritis severity was decreased in MIF-deficient mice (Leech et al. 2003; 
Mikulowska et al. 1997; Santos et al. 2001; Santos et al. 2008). Synovial MIF expression and 
polymorphisms in the MIF promoter have been reported to correlate with disease activity and 
increased risk of erosions in RA (Morand 2002, Baugh 2002, Radstake 2005). 
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Epidermal growth factor (EGF) is a pleiotropic cytokine with roles in cell proliferation, 
apoptosis, angiogenesis, invasion, and metastasis. EGF is a mitogen for fibroblasts, epithelial 
cells and endothelial cells. EGF stimulates expression of inflammatory mediators such as 
COX2 and PGE2, and is found at high levels in the synovial fluid of RA patients (Maruotti et 
al. 2006; Satoh et al. 2001). EGF has also been found to be constitutively produced by RA 
synovial fibroblasts (Bucala et al. 1991).  
 
The transforming growth factor-β (TGF-β) family includes a large number of structurally and 
functionally related growth factors which regulate many cellular functions including cell 
growth, adhesion, migration, differentiation and apoptosis. The first member of the family, 
TGF-β, was identified by its ability to induce or ‘transform’ the growth of cultured 
fibroblasts. Among the TGF-βs, six distinct isoforms with a variable degree of homology 
have been identified. Three closely related isoforms, TGF-β1, TGF-β2, and TGF-β3 are 
expressed in mammals. TGF-βs are secreted in an inactive form and are activated by 
proteolytic processing which releases them from a multiprotein complex. Recent studies have 
demonstrated a critical role for TGF-β in the regulation of immune responses due to its role in 
differentiation of Th17 cells and regulatory T cells. TGF-β also has an important role in 
cartilage matrix metabolism. Serum levels of TGF-β1 have been found to correlate with joint 
damage in RA (Mieliauskaite et al. 2009). 
 
The family of fibroblast growth factors (FGFs) are involved in many aspects of development, 
including the regulation of cell proliferation and differentiation, survival and migration. FGFs 
regulate developmental pathways from the early embryo stage through to angiogenesis and 
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wound repair in the adult. The mammalian FGF family comprises 18 structurally-related 
members which signal through four highly conserved receptors. One member of the FGF 
family, FGF-2 was originally identified based on its stimulatory activity on fibroblast 
proliferation, and has subsequently been found to be involved in numerous cellular functions 
in various cell types, including angiogenesis, cell proliferation and differentiation, wound 
healing and tissue remodelling. The relevance of these processes in the pathogenesis of RA 
has promoted interest in the role of FGF-2 in RA. FGF-2 is detected in RA synovial tissue and 
synovial fluid, and expression in the synovium has been localised to mast cells and vascular 
cells (Qu et al. 1995).  
 
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that induces 
proliferation and migration of endothelial cells to form new blood vessels. VEGF also 
increases vascular permeability and directly increases production of the pro-inflammatory 
cytokines TNF-α and IL-6. VEGF is found to be elevated in the serum and synovium of 
patients with RA and raised serum levels have been associated with disease activity (Lee et al. 
2001; Sone et al. 2001). Expression of VEGF in the RA synovium is associated with distinct 
vascular morphological patterns including the formation of new blood vessels (Fearon 2003). 
The hypoxic environment of the RA joint results in increased VEGF gene transcription 
through the binding of hypoxia-inducible transcription factors such as HIF-1 which is 
upregulated in the RA synovium (Hollander 2001). In the CIA model of arthritis, 
administration of an antibody specific for VEGF prevents disease (Choi et al. 2009b). 
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1.4.10 Chemokines 
Chemokines, or “chemotactic cytokines”, are small peptide molecules (8-12 kDa) which have 
the ability to regulate cell migration and are involved in multiple processes including 
lymphoid organ development, lymphocyte trafficking, angiogenesis and inflammation (Rot 
and von Andrian 2004). To date, approximately 50 chemokines have been discovered with 
shared sequence homology (Borish and Steinke 2003). Chemokines mediate their biological 
effects by binding to their own family of chemokine receptors which are G Protein Coupled 
Receptors (Murphy et al. 2000). Chemokines are often described as “promiscuous” due to 
their ability to bind to multiple receptors. 
 
Chemokines were originally named for their presumed function, but due to the large number 
of chemokines discovered, a systematic nomenclature system has been established. 
Chemokines are classified according to the spacing and positioning of the first two N-terminal 
cysteine residues in specific motif, and can be thus divided into four families (CC, CXC, XC 
and CX3C). Chemokines in the CC family have the first two N-terminal cysteine residues 
adjacent to each other. The CC family is the largest chemokine family, consisting of 28 
members, CCL1 through CCL28. The majority of CC chemokines have important roles in 
recruiting cells to sites of inflammation, including CCL2, CCL3, CCL5, CCL7, CCL8 and 
CCL13. 
 
The levels of several chemokines are increased in the synovium of RA patients. Chemokines 
are implicated in RA pathology primarily due to their ability to recruit and retain leukocytes 
in the joint. In addition, chemokines can stimulate the release of inflammatory cytokines and 
proteases by other cell types. For example, CCL2, CCL5 and CXCL12 induce synovial 
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fibroblasts to increase production of IL-6 and IL-8 (Nanki et al. 2001). CCL2 and CCL5 are 
also known to increase gelatinase and collagenase activities, and stimulate MMP3 and 
proteoglycan release by chondrocytes (Borzi et al. 2000; Garcia-Vicuna et al. 2004; Yuan et 
al. 2001). Chemokines can also enhance cell proliferation, thus contributing to synovial 
hyperplasia. CCL2 and CXCL12 are able to enhance proliferation of synovial fibroblasts 
(Garcia-Vicuna et al. 2004; Iwamoto et al. 2007). Several chemokines such as CXCL8 and 
CXCL1 have angiogenic properties. 
 
1.4.11 Adipokines 
Adipokines are a family of soluble mediators with metabolic activities which are now known 
to also have inflammatory properties. They are produced primarily by adipose tissue, but are 
also expressed by chondrocytes, synoviocytes and immune cells. Emerging evidence suggests 
that adipokines may promote and perpetuate inflammatory responses in RA. There are several 
adipokines, which include leptin, adiponectin, resistin, visfatin, ghrelin, chemerin, lipocalin 2, 
serum amyloid 3, vaspin and omentin. The roles of some of these family members and their 
potential involvement in RA, are discussed here. 
 
The first adipokine to be cloned was leptin, a protein belonging to the class I cytokine 
superfamily. Leptin decreases food intake and increases energy consumption, and also acts as 
a pro-inflammatory cytokine which induces T cell activation and promotes Th1 
differentiation. Leptin also has anabolic effects, such as stimulating the expression of cartilage 
growth factors and increasing proteoglycan synthesis (Loeser 2003). Adipocyte-derived leptin 
is associated with maintaining a balance between Th1 cells and Tregs (Matarese et al. 2010). 
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Several studies have reported a strong correlation between the risk of an aggressive disease 
course of RA and leptin levels (Lee et al. 2007; Targonska-Stepniak et al. 2010; Targonska-
Stepniak et al. 2008). Leptin levels are elevated in patients with RA, and serum levels and 
synovial fluid:serum ratio of serum are correlated with disease duration and activity (Olama et 
al. 2010). However, it has also been reported that leptin levels correlate inversely with 
radiographic joint damage, and conflicting results concerning the effect of leptin on joint 
damage have been reported in experimental models of arthritis (Rho et al. 2009). Leptin has a 
pro-inflammatory activity in chondrocytes (Otero et al. 2003; Otero et al. 2007; Otero et al. 
2005) and synovial fibroblasts (Kitahara et al. 2009; Tong et al. 2008), and can also induce 
anergy in Tregs (Notley and Ehrenstein 2010). 
 
Adiponectin has structural homology with collagens VIII and X and complement factor C1q. 
It increases fatty acid oxidation and reduces glucose synthesis in the liver. Adiponectin has 
been reported to have both pro-inflammatory and anti-inflammatory properties. High levels of 
adiponectin have been reported in RA which correlate with disease severity (Ebina et al. 
2009). Adiponectin induces the production of pro-inflammatory cytokines and MMPs in 
synovial fibroblasts which may contribute to joint destruction in RA, and also recruits 
inflammatory cells to the synovium (Choi et al. 2009a; Frommer et al. 2010; Tang et al. 
2007). 
 
Resistin is a dimeric protein, so named for its apparent induction of insulin resistance in mice. 
It has been found in adipocytes and macrophages, and induces production of IL-6 and TNF-α 
(Bokarewa et al. 2005). Resistin levels are elevated in the serum of patients with RA, and 
levels have been found to correlate with inflammation and joint destruction  (Forsblad d'Elia 
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et al. 2008). Resistin is also detected in the RA synovium, being expressed by macrophages, 
B cells and plasma cells (Senolt et al. 2007). Resistin levels in RA synovial fluid are higher 
than in osteoarthritis and correlate with CRP levels and Disease Activity Score for 28 joints 
(DAS28) (Gonzalez-Gay et al. 2008). 
 
Visfatin is an insulin-mimetic adipokine which was originally described as a growth factor for 
B lymphocyte precursors (hence its alternative name, pre-B-colony enhancing factor). 
Visfatin has pro-inflammatory properties such as inducing the production of IL-1β, TNF-α 
and IL-6 by monocytes (Moschen et al. 2007). Levels of visfatin are elevated in the serum 
and synovial fluid of RA patients, and correlate with inflammation, clinical disease  activity, 
rheumatoid factor levels and radiographic joint damage (Otero et al. 2006; Rho et al. 2009). 
Visfatin is expressed in RA synovial fibroblasts, and high levels are found in the synovial 
lining layer and at the site of cartilage destruction. It promotes the expression of pro-
inflammatory cytokines and MMPs by RA synovial fibroblasts, and also induces pro-
inflammatory cytokine production by monocytes (Brentano et al. 2007). 
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1.5 Objectives 
Cytokines are directly implicated in many processes involved in RA pathogenesis. Multiple 
inflammatory cell populations infiltrating the RA synovium contribute to the local cytokine 
environment. There remains a need for systematic characterisation of cytokine expression by 
each of the major cell populations present in the rheumatoid joint. An important objective of 
this work was therefore to determine the cellular sources of cytokines in separated populations 
of the synovial fluid and peripheral blood of patients with RA.  
 
When a patient first presents with an inflammatory arthritis, it is often difficult to distinguish 
patients destined to develop RA from those with a self-limiting synovitis. Differences 
between early synovitis patients with divergent outcomes may be reflected at the level of 
synovial cytokine gene expression, as indicated by a previous study which found a differences 
in cytokine protein expression patterns in the synovial fluid of patients with early synovitis 
(with a symptom duration up to 3 months) who subsequently developed RA, compared to 
early resolving synovitis patients and established RA patients (Raza et al., 2005). The present 
study set out to explore the mRNA expression of a wide range of cytokines, chemokines and 
growth factors in synovial tissue from early synovitis patients with divergent clinical 
outcomes (resolving synovitis and persistent RA) and patients with established RA. In 
addition, I sought to investigate mRNA cytokine expression by individual synovial fluid cell 
populations in early synovitis patients with diverging clinical outcomes and at different stages 
of RA. Finally, I aimed to follow up novel observations made in mRNA profiling studies by 
characterising expression on the protein level in synovial fluid and synovial tissue. 
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2 METHODS 
2.1 Patient selection and sample collection 
2.1.1 Samples from early arthritis and established RA patients 
All studies involving patients and controls were approved by the Solihull Local Research 
Ethics Committee. All participating patients gave informed, written consent before samples 
were taken. Samples were obtained from patients seen by consultant rheumatologists, Dr 
Karim Raza or Dr Andrew Filer. Samples (blood, synovial fluid and synovial tissue) were 
obtained from patients presenting with early synovitis or with established RA. RA was 
diagnosed using the 1987 ACR  criteria (Arnett et al. 1988). Patients with early synovitis 
were selected on the basis of having at least one swollen joint and symptoms (inflammatory 
joint pain and/or early morning stiffness and/or joint related soft tissue swelling) for ≤3 
months. Early synovitis patients were followed for 18 months then diagnosed as having RA, 
non-RA persistent synovitis or self-limiting synovitis. RA was diagnosed using the 1987 ACR 
criteria; non-RA persistent synovitis was diagnosed if the patient showed clinical evidence of 
persistent joint swelling (or had been established on a DMARD) but did not satisfy the 1987 
ACR criteria for RA; self-limiting synovitis was diagnosed if clinically apparent joint 
swelling was not clinically apparent at the 18-month assessment and the patient had not 
received glucocorticoid or DMARD treatment within the previous 3 months. At initial 
assessment, the disease activity score in 28 joints (DAS28) was calculated, and blood samples 
were analysed for CRP, erythrocyte sedimentation rate (ESR), rheumatoid factor and anti-
CCP antibody.  
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For comparison, peripheral blood samples were obtained from age and sex-matched healthy 
control individuals, and synovial biopsies were obtained from patients undergoing surgery 
following joint trauma who had no previous history of inflammatory disease. 
 
Synovial fluid was aspirated from joints under palpation or ultrasound guidance. Paired 
peripheral blood was collected in heparinised tubes. Synovial tissue biopsies were collected 
by needle arthroscopy under ultrasound guidance. To minimise sampling error, eight biopsy 
samples were obtained from the different sites in the joint. Specimens were directly embedded 
in TissueTek OCT and snap-frozen in liquid nitrogen. From each frozen tissue block, sections 
of 20 μm thickness were cut for real-time PCR analysis. Serial sections of 5μm thickness were 
cut for immunofluorescence staining. Sections were stored at -80°C. 
 
2.1.2 Samples from rituximab-treated patients 
Synovial tissue samples from patients treated with rituximab were obtained from the 
Academic Medical Center, Amsterdam, The Netherlands.  The study was approved by the 
Medical Ethics Committee of the Academic Medical Centre/University of Amsterdam and all 
patients gave written informed consent before participation. All patients enrolled in the study 
had active RA. RA was diagnosed according to the 1987 ACR classification criteria for RA, 
and active disease was defined as having ≥4 tender joints and ≥4 swollen joints of 28 joints 
assessed, and at least one of the following: ESR ≥28 mm/h, serum CRP levels ≥15 mg/l or 
morning stiffness ≥45 minutes. All patients were treated with two intravenous infusions of 
1,000 mg rituximab on days 1 and 15 after premedication with 2 mg clemastine fumarate 
intravenously and 1000 mg acetaminophen orally. The DAS28 was measured before and 
every month after treatment. Serum and synovial tissue were obtained at three time points: 
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before treatment, and 4 and 16 weeks after the first infusion of rituximab. Synovial biopsies 
were collected by needle arthroscopy from the same inflamed joint at each time point. To 
minimise sampling error, at least six biopsy samples were obtained from the different sites in 
the joint. Specimens were directly embedded in TissueTek OCT (Miles Diagnosis, USA) and 
snap-frozen in liquid nitrogen. From each frozen tissue block, serial sections of 5μm thickness 
were cut. Sections were stored at -80°C. 
 
2.2 Isolation of cells from synovial fluid and peripheral blood 
2.2.1 Isolation of mononuclear cells  
Synovial fluid was incubated with 10µl/ml hyaluronidase (1000 U/ml, endotoxin tested, 
formulated for injection) at 37°C for 15 mins to reduce viscosity. Peripheral blood was 
collected in a heparinised tube. Blood was diluted with an equal volume of RPMI. Synovial 
fluid and peripheral blood were layered onto Ficoll-Paque in a 3:1 ratio and centrifuged at 300 
g for 30 minutes at 22°C with no brake. The mononuclear cell population at the Ficoll-Paque 
interface was removed using a plastic Pasteur pipette and transferred to a fresh tube. Cells 
were suspended in 20 ml RPMI, centrifuged at 300 g for 8 mins, then the supernatant was 
removed and the cell pellet was resuspended by gently flicking the tube. Cells were washed 
twice more in 20 ml RPMI, then resuspended in freezing medium containing HIFCS 
supplemented with 10% dimethyl sulphoxide (DMSO) which was pre-warmed to 37°C. Cells 
were frozen at -80°C in a freezing container with isopropranol. 
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2.2.2 Isolation of neutrophils  
Neutrophils were isolated using magnetic anti-CD15 microbeads (Miltenyi Biotech). Whole 
blood was incubated with 50 µl/ml anti-CD15 microbeads for 15 mins at 4˚C, then washed 
with 5 ml MACS buffer (phospho-buffered saline (PBS, Sigma) supplemented with 0.5 % 
bovine serum albumin (BSA, Sigma) and 20 mM ethylenediamine tetra-acetic acid (EDTA, 
Sigma) per ml of blood. Cells were centrifuged at 445 g for 10 mins with no brake. The 
supernatant was aspirated leaving 1-2 mm above the cell pellet. The cell pellet was 
resuspended in a total volume of 1 ml with MACS buffer. The labelled cells were then applied 
to a MACS column, which had been primed by adding 3 x 3 ml MACS buffer in the presence 
of a strong magnetic field. Unlabelled cells were washed through the column with 10 x 3 ml 
cold MACS buffer. The column was then removed from the magnetic field and the 
magnetically-labelled cells were eluted by adding 5 ml of Elution Buffer (Miltenyi Biotech) 
and immediately flushing cells through with a plunger. Collected cells were washed twice by 
resuspending in 20 ml PBS supplemented with 0.5% BSA and centrifuging at 300 g for 6 min. 
To determine the purity of the separated cell population, a sample of the cells was stained by 
resuspending the cell pellet in FITC-labelled anti-CD15 antibody diluted in freshly-prepared 
PBS supplemented with 0.5% BSA at 1 ml/108 cells. Cells were incubated on ice in the dark 
for 20 min. Cells were then washed twice by resuspending in 100 μl PBS supplemented with 
0.5% BSA and centrifuging at 300 g for 4 minutes. A sample of the isolated cells was used to 
assess purity. Cells were labelled with mouse anti-CD15 FITC (BD Pharmingen, 1:40 
dilution) or mouse IgM FITC (Immunotools) using the staining protocol described. The 
percentage of cells labelled with anti-CD15 was measured by flow cytometry.  
 
67 
 
2.2.3 FACS sorting of mononuclear cell populations 
Staining was carried out in a flexible 96-well plate coated with heat-inactivated foetal calf 
serum (HIFCS, Sigma) on ice. Freshly-prepared PBS supplemented with 0.5% BSA was used 
as antibody diluent and wash solution. 100 μl wash solution was used for each wash and 
centrifugation was performed at 300 g for 4 minutes at 4°C. Wash solution was removed by 
inversion of the plate. Antibodies used to stain cells are shown in Table 2.1 Cells were 
incubated with antibody on ice for 20 min in the dark. Following staining, cells were washed 
and re-suspended in 500μl wash solution, filtered using 50µm filters and transferred to FACS 
tubes. Cells were sorted by FACS using a MoFlo TM high speed cell sorter (Dako, Ely, UK). 
 
Cells stained with isotype control antibodies were used to determine the level of background 
non-specific binding. Compensation was performed using cells stained with each 
fluorochrome conjugated-antibody individually. Debris and dead cells were excluded from 
analysis by gating on forward and side scatter. Doublets were excluded by gating on the 
forward scatter versus pulse width.  
 
The purity of each sorted cell population was determined by measuring the percentage of cells 
in the sample that were labelled with the antibody specific for the population by flow 
cytometry. For this purpose the forward scatter/side scatter region examined was enlarged to 
include all live cells. 
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Antibody  Dilution Supplier 
CD4 APC 1:40 eBioscience 
CD8 PE Cy7 1:100 eBioscience 
CD45RO FITC 1:40 Biostat 
CD14 FITC 1:50 Immunotools 
CD19 PE  1:40 Immunotools 
IgG2a APC * Immunotools 
IgG1 PECy7 * Immunotools 
IgG1 PE * Immunotools 
IgG1 FITC * Immunotools 
Table 2.1 Antibodies used for sorting mononuclear cell populations by FACS. All 
antibodies were mouse monoclonal antibodies raised against human antigens. 
 
2.3 RNA extraction 
2.3.1 RNA extraction from isolated cell populations  
RNA was extracted from synovial fluid and peripheral blood mononuclear cell populations 
and neutrophils using the Nucleospin XS kit (Macherey-Nagel). In this method, cells are 
lysed by incubation in a solution containing high concentrations of chaotropic ions which 
immediately inactivates RNases which would otherwise degrade RNA. Ethanol is added to 
create appropriate binding conditions, then RNA is adsorbed to a silica membrane. 
Contaminating DNA, which is also bound to the silica membrane, is removed by applying 
rDNAse solution to the membrane within a column. The membrane is then washed with two 
different buffers to remove salts, metabolites and macromolecular cellular components. Pure 
RNA is eluted under low ionic strength conditions with water. RNA extraction was performed 
according to manufacturer’s instructions as follows. Cells were centrifuged at 4000 g for 5 
min. The cell pellet was resuspended in 100 µl Lysis Buffer RA1 + 2 µl TCEP. Cells were 
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vortexed twice for 10 sec then frozen at -80˚C. Cells were defrosted at room temperature. 5 µl 
of 20 ng carrier RNA was added to lysate. 100 µl of 70% ethanol was added to the lysate and 
mixed well by pipetting. The sample was applied to a Nucleospin column placed in a 
collection tube and centrifuged for 30 sec at 11000 g to bind the sample to the column. The 
column was placed in a new collection tube. 100 µl of Membrane Desalting Buffer was added 
to the column and centrifuged for 30 sec at 11000 g.  A DNase reaction mixture was prepared 
with 3 µl rDNAse and 27 µl DNAse reaction buffer, then 25 µl of the mixture was added to 
the column and incubated for 15 min at room temperature. 100 µl of Buffer RA2 was added to 
the column and incubated for 2 min at room temperature, then centrifuged for 30 sec at 11000 
g. The column was placed in a new collection tube. The column was washed by adding 400 µl 
of Buffer RA3 then centrifuging for 30 sec at 11000 g. A further 200 µl of Buffer RA3 was 
added, then the sample was centrifuged for 2 min at 11000 g. Finally, RNA was eluted by 
adding 10 µl of RNase-free water to the column and centrifuging for 30 sec at 11000 g.     
 
2.3.2 RNA extraction from synovial tissue 
RNA was extracted from 20 µm synovial tissue sections using an RNeasy kit (Qiagen). In this 
method, cells are lysed in a buffer containing guanidine isothiocyanate which immediately 
inactivates RNases. Ethanol is added to provide appropriate binding conditions, then the 
sample is applied to a column where it binds to a silica membrane. Contaminants are washed 
away using two wash buffers. Finally RNA is eluted in water. RNA extraction was performed 
according to manufacturer’s instructions as follows. Cells were lysed by adding 350 µl Buffer 
RLT, vortexing for 1 min, then freezing at -80˚C. Cells were defrosted at room temperature 
and 350 µl of 70% ethanol was added. The sample was applied to a column and centrifuged 
for 15 sec at 13000 g to bind the sample to the column. The flow-through was discarded. 700 
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µl of Buffer RW1 was added to the column, the sample was centrifuged for 15 sec at 13000 g, 
and the flow-through discarded. 500 µl of Buffer RPE was added to the column and the 
sample was centrifuged for 15 sec at 13000 g. The flow-through was discarded. A further 500 
µl of Buffer RPE was added and the sample was centrifuged for 2 mins at 13000 g. The 
column was transferred to a new collection tube. Finally, 30 µl RNase-free water was added 
to the column, and the sample was centrifuged for 1 min at 13000 g to elute the RNA.  
 
RNA was also isolated from a second synovial tissue sample from each patient using a 
procedure which included DNA digestion. Contaminating DNA was removed using a DNase 
kit (Qiagen) in conjunction with an RNeasy RNA extraction kit (Qiagen), according to the 
manufacturer’s instructions. Cells were lysed by adding 350 µl Buffer RLT, vortexed for 1 
min, then frozen at -80˚C. Cells were defrosted at room temperature and 350 µl 70% ethanol 
was added. The sample was applied to a column and centrifuged for 15 sec at 13000 g to bind 
the sample to the column. The flow-through was discarded. 350 µl of RW1 was added to the 
column, the column was centrifuged for 15 sec at 13000 g, and flow-through was discarded. 
10 µl DNAse I stock solution was added to 70 µl of Buffer RDD and mixed by gentle 
inversion. The DNase I mix was added to the membrane and incubated at room temperature 
for 15 min. 350 µl of Buffer RW1 was added, the sample was centrifuged for 15 sec and the 
flow-through discarded. 500 µl of Buffer RPE was added to the column and the sample was 
centrifuged for 15 sec at 13000 g. The flow-through was discarded. A further 500 µl of Buffer 
RPE was added and the sample was centrifuged for 2 mins at 13000 g. The column was 
transferred to a new collection tube. Finally, 30 µl RNase-free water was added to the column, 
and the sample was centrifuged for 1 min at 13000 g to elute the RNA.  
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2.4 Microfluidic cards 
2.4.1 Microfluidic card design 
Microfluidic cards containing 384 real-time PCR assays were custom ordered from Applied 
Biosystems. Each assay contained gene-specific primers, probes and a reaction buffer for 
reverse transcription and real-time PCR. RNA samples from cell populations isolated from 
synovial fluid and peripheral blood were analysed using a microfluidic card containing 48 
real-time PCR assays per sample (listed in Appendix 8.1). 
 
Synovial tissue samples were analysed using the following microfluidic cards:  
i) Two sets of microfluidic cards, each containing 96 real-time PCR assays per sample 
(listed in Appendix 8.2), were used to analyse RNA from synovial tissue extracted 
without DNase treatment. One-third of the total RNA isolated from each synovial 
tissue section was used per 96 genes analysed.  
ii) A microfluidic card containing 48 assays which detect genomic DNA and assays for 
genes that were weakly expressed (listed in Appendix 8.3) was used to analyse RNA 
from synovial tissue was treated with DNase. The total RNA isolated from each 
synovial tissue section was used per 48 genes analysed 
 
The microfluidic card designed to include the assays listed in 8.3 was designed in order to 
address two issues: 
i) For some genes, the real-time PCR assays contained primers which were designed 
within a single exon and thus by definition would detect genomic DNA. Some real-
time PCR assays were described as assays that may detect genomic DNA. Therefore 
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RNA which was treated with DNase to remove contaminating genomic DNA was used 
to detect expression of these genes. 
ii) Several cytokines were expressed at low levels in synovial tissue. Therefore RNA 
obtained from a whole synovial tissue section rather than one-third of the section was 
used to detect expression of these genes. 
 
2.4.2 Reverse transcription and real-time PCR 
Reverse transcription and real-time PCR was performed using a Quantitect Probe RT-PCR kit 
(Qiagen). A reaction mix was made with 90 µl of RNA, 50 µl of Quantitect-RT Master Mix 
and 1 µl of QuantiTect Reverse Transcriptase Mix. 95 µl of the sample was loaded into each 
port of the microfluidic card. The microfluidic card was centrifuged twice at 300 g for 1 min 
in a vertical centrifuge, then the plate was sealed and the loading ports were cut off. The card 
was placed in an Applied Biosystems 7900 PCR machine. The cycling program used for 
reverse transcription and real-time PCR was 50˚C for 30 min, 94.5˚C for 15 sec then 40 
cycles of 96˚C for 30 sec and 59.7˚C for 1 min.  
 
Gene expression was analysed by setting the baseline and threshold values on the 
amplification plot for each gene. The threshold cycle (Ct) value was then used to calculate the 
fold change in expression of each gene relative to the housekeeping gene by using the 2-∆∆Ct 
method, and the relative quantification was plotted. In the synovial fluid and peripheral blood 
study, expression was normalised to 18S. In the synovial tissue study, expression was 
normalised to GAPDH. For real-time PCR, a program of 40 cycles was used. Genes which 
had a Ct value > 40 were below the level of detection of the assay and were and assigned an 
RQ value of zero.  
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2.5 Flow cytometry 
Cells were stained as described earlier for FACS in 2.2.4. Antibodies used are shown in Table 
2.2. Flow cytometry was performed using a Dako Cyan ADP High Performance flow 
cytometer (Dako, Ely, UK). Flow cytometry data were analysed using SUMMIT software 
(Dako). 
 
Antibody  Dilution Supplier 
CD19 Pacific Blue  1:100 Biolegend 
CD27 APC  1:100 BD Pharmingen 
IgD FITC 1:100 BD Pharmingen 
RANKL PE 1:500 eBioscience 
IgG1 Pacific Blue  * Biolegend 
IgG1 APC  * Immunotools 
IgG2a FITC * Immunotools 
IgG2b PE * eBioscience 
Table 2.2 Antibodies used for flow cytometry. All antibodies were mouse monoclonal 
antibodies raised against human antigens. 
 
2.6 Confocal microscopy 
Antibodies were incubated at room temperature in the dark on a shaking tablet. Sections were 
firstly adsorbed with PBS supplemented with 10% fetal calf serum for 10 mins. Primary 
antibodies were incubated overnight at 4˚C in PBS supplemented with 10% fetal calf serum, 
then washed for 5 mins in PBS. Secondary antibodies were incubated for 45 mins respectively 
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at room temperature. Sections were immersed in Hoechst 33258 (Sigma) for 2 mins for 
nuclear staining, then mounted and kept in the dark at -20˚C. 
Antibodies used are shown in Table 2.3. CD19 was developed with goat Alexa 488 anti-
FITC, CD22 was developed with goat-anti mouse FITC and goat Alexa 488 anti-FITC, and 
RANKL was developed with donkey anti-rabbit rhodamine. A Zeiss confocal LSM 510 
microscope (Zeiss) was used to visualise staining of synovial tissue stained for RANKL and 
CD19. Images were captured and processed using Zeiss LSM Image Examiner software 
(Zeiss). Synovial tissue sections from the rituximab study were visualised using a Zen 
confocal microscope (Zeiss). Images were captured and analysed using Zen software (Zeiss). 
 
Antibody Dilution Supplier 
Primary antibodies 
Rabbit anti-human RANKL 
Mouse anti-human CD19 FITC 
Mouse anti-human CD22 
Mouse IgG1 
Mouse IgG2b 
Rabbit Ig 
 
 
1:50 
1:50 
1:500 
* 
* 
* 
 
AbCam 
Dako 
UoB 
Southern Biotech 
Southern Biotech 
Sigma 
Secondary/Tertiary antibodies 
Goat AlexaFluor 488-anti FITC 
Donkey anti-rabbit rhodamine 
Goat anti-mouse FITC 
 
1:100 
1:50 
1:250 
 
Invitrogen 
Jackson ImmunoResearch 
Jackson ImmunoResearch 
Table 2.3 Antibodies used for confocal staining 
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3 CYTOKINE PRODUCTION BY SYNOVIAL FLUID 
CELL POPULATIONS  
3.1 Introduction 
Cytokines are recognised as important factors in the pathogenesis of RA. Many cytokines are 
present in the synovium, and murine and rodent models of arthritis have demonstrated the 
effectiveness of cytokine modulation in altering disease outcome. Furthermore, the use of 
anti-TNF therapy as a treatment for RA has provided proof of principle that cytokine targeting 
is an acceptable and effective therapeutic strategy. This highlights the importance of 
investigating the role of cytokines in RA in order to further our understanding of disease 
pathogenesis and identify new targets for therapy. In RA, the joint is infiltrated by multiple 
inflammatory cell populations including T cells, B cells, macrophages and neutrophils, all of 
which contribute to the local cytokine network. Elucidating the cytokine network in RA 
represents an important challenge for furthering our understanding of disease pathogenesis. 
The first step towards achieving this goal is to determine the cellular sources of the cytokines 
found in the rheumatoid joint.  
 
Early studies of cytokine expression by T cells indicated that synovial T cells produce low 
levels of IL-2 and IFN-γ (Combe et al., 1985; Firestein et al., 1988; Smeets et al., 1998).  
More recently, IL-17-producing T cells have been reported in the RA synovium, where they 
are thought to promote inflammation by activating local stromal cells (Chabaud et al. 1999; 
Kotake et al. 1999). Furthermore, RA synovial T cells are reported to produce pro-
inflammatory cytokines including TNF-α and IL-6 (Chu et al. 1991; Field et al. 1991). They 
are also known to produce BAFF and APRIL, LT-α/LT-β and RANKL (Crotti et al. 2002; 
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Takemura et al. 2001a). Until recently, cytokine production by B cells in RA has remained 
relatively unstudied. It is known that B cells are capable of producing several cytokines which 
are relevant to RA pathogenesis including IL-1, TNF-α, IL-15 and IL-6, indicating a direct 
pro-inflammatory role. Production of LT-β by synovial B cells is thought to be required for 
synovial lymphoid neogenesis (Weyand et al. 2005). 
 
Macrophages are regarded as an important source of pro-inflammatory cytokines found in the 
RA synovium such as TNF-α, IL-1 and IL-18 (Chu et al. 1991; Tanaka et al. 2001; Wood et 
al. 1992). Through expression of IL-7, IFN-β, IL-23, BAFF and APRIL, they are thought to 
play a role in synovial T cell and B cell differentiation and survival (Gabay et al. 2009; Seyler 
et al. 2005; Stamp et al. 2009; van Holten et al. 2005; van Roon et al. 2007). Neutrophils 
represent the largest cell population in RA synovial fluid and are known to produce a range of 
cytokines including IL-1β, BAFF, APRIL and TGF-β (Assi et al. 2007; Beaulieu and McColl 
1994; Gabay et al. 2009; Quayle et al. 1994). They are also sources of chemokines such as 
CCL3 and CXCL8 (Beaulieu and McColl 1994; Hatano et al. 1999).  
 
Our present knowledge of cytokine sources within the RA joint is largely based on studies 
which have determined cytokine expression in a limited number of cell populations. Many in 
vitro and in vivo models have demonstrated the effect of cytokine modulation on various cell 
types, but not the cellular source of the cytokine itself. Thus for many cytokines it is assumed 
that the cellular sources reported in physiological conditions or in vitro studies are the same as 
in the RA joint. To date, no study has systematically determined cytokine production by each 
of the major synovial cell populations simultaneously. The aim of the present study was 
therefore to identify the predominant cellular sources of cytokines in RA by comparing 
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expression across the five cell populations in RA synovial fluid and peripheral blood. To 
achieve this we developed a new approach which has the advantage of characterising cytokine 
mRNA profiles in cells directly ex vivo without culture or prior stimulation in order to reflect 
the in vivo situation as closely as possible.  
 
3.2 Method development and validation 
We developed a novel technical approach to determine the mRNA expression of 41 cytokines 
in T cells, B cells, macrophages and neutrophils isolated from a single sample of synovial 
fluid or peripheral blood from RA patients. In each of the isolated cell populations, the 
cytokine mRNA expression profile was determined by real-time PCR using microfluidic 
cards. In a series of validation experiments we excluded bias due to sample preparation, 
normalisation and staining techniques. The results of these preliminary experiments 
confirmed the robustness of the experimental approach taken. 
 
CD4 T cells, CD8 T cells, B cells and macrophages were sorted by FACS based on their 
expression of CD4/CD3/CD45R0, CD8/CD3/CD45R0, CD19 and CD14, respectively (Figure 
3.1A and B). Neutrophils were isolated with CD15-coated magnetic beads (Figure 3.1C). 
Samples were reanalysed after sorting by flow cytometry and only samples with a purity of 
≥95% were included in the study (Figure 3.1D).  
 
In some instances, only a small volume of synovial fluid containing a low number of cells can 
be aspirated from the joint. Therefore it was important to establish the minimum number of 
cells needed for the detection of cytokine gene expression using microfluidic card real-time 
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PCR assays. mRNA expression from samples containing 1x103, 1x104 or 1x105 cells were 
directly compared in three independent experiments (Figure 3.2A). A close correlation was 
observed between results yielded by detection of 43 cytokine genes in 1x104 and 1x105 cells, 
whereas comparison of the results from 1x103 genes and 1x105 cells showed a large degree of 
variation. This confirmed that using a minimum cell number of 1x104 would be sufficient for 
the sensitivity of the real-time PCR microfluidic card assay.  
 
We also sought to determine if an anti-CD3 antibody could be used as a specific marker to 
sort T cells without inducing cytokine gene expression under the experimental conditions 
used. The cytokine gene expression for mononuclear cells sorted on the basis of CD3 and 
CD4 expression was compared with T cells sorted on the basis of CD4 expression and lack of 
expression of the myeloid cell markers CD11c and CD11b (Figure 3.2B). Under controlled 
experimental conditions,  keeping the cells below 4°C, T cells sorted using anti-CD3 antibody 
did not have an altered expression profile compared to T cells sorted using alternative 
markers, showing that under these conditions there is no induction of cytokine gene 
expression by the anti-CD3 antibody.  
 
Due to the limited availability of the cell sorter, we determined whether mononuclear cells 
and neutrophils could be stored in freezing medium before sorting. As shown in Figure 3.2C, 
the cytokine mRNA expression was not altered by storing synovial fluid mononuclear cells in 
HIFCS supplemented with 10% DMSO at -80°C, compared to using freshly isolated cells. In 
the case of neutrophils, the majority of genes expressed by freshly isolated neutrophils were 
not detectable in neutrophils that had been stored in freezing medium (Figure 3.2C). 
Therefore throughout the study, mononuclear cells were stored in freezing medium prior to 
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sorting, whereas neutrophils were isolated immediately after samples were received. mRNA 
from peripheral blood mononuclear cells stimulated with magnetic beads coated with anti-
CD3 and anti-CD28 antibody was used as a positive control to test the real-time PCR assays. 
With the exception of G-CSF, CCL11 and CXCL12, expression of all cytokine genes was 
detected (Figure 3.2D).  
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Figure 3.1 Isolation of mononuclear cell populations from synovial fluid and peripheral 
blood. (A, B) CD4 and CD8 T cells, B cells and monocytes were sorted based on their 
expression of CD4/CD3/CD45RO, CD4/CD3/CD45RO, CD19 and CD14 respectively. Purity 
of each sorted cell sample is indicated. (C) Neutrophils were isolated using CD15-coated 
magnetic beads. Percentages indicate purity of isolated populations as determined by flow 
cytometry. (D) Purity of all isolated population after isolation. Samples with more than 5% 
contaminating cells were rejected. 
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Figure 3.2 Method validation. (A) Comparison of cytokine mRNA expression from samples 
containing 103, 104 and 105  cells in order to establish the cell number needed for detection of 
cytokine expression. (B) Comparison of cytokine mRNA expression of cells stored in 
freezing medium at -80°C and freshly isolated cells. Gene expression is shown for synovial 
fluid mononuclear cells (left) and neutrophils (right). (C) Comparison of cytokine mRNA 
expression of mononuclear cells sorted on the basis of CD3 and CD4 expression compared to 
T cells sorted on the basis of CD4 expression and lack of expression of myeloid cell markers 
CD11c and CD11b. (D) Cytokine expression in PBMC stimulated with anti-CD3/anti-CD28-
coated beads used as a positive control for the real-time PCR assays. 
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3.3 Cytokine expression in synovial fluid cell populations 
Having established and validated the methods to be used in the study, we set out to determine 
cellular cytokine sources in RA synovial fluid and peripheral blood. Synovial fluid and 
peripheral blood were obtained from 12 patients with established RA. Clinical details of 
patients are shown in Appendix Table 8.4. CD4 T cells, CD8 T cells, B cells, macrophages 
and neutrophils were isolated from synovial fluid and peripheral blood as described 
previously. In each population mRNA expression of the following cytokines was determined 
by real-time PCR: IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12p35, IL-
12p40, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22, IL23p19, IL-27, TNF-α, LT-β, RANKL, 
APRIL, BAFF, TGF-b1, CCL2, CCL3, CCL4, CCL5, CCL11, CXCL8, CXCL12, MIF, IFN-
γ, IFN-α1, IFN-β1, CSF-2, CSF-3, EGF, FGF2 and VEGF-α. Levels of expression were 
quantified relative to 18S. mRNA expression was not detected for IL-4, IL-5, IL-13, IL-22, 
CCL11, CXCL12, CSF-3 or EGF. The complete set of data showing cytokine expression by 
all five cell populations in peripheral blood and synovial fluid of RA patients is shown in 
Appendix 8.3.5.  
 
Cytokines expressed predominantly by synovial fluid lymphocytes are shown in Figure 3.3. In 
synovial fluid T cells we detected the expression of IFN-γ and IL-2 mRNA. In the CD4 T cell 
population we observed mRNA expression of the Th17 cell-related cytokines, IL-17 and IL-
21. The CD4 T cell population also expressed high levels of mRNA for the neutrophil and 
macrophage survival factor, GM-CSF. CD4 and CD8 T cell populations both expressed 
mRNA for IL-11, IL-12p35, IL-23p19 and CCL5. Interestingly, T cells did not express IL-
12p40 mRNA which is required for production of functional IL-12 and IL-23. Synovial B 
cells expressed mRNA for IL-12p40 in addition to IL-12p35. T cell and B cell populations 
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expressed comparable levels of mRNA for the T cell and B cell development and survival 
factors IL-7 and LT-β. Intriguingly, we observed that RANKL mRNA was expressed 
predominantly by B cells, while lower levels were expressed by CD4 T cells. 
 
Cytokines expressed predominantly by the synovial fluid myeloid cell populations 
investigated are shown in Figure 3.4. Macrophages were found to express the highest levels of 
mRNA for the Th1-differentiation factors IL-18 and IL-27, and were also found to be the 
predominant mRNA source of APRIL, CCL2 and VEGF-a.  Synovial fluid neutrophils were 
found to have a cytokine expression pattern very similar to macrophages. Both populations 
expressed comparably high mRNA levels of the pro-inflammatory cytokine IL-1β, and the 
chemokines CCL3 and CXCL8. Neutrophils expressed the highest mRNA levels of BAFF, 
which was also expressed by macrophages. In addition, neutrophils expressed the highest 
mRNA levels of IFN-α1 and IFN-β1.  
 
Several cytokines were highly expressed both in lymphoid and myeloid populations, as shown 
in Figure 3.5. IL-1α mRNA was expressed at similar levels by macrophages, neutrophils and 
B cells in synovial fluid. B cells and macrophages expressed the highest levels of IL-6 
mRNA, while T cell and macrophage populations expressed high levels of IL-10 mRNA. T 
cells, B cells and neutrophils expressed comparable levels of IL-15 mRNA. All lymphocyte 
and myeloid cell populations investigated expressed high mRNA levels of TNF-α, TGF-β1, 
MIF and CCL4. 
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Comparison of cytokine profiles in synovial fluid and peripheral blood populations showed 
that a wide range of cytokines was expressed at a higher level in synovial fluid (Figure 3.6 
and Appendix 8.3.5). In the T cell, B cell and macrophage populations the majority of 
cytokines detected were more highly expressed in the synovial fluid. Interestingly, this was 
not the case for neutrophils. In addition, IFN-γ expression was found to be up-regulated in 
synovial fluid T cells whereas IL-2 expression was down-regulated in synovial fluid T cells. 
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Figure 3.3 Cytokines expressed predominantly by synovial fluid lymphoid cells. mRNA 
expression of cytokines expressed predominantly by CD4 T cells, CD8 T cells or B cells. 
Cytokine expression is shown for CD4 T cells (CD4), CD8 T cells (CD8), B cells (B), 
macrophages (M) and neutrophils (N). Kruskal-Wallis test; *p<0.01, **p<0.001, 
***p<0.0001. 
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Figure 3.4 Cytokines expressed predominantly by synovial fluid myeloid cells. mRNA 
expression of cytokines expressed predominantly by macrophages or neutrophils. Cytokine 
expression is shown for CD4 T cells (CD4), CD8 T cells (CD8), B cells (B), macrophages 
(M) and neutrophils (N). Kruskal-Wallis test; *p<0.01, **p<0.001, ***p<0.0001. 
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Figure 3.5 Cytokines expressed predominantly by both synovial fluid lymphoid and 
myeloid cell populations. mRNA expression of cytokines expressed by at least one of the 
lymphoid cell populations, CD4 T cells (CD4), CD8 T cells (CD8) or B cells (B), as well as 
either macrophages (M) or neutrophils (N). Kruskal-Wallis test; *p<0.01, **p<0.001. 
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Figure 3.6 Comparison of cytokine mRNA expression in sorted populations from peripheral 
blood (white bars) and synovial fluid (grey bars) in established RA. For each population, 
mRNA expression is shown for the cytokines which had a median RQ value above the 
threshold value of 10-5. Data are arranged hierarchically according to fold change in cytokine 
expression between synovial fluid and peripheral blood. Error bars indicate the range. 
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3.4 Discussion  
In this study a novel strategy was used to compare cytokine expression in the five dominant 
immune cell populations in the synovial fluid and peripheral blood of RA patients without ex 
vivo stimulation. While many cytokines were found in the populations we would have 
predicted based on the existing literature, we also made several unexpected findings. Notably, 
we observed that synovial fluid B cells express high levels of pro-inflammatory cytokines. 
The B cell population was the only synovial fluid population that expressed both IL-12p35 
and IL-12p40, the two subunits that are required for the production of functional IL-12. This 
observation is supported by previous reports of IL-12 production by B cells (Airoldi et al. 
2002). Synovial fluid B cells also expressed IL-23p19, the subunit that heterodimerises with 
IL-12p40 to form IL-23, indicating that synovial fluid B cells also have the capacity to 
produce functional IL-23. We found that IL-23p19 was expressed predominantly by synovial 
fluid T cells, in agreement with the original publication that reported high levels of IL-23p19 
in polarised Th1 cells (Oppmann 2000). However, our observation that synovial fluid CD4 
and CD8 T cells do not express IL-12p40 mRNA raises the question of whether synovial fluid 
T cells express a yet undescribed alternative binding partner for IL-23p19. A discrepancy 
between the level of IL-23p19 mRNA expression and functional expression of IL-23 at the 
protein level has also been described in RA synovial tissue and fibroblast-like synoviocytes. 
 
While B cells are regarded as an important cell type in RA, little is known about direct 
cytokine production by B cells in the RA synovium. An anti-inflammatory role has been 
proposed for a subset of B cells that can produce IL-10 (Iwata et al. 2011; Llorente et al. 
1994; Mauri et al. 2003). These cells have been observed in peripheral blood of patients with 
autoimmune diseases including RA, but so far have not been reported in the rheumatoid joint. 
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Overall, the mRNA cytokine profile of synovial fluid B cells detected in this study supports a 
generally pro-inflammatory role for this cell type in the synovial fluid. 
 
This is the first study to report that B cells contribute to RANKL production in the inflamed 
rheumatoid joint. Previous studies have reported the expression of RANKL by RA synovial 
fibroblasts, T cells, macrophages and chondrocytes (Crotti et al. 2002; Gravallese et al. 2000; 
Shigeyama et al. 2000; Skoumal et al. 2005).  We also found RANKL was expressed by 
synovial fluid CD4 T cells, which is consistent with previous studies of expression by T cells 
in RA synovial tissue (Crotti et al. 2002). The study by Crotti et al also reported RANKL in 
approximately 40% of macrophages in RA synovial tissue, although it was noted that it was 
not possible to verify whether macrophages were the source of RANKL or bound RANKL 
that was produced by other cells. We did not consistently detect RANKL expression in 
synovial fluid macrophages, although a low level of expression was observed in a minority of 
samples. Consistent with our results, a previous study has reported that RANKL expression is 
not increased in RA synovial fluid neutrophils compared to peripheral blood neutrophils 
(Poubelle et al. 2007). RANKL is known to be required for osteoclast development and plays 
a key role in mediating bone erosion. Its clinical importance is underlined by the effectiveness 
of the monoclonal antibody against RANKL, denosumab, in limiting erosive progression in 
RA. Our observation of B cells as a novel source of RANKL in the rheumatoid joint was 
subsequently followed up on the protein level, as described in Chapter 5. 
 
We detected IFN-γ expression in synovial fluid T cells and low IL-2 expression compared to 
peripheral blood, consistent with previous reports in synovial tissue and fluid (Abreu et al. 
2009; Combe et al. 1985; Dolhain et al. 1996; Firestein et al. 1988; Raza et al. 2005; Steiner 
et al. 1999; Yamada et al. 2011). Detection of these cytokines in the expected populations 
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confirmed the robustness of our experimental strategy. We found synovial fluid CD4 T cells 
expressed mRNA for IL-17 supporting the notion of a Th17 population in the synovium as 
has been suggested by other studies (Chabaud et al. 1999; Kotake et al. 1999; Raza et al. 
2005; Yamada et al. 2011; Ziolkowska et al. 2000). Interestingly a T cell subset producing 
both IL-17 and IFN-γ has recently been described in humans, which is elevated in the blood 
and inflamed tissues of patients with chronic inflammatory diseases (Annunziato et al. 2007; 
Kebir et al. 2009). In addition, a recent study has provided evidence for an IFN-γ+IL-17- 
subset of T cells which can arise under Th17-inducing conditions and has distinct properties 
from the Th1 lineage  (Boniface et al. 2010). It is becoming increasingly apparent that the 
plasticity of T cells, and in particular the relationship between Th17 and Th1 subsets, needs to 
be taken into account when analysing IL-17 and IFN-γ-producing T cells in RA. Recent 
studies suggest that Th1 cells rather than Th17 cells are the predominant effector subset in the 
RA synovium (Yamada et al 2011.; Yamada et al. 2008). Further studies are required to 
elucidate the relative contribution and relevance of these T cell subsets in RA. In keeping with 
the notion that Th2 cells do not have a central role in established RA, we did not detect 
expression of Th2-associated cytokines IL-4, IL-5 and IL-13 in synovial fluid T cells. Other 
studies have reported that levels of these cytokines are not elevated in synovial fluid 
compared to peripheral blood (Berner et al. 2000; Isomaki et al. 1999). 
 
Macrophages are considered an important source of synovial pro-inflammatory cytokines in 
RA. We found that synovial fluid macrophages expressed high levels of TNF-α, IL-6 and IL-
1α, but other synovial fluid populations also expressed comparable levels of mRNA for these 
cytokines. In addition, several cytokines and chemokines that were highly expressed by 
macrophages were also expressed at comparable levels by neutrophils including IL-1β, CCL3 
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and CXCL8. The neutrophil population was found to express high levels of mRNA for IFN-
α1 and IFN-β1, which has not been previously described in RA. 
 
The results of this study have allowed us to map cytokine mRNA production in the five 
largest cell populations in established RA synovial fluid. It should be noted that there are 
many other synovial fluid cell populations which were not assessed including NK cells, NKT 
cells and mast cells which represent small populations in RA synovial fluid. Furthermore, 
cytokine production by stromal cells in the synovial tissue such as synovial fibroblasts, 
macrophage-like synoviocytes and endothelial cells were not investigated. For example, mast 
cells have been reported as a source of IL-17 in the RA synovium (Hueber et al. 2010). It 
would be interesting to further investigate cytokine expression by different subsets of the cell 
populations analysed here, for example in the case of T cells, B cells and macrophages. It 
should also be noted that the cytokine-expressing characteristics of cell populations present in 
the RA synovial fluid may not necessarily be representative of those found in the synovial 
tissue. Indeed, differential regulation of cytokines has been reported in these two 
compartments, for example, different components of the IL-6 receptor expressed are at 
different levels in RA synovial fluid and synovial tissue (Hidalgo et al. 2011).  
 
In this study, gene expression was normalised to ribosomal 18S RNA. The use of any 
normalisation strategy across different cell populations is always a potential weakness, 
whether expression is normalised to metabolic enzymes such as GAPDH, structural proteins 
such as β-actin, or ribosomal RNA. Due to the nature of the strategy used to detect cytokine 
gene expression, it is intrinsically a screening assay. Eventually, the success of such a 
screening strategy is validated by the novel and important findings made, and whether these 
findings can be confirmed at the level of protein production.  
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Characterisation of cytokine expression by individual synovial populations is the first step 
towards understanding the complex cytokine network that operates in the joint in RA. One of 
the strengths of this study is that cytokine expression has been determined directly ex vivo in 
order to try to reflect the situation within the inflamed joint as closely as possible. 
Considerable effort was made to avoid stimulation of cells during the process of isolation. 
However, it is still conceivable that cytokine mRNA may be affected by the isolation 
procedure. It should be taken into account that mRNA expression as determined in this study 
is not necessarily reflective of protein production due to post-transcriptional regulation of 
cytokine expression. Interpretation of the results of this study also needs to take into account 
multiple factors that influence the biological activity of cytokines in the joint. The biological 
activity of a given cytokine depends on the simultaneous production of agonist and 
antagonistic cytokines, the presence of inhibitors, and the extent to which its receptor is 
expressed. Cytokine activity is also regulated by interactions between intracellular signals 
which may occur due to priming or reprogramming of signalling, or the uncoupling of 
ligand/receptor pairing from signal transduction. Importantly, some cytokines such as IL-10 
can have pro-inflammatory or anti-inflammatory activities depending on the cytokine 
environment. In addition, mediators belonging to other families of molecules, such as 
hormones and adipokines, can also regulate cytokine activity. Understanding the complex 
crosstalk that exists in the cytokine network in the RA joint and the functional hierarchies 
therefore remains an important challenge. 
 
In summary, our data have allowed us to determine cytokine mRNA expression by each of the 
five main cell populations present in the synovial fluid of patients with established RA 
(Figure 3.6). We have been able to compare relative expression of cytokines between cell 
types, and also determine cytokine expression of cell populations in synovial fluid compared 
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to peripheral blood. Several novel observations of cytokine gene expression have been made 
in the context of this study which will need to be followed up and validated on the protein 
level.  
 
Figure 3.7 Summary of cytokines expressed by CD3+CD45RO+CD4+ T cells, 
CD3+CD45RO+CD8+ T cells, CD19+ B cells, CD14+ macrophages and CD15+ 
neutrophils in RA synovial fluid. For each population, cytokines are shown if their level of 
expression was at least 2 logs higher than in other cell populations. 
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4 CYTOKINE PROFILING IN EARLY AND 
ESTABLISHED ARTHRITIS 
4.1 Introduction 
When a patient presents with inflammatory arthritis, it is frequently unclear whether the 
synovitis will resolve or if the patient will develop a persistent inflammatory arthritis such as 
RA. In the Birmingham Early Arthritis cohort of patients with recent onset arthritis of up to 
12 weeks’ duration, approximately half of the patients had spontaneously resolving synovitis 
whereas the rest went on develop a persistent synovitis such as RA (Raza et al. 2005). In 
other early inflammatory arthritis cohorts, self-resolving synovitis was reported in 25% of 
patients (Harrison et al. 1996), 55% of patients (Tunn and Bacon 1993) and 60% of patients 
(Visser et al. 2002). It is important to differentiate individuals destined to develop RA from 
those whose disease will resolve in order to be able to inform patients of their prognosis and 
target treatment to the appropriate individuals. Furthermore, early recognition of RA is 
necessary to facilitate early therapeutic intervention, as initiation of DMARD therapy within 
the first few months of symptom onset is associated with better outcome than when treatment 
is commenced later in the course (Mottonen et al. 2002; Nell et al. 2004; van der Linden et al. 
2010). 
 
Clinical prediction models have been developed to determine outcomes of patients with early 
arthritis at presentation. A prediction rule for use in patients with undifferentiated arthritis, 
developed by van der Helm van Mil and colleagues, based on nine clinical variables (sex, age, 
localization of symptoms, morning stiffness, tender joint count, swollen joint count, CRP 
level, and positivity for rheumatoid factor and ACPA) was found to have a positive predictive 
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value of 84% and a negative predictive value of 91%, and has been validated in several 
cohorts (Kuriya et al. 2009; van der Helm-van Mil et al. 2008). However, the biological 
characteristics of synovial pathology have not yet been systematically assessed to see if they 
would contribute meaningfully to predictive algorithms. 
 
Assessment of synovial histology using haematoxylin and eosin-based staining of tissue 
sections and electron microscopic analysis of synovial tissue from patients with synovitis of 
less than 2 months’ duration found no clear differences between patients with self-limiting 
synovitis and those who subsequently developed RA (Schumacher and Kitridou 1972). In 
contrast, a study which compared the level of cytokines in the synovial fluid of early synovitis 
patients with diverging clinical outcomes showed that patients who developed RA could be 
distinguished from those who developed non-RA persistent disease or resolving arthritis 
based on their synovial fluid cytokine pattern (Raza et al. 2005). Synovial fluid from patients 
with early RA contained higher levels of the T cell, macrophage and stromal cell-related 
cytokines, IL-2, IL-4, IL-15 and GM-CSF.  
 
Several studies have investigated whether differences can be found in synovial pathology 
during the early and established phases of RA. In studies comparing early RA (defined as a  
duration of <1 year since the diagnosis of RA) and established RA, immunohistological 
analysis of the synovium (Tak et al. 1997) and cytokine mRNA expression in synovial fluid 
mononuclear cells (Bucht et al. 1996) were found to be similar. However, higher levels of T 
cell, macrophage and stromal cell-related cytokines have been reported in the synovial fluid 
of patients with early RA compared to patients with established RA (Raza et al. 2005), and 
levels of BAFF and APRIL are higher in the serum in early compared to established RA 
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(Moura et al. 2010). In addition, in gene expression profiling studies of peripheral blood cells, 
early and long-standing RA have been found to have distinct molecular signatures associated 
with different biological processes (Lequerre et al. 2009; Olsen et al. 2004). This supports the 
notion that different molecular and cellular mechanisms operate in early versus established 
RA, and features of early synovitis could relate to disease outcome.  
 
As cytokine production in the RA synovium can be considered to reflect the pathological 
processes operating in a given stage of disease, we hypothesised that cytokine expression in 
the synovial tissue and fluid would differ between patients in the early and established stages 
of RA. We also hypothesised that cytokine expression in the synovial tissue and fluid of early 
synovitis patients who developed RA would differ from patients with self-resolving disease. 
Genes selected for investigation were cytokines or cytokine-related molecules belonging to 
families which have been associated with RA; these included interleukins, TNF family 
members, chemokines, growth factors, adipokines and interferons. In this study we examined 
the cytokine gene expression profiles of patients with early synovitis within 12 weeks of 
symptom onset, which represents a phase of disease that has not previously been studied 
using this approach.  
 
4.2 Synovial tissue cytokine expression in early and established 
arthritis 
Synovial tissue biopsies were prospectively obtained from 18 early synovitis patients who 
developed RA, 13 early synovitis patients with self-limiting synovitis, 12 patients with 
established RA, and 12 control subjects. The control subjects were patients undergoing 
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arthroscopy with no macroscopic or radiological evidence of inflammatory pathology. These 
patients were undergoing arthroscopy for treatment of non-inflammatory conditions, such as 
ligament or meniscal repair. A microfluidic card was designed to analyse expression of a 
panel of genes which included 135 cytokines and related molecules (interleukins, TNF family 
members, chemokines, growth factors, interferons, adipokines and other cytokine-like factors; 
see Appendix Table 8.2) and housekeeping genes. mRNA expression was determined by real-
time PCR, and the expression of each gene was calculated relative to the levels of GAPDH. 
Of the three housekeeping genes included (GAPDH, β2 microglobulin and 18S), GAPDH was 
selected because it showed the least variation in expression across samples. mRNA from 
PBMC stimulated with magnetic beads coated with anti-CD3 and anti-CD28 antibodies, and a 
commercially available blend of RNA from human cell lines representing different tissues 
(Stratagene) were used as positive controls to test whether the microfluidic card real-time 
PCR assays worked. With the exception G-CSF, CCL23, XCL2 and RETN, expression of all 
cytokine genes was detected (Figure 4.1A,B). As described in 2.4.1, gene expression was 
assessed using two approaches: (i) expression of all genes was analysed using RNA which 
was not treated with DNase, and (ii) expression of genes with real-time PCR assays 
containing non-intron spanning primers or genes expressed at very low levels was analysed 
using RNA treated with DNase, and using six times more RNA per assay than originally used. 
Variability between the real-time PCR assays on separate microfluidic cards was assessed by 
running a sample of reference RNA or RNA extracted from a synovial tissue biopsy section 
on two different cards (Figure 4.1C). Comparison of mRNA expression between the two 
cards showed that results were very similar, emphasising the reproducibility of this approach.  
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Figure 4.1 Method validation. (A) Cytokine mRNA expression in PBMC stimulated with 
anti-CD3/anti-CD28-coated beads was used as a positive control for the real-time PCR 
assays. (B) Cytokine mRNA expression in human reference RNA (Stratagene) was used as a 
positive control. (C) Comparison of cytokine mRNA expression in two batches of 
microfluidic cards using human reference RNA (left) and RNA extracted from a synovial 
tissue biopsy section (right). The expression of all genes detected in split samples using two 
cards from different batches is plotted . 
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Genes that were differentially expressed between groups were identified by performing the 
Kruskal-Wallis test followed by the Dunn’s post-test between groups for each genes. Of the 
135 cytokines analysed, 4 genes were found to be differentially expressed between groups, 16 
genes were not detected, and 105 genes did not show significant differences between groups. 
The complete set of mRNA expression data is shown in Appendix 8.3.1. Genes not detected 
were IL-3, IL-4, IL-5, IL-9, IL-13, IL-17A, IL-17F, IL-19, IL-20, IL-22, IL-24, IL-25, IL-29, 
XCL2, RETN and EPO. Cytokines that were found to be differentially expressed between 
groups are shown in Figure 4.2 and Table 4.1. mRNA levels of IL-2 were significantly higher 
in established RA than resolving synovitis patients; IL-21 was higher in established RA than 
resolving synovitis patients and control subjects; CCL2 and CXCL13 were higher in 
established RA than controls; CXCL4 and CXCL7 were both higher in established RA and 
early RA compared to controls; and CXCL7 was also higher in resolving synovitis patients 
compared to controls. 
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Figure 4.2 mRNA expression of cytokines differentially expressed between established 
RA, early RA, early resolving synovitis and control groups. Established RA (circle), early 
RA (squares), early resolving synovitis (upward triangles), and controls (downward triangles), 
Expression is quantified relative to GAPDH. Kruskal Wallis test with Dunn’s post hoc test 
adjusted for multiple comparisons. *p<0.01. 
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Groups compared in Dunn’s post test 
analysis 
Differentially expressed genes 
Est RA > Early resolving synovitis IL-2, IL-21 
Est RA > Control IL-21, CXCL4, CXCL7, CXCL13, CCL2 
Early RA > Control CXCL4, CXCL7 
Early resolving synovitis > Control CXCL7 
Table 4.1 Cytokines and chemokines differentially expressed in synovial tissue of early 
and established arthritis patients and controls. 
 
The synovial tissue cytokine mRNA expression data was also analysed using principle 
component analysis (PCA). PCA is an algorithm commonly used to represent relationships 
between samples which seeks to reduce the dimensionality of a data set while retaining as 
much as possible of the variation present within the original data. In this analysis, samples are 
clustered into groups displayed in two dimensions. The axis of the first principal component 
(x-axis) represents the direction incorporating the maximum variability of all genes. The 
remaining variation within the data is represented in the direction of the second principal 
component (y-axis). Samples are thus visualised in “principal component space” by their 
expression of the most variable genes which make up the principal components. PCA was 
used to analyse relationships between cytokine expression in the synovium of patients with 
early RA, resolving synovitis, established RA and controls, as shown in Figure 4.3. Using 
genes that were differentially expressed by >1.5 fold, pair-wise comparisons were made 
between each of the groups. Comparison of established RA and early RA showed a degree of 
clustering by each of the two groups that could enable them to be separated visually along the 
first component, whereas early RA and early resolving synovitis patient groups did not cluster 
separately. Early resolving synovitis and established RA patients showed some degree of 
separation along the first principle component. When the patient groups were compared to the 
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controls, the control subjects tended to cluster separately from RA patients or early RA 
patients. In contrast, early resolving synovitis patients and control individuals did not cluster 
separately. Together these results indicate that based on synovial cytokine expression, it may 
be possible to distinguish established RA and early RA from each other and from the control 
group, whereas early resolving synovitis patients could not be readily distinguished from 
patients with early RA or controls. However, the sample size is small and more samples will 
be needed to assess the robustness of the differences observed. 
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Figure 4.3 Comparison of synovial tissue cytokine expression in early RA, early 
resolving synovitis, established RA and controls. Principle component analysis was 
performed using genes showing >1.5 fold change. Red and green labelling is used to denote 
the different groups being compared. Established RA (RA), early RA (ERA), early resolving 
synovitis (RES), control (CTR). 
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The presence of circulating ACPA distinguishes two distinct subsets of RA, mainly based on 
differences in genetic and environmental associations. In this study, established and early RA 
patients were split into ACPA-positive and ACPA-negative groups, and differences in gene 
expression were calculated using Mann-Whitney tests. All data comparing cytokine 
expression in ACPA-positive and ACPA-negative patients is shown in Appendix 8.3.2. Of the 
135 cytokines analysed, 1 gene showed a significant difference between the two groups, 
shown in Figure 4.4. In established RA patients, expression of CXCL16 was higher in the 
ACPA-positive group than the ACPA-negative group. 
CXCL16
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Figure 4.4 mRNA expression of CXCL16 in ACPA-positive and ACPA-negative 
patients. ACPA-negative patients (closed symbols) and ACPA-positive patients (open 
symbols) with established RA (circles) or early RA (squares). Expression quantified relative 
to GAPDH. Mann-Whitney unpaired t-test; p*<0.01. 
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4.3 Cytokine expression in sorted synovial fluid cell populations in 
early and established arthritis 
In addition to examining cytokine expression in whole sections of synovial tissue, we also 
assessed cytokine expression in the five cell populations sorted from synovial fluid of early 
synovitis and established RA patients. By enriching specific populations, this approach has 
the benefit of detecting cytokines that may not have been detected in the whole tissue as their 
expression may have been obscured by that of larger synovial tissue populations. Cell 
populations were sorted from synovial fluid and peripheral blood from 5 early synovitis 
patients who progressed to RA, 4 early synovitis patients whose disease resolved and 10 
patients with established RA. Cell populations were also sorted from peripheral blood from 5 
healthy controls. CD4 and CD8 T cells, B cells, macrophages and neutrophils were isolated 
from each synovial fluid or peripheral blood sample as described previously. Often only small 
volumes of synovial fluid could be aspirated from the joints of patients with early synovitis. 
Due to the low cell numbers in the samples obtained, and the requirement for isolated 
populations to have ≥95% purity, there were relatively few samples from early synovitis 
patients which were suitable for using in the study. Microfluidic cards containing assays for 
41 cytokines were used to determine mRNA expression by real-time PCR (see Appendix 
Table 8.1), and expression of each gene was normalised to 18S. Genes that were not detected 
were IL-4, IL-13, G-CSF, CCL11, CXCL12 and EGF. 
 
To determine significant differences between patient groups, the Kruskal-Wallis test were 
performed to see if there were differences in gene expression within each sorted cell 
population. The Dunn’s post-test was used to determine which groups differed significantly 
from each other. The complete set of mRNA expression data from synovial fluid and 
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peripheral blood sorted cells is shown in Appendix 8.3.3. Genes that were differentially 
expressed in synovial fluid cell populations between patient groups are shown in Figure 4.5. 
mRNA expression of IFN-β1 by CD8 T cells was significantly higher in early synovitis 
patients whose disease resolved than early synovitis patients who developed RA and patients 
with established RA. The level of IFN-β1 produced by CD8 T cells in early resolving 
synovitis patients were similar to levels produced by neutrophils in established RA patients. 
However, as there was only one synovial fluid neutrophil sample available in the early 
resolving synovitis group, it is not possible to compare expression in neutrophils and CD8 T 
cells. Levels of IL-10 in CD8 T cells and VEGF-α in B cells were higher expressed in 
established RA synovial fluid cell populations compared to early resolving synovitis patients. 
 
 
 
 
 
 
 
 
Figure 4.5 mRNA expression of genes differentially expressed between established RA, 
early RA and early resolving synovitis in cell populations sorted from synovial fluid. 
Established RA (circles), early RA (squares), early resolving synovitis (upward 
triangles).CD3+CD45RO+CD4+ T cells, CD3+CD45RO+CD8+ T cells, CD19+ B cells, 
CD14+ macrophages and CD15+ neutrophils were sorted from synovial fluid. Expression was 
quantified relative to 18S. Kruskal-Wallis test with Dunn’s post-hoc test for multiple 
comparisons; *p<0.01. 
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Groups compared in 
Dunn’s post test analysis 
Differentially 
expressed gene 
Cell population in which 
gene differentially expressed 
Dunn’s post 
test result 
Early resolving synovitis 
vs Early RA  
IFN-β1 CD8 T cell ** 
Early resolving synovitis 
vs Established  RA 
IFN-β1 
IL-10 
VEGF-α 
CD8 T cell 
CD8 T cell 
B cell 
* 
* 
* 
Table 4.2 Cytokines differentially expressed in synovial fluid cell populations from early 
and established arthritis patients. Dunn’s post test analysis following Kruskal-Wallis test:  
* p<0.05, **p<0.01. 
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4.4 Discussion 
We hypothesised that within the first three months of onset of synovitis, patients destined to 
develop RA would show a distinct synovial pathology, reflected in cytokine expression, 
which would enable them to be distinguished from early synovitis patients with self-limiting 
disease. In sorted cells from the synovial fluid, we found that IFN-β was expressed at higher 
levels in CD8 T cells from patients with resolving synovitis compared to patients with early 
RA. As IFN-β is produced in direct response to virus infection, this may indicate a heightened 
anti-viral response in resolving synovitis patients whose disease was likely caused by a viral 
infection. Of the three resolving synovitis patients, one had post-streptococcal resolving 
synovitis, one patient had unclassified resolving synovitis, and data for the other patient is not 
available. 
 
Cytokine mRNA profiling of synovial tissue from patients with resolving synovitis and early 
RA did not reveal any significant differences between the two groups, suggesting that at the 
level of the cytokines studied, the synovium of patients destined to develop RA largely 
resembles those with disease destined to self-limit. Assessing cytokine expression within the 
whole synovial tissue biopsy section may have concealed differences in expression as a 
mixture of synovial cell populations were studied, and production of cytokines by cell 
populations which are only found at a low frequency in the synovium may not have been 
identifiable. Furthermore, it should be noted that the early resolving group was very 
heterogeneous. In addition, these patients may have been seen at different stages of their 
disease course; for example, one patient may have been seen at the peak of an inflammatory 
flare, whereas another patient may have been seen during the resolution phase of 
inflammation; however this information was not systematically collected. The heterogeneity 
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of this group of patients may help to explain why so few significant differences were observed 
when compared to patients with early RA. In the future it would be interesting to look at these 
findings in relation to the clinical phase of the resolving synovitis.  
 
Overall, comparison of early synovitis patients with self-limiting disease or that leading to RA 
revealed that cytokine expression in the synovium in these groups is largely similar. This 
finding implies that the synovial cytokine expression observed is largely reflective of general 
inflammation. If cytokine production can be considered to some degree to represent the cell 
populations present in the synovium, these findings may be considered broadly consistent 
with the finding that no clear histological differences are observed between early synovitis 
patients with self-limiting synovitis and patients who go on to develop RA (Schumacher and 
Kitridou 1972). Furthermore, the histopathological features of parallel biopsies were analysed 
in paraffin-embedded tissue stained with haematoxylin and eosin, and it was found that 
patients with early and resolving RA were similar in terms of patterns of leukocyte infiltration 
and lining layer thickness (data not shown). These findings are compatible with my results 
which indicate that the features of inflammation are broadly similar in both groups. Here, we 
studied synovitis patients within the first 3 months after symptom onset. The similarity of 
patients who developed RA and patients with self-resolving disease suggests that if there is a 
“switch to persistence” leading to development of RA, this occurs outside the time frame 
studied, or is simply not reflected in the cytokine expression by synovial populations. Indeed, 
evidence to support the former concept is provided by the observation that immunological 
abnormalities precede the development of clinically apparent RA. This indicates that due to 
genetic predisposition for development of RA, for example, it is determined during the pre-
clinical phase whether an individual will develop RA following development of synovitis 
which may be triggered by a non-specific stimulus such as minor trauma or infection. 
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Therefore in patients who develop RA and patients whose synovitis resolves, it is possible 
that the same initiating factors are responsible for triggering inflammation, accounting for the 
observation that in the first 3 months after symptom onset, inflammation in the synovium, as 
reflected at the level of cytokine expression, is broadly similar in the two groups of patients. 
As alluded to previously, it is possible that the pathological differences in early RA and 
resolving synovitis patients are not reflected in synovial cytokine expression. While cytokines 
clearly have important roles in regulating cellular infiltration in the RA synovium by their 
ability to recruit and maintain cells at sites of inflammation, multiple additional factors are 
responsible for the persistence of cells in the synovium such as pro-inflammatory pathways 
involving lipid mediators, anti-apoptotic pathways, and hormonal influences. In patients with 
disease destined to self-limit compared with those with disease destined to persist, it may be 
more informative to compare features of resolution of inflammation, as these may be more 
important in determining outcome than the cytokines and related molecules assessed in this 
study. Another important factor determining the development of RA may involve phenotypic 
changes in the stromal cells of the synovium, and these changes would not necessarily be 
observed by assessing the genes selected in the panel investigated. Therefore there remains a 
need to identify persistent versus resolving disease to inform identification of therapeutic 
strategies and biomarkers of outcome for use in clinical practice.  
 
Another important question we wished to address was whether cytokine expression differs in 
the early and established phases of RA. In the synovial tissue, cytokine mRNA expression 
was not significantly different in patients with established RA and early RA These results are 
compatible with an existing body of literature which suggests that that features of synovial 
inflammation in patients with early RA are similar to those observed in longstanding disease, 
in terms of cell infiltration and expression of cytokines, chemokines, granzymes, adhesion 
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molecules and MMPs (Baeten et al. 2000; Smeets et al. 1998b; Tak et al. 1997; Tak et al. 
1995). Overall, these studies suggest that synovial inflammation observed in early arthritis is 
representative of chronic inflammation seen in established disease. A previous study of 
patients with recent-onset arthritis reported that distinct cytokine profiles could be found in 
different phases of disease (Raza et al. 2005), which differs from the results of the present 
study. Differences in study design may account for some of the discrepancies observed, for 
example, the study by Raza and colleagues measured protein expression of cytokines in 
synovial fluid, whereas in this study we measured expression of cytokines at the mRNA level.  
 
It should be noted that whereas the “duration” of RA is timed by many groups in relation to 
either the first patient-reported joint swelling or the date of initial fulfilment of classification 
criteria for RA, in the Birmingham cohort, duration is timed from the date of the first 
symptoms (including joint pain and stiffness) attributed to inflammatory joint disease by the 
assessing rheumatologist. Patients in our cohort included in the “early RA” category may well 
not have had disease classified as RA at the time of sample collection – although they would 
have developed RA on follow-up assessment. The patients included in this study thus 
represent a unique cohort in the study of early inflammatory arthritis, capturing a much earlier 
phase of disease than has been studied by other early arthritis centres. This does however 
make it difficult to compare results between studies; a new EULAR initiative is addressing 
this issue of dating to onset of disease to aim for greater clarity. It appears that within the 
three-month window following symptom onset we have studied, it is not possible to observe a 
synovial cytokine profile in early RA that is distinct from established RA. Indeed, evidence 
suggests that important immunological changes occur prior to the development of clinical 
symptoms of RA. In a recent study it was reported that the levels of several cytokines, 
cytokine receptors and chemokines were significantly increased in the blood of asymptomatic 
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individuals who went on develop RA (Kokkonen et al. 2010). Genes that were significantly 
upregulated in these individuals compared to healthy controls included IL-1β, IL-2, IL-6, IL-
1Ra, TNF-α, IFN-γ, IL-12, IL-4, IL-10, IL-7, GM-CSF, G-CSF, CCL2 and CCL3. When 
cytokine expression was assessed in the same individuals after disease onset, expression of 
the majority of the analysed variables was increased further, but interestingly, levels of TNF-
α, IL-5, IL-7, IL-13, GM-CSF, G-CSF, FGF-2, CCL3, MIF and IL-17 were not significantly 
changed. These results support the concept of the immune system being activated before 
development of RA becomes clinically apparent, and may explain why we do not detect 
significant changes in cytokine expression in early and established disease. 
 
It is recognised that ACPA-positive and ACPA-negative RA patients differ in respect to 
genetic association, degree of radiological destruction and outcome, and we compared 
cytokine expression in ACPA-positive and ACPA-negative groups to determine whether 
expression patterns would reflect distinct pathogenic mechanisms in these patients. ACPA-
positive patients with early RA were found to express higher levels of CXCL16, a chemokine 
that promotes angiogenesis and is expressed by a number of different cell types including 
leukocytes and endothelial cells. CXCL16 has previously been implicated in mononuclear cell 
chemotaxis in RA (Ruth et al. 2006), but has not previously been specifically associated with 
ACPA-positive RA. The majority of cytokines were expressed at similar levels in the two 
patient subgroups. These similarities observed between ACPA-positive and ACPA-negative 
patients in the early RA group suggest that irrespective of ACPA status and potentially 
differing aetiology, in all patients ultimately diagnosed as having RA the mechanisms leading 
to chronic synovial inflammation converge on a final common pathway which is reflected in 
the similar cytokine expression profiles observed. In keeping with this notion, a study of RA 
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patients presenting within two years of symptom onset suggested no clinical phenotypic 
differences according to ACPA status (van der Helm-van Mil et al. 2005), and similarly 
within three months of symptom onset, clinical presentation is similar in patients with or 
without ACPA (Cader et al. 2010). It is interesting that although ACPA-positive patients 
show greater radiological destruction than ACPA-negative patients on follow-up (van der 
Helm-van Mil et al. 2005), we did not detect differences in cytokines in ACPA-positive and 
ACPA-negative patients within the established RA group.  
 
Histological assessment of synovial biopsies from early RA patients included in this study 
showed that the type of infiltrate, lining layer thickness and vascularity look remarkably 
similar between the ACPA-positive and ACPA-negative patients (data not shown) which is 
consistent with the similar cytokine profiles observed. A study examining differences in 
synovial tissue infiltrates between ACPA-positive and ACPA-negative patients found ACPA-
positive patients had a thinner synovial layer and greater infiltration of T cells (van 
Oosterhout et al. 2008). Interestingly, most parameters were the same in both groups, 
including infiltration of macrophages, B cells, neutrophils, plasma cells and germinal centre-
like structures. These findings may be considered to be broadly consistent with our results 
which indicate that ACPA-positive and ACPA-negative RA patients have similar synovial 
cytokine expression profiles. 
 
In the study comparing cytokine expression in sorted synovial fluid cell populations, a 
minimum of 10,000 cells were used per each sample. However, in the study comparing 
synovial tissue cytokine mRNA expression profiles, a cut-off for a minimal amount of 
material was not applied. It is therefore possible that in samples containing a relatively low 
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amount of RNA, genes with a low level of expression may have not been detected. This 
should be taken into consideration when comparing the expression of weakly-expressed genes 
in samples with variable amounts of RNA. 
 
In the synovial tissue cytokine mRNA expression study, the dataset was analysed by 
performing Kruskal-Wallis tests to determine significant differences between groups for each 
gene, and PCA was used to cluster samples based on their cytokine gene expression profile. 
However, these methods do not take into account the relative significance of individual 
variables or groups of variables which may be important in differentiating between different 
patient groups. Therefore it will be important to apply alternative methods to analyse these 
data, for example machine-based learning approaches such as relevance learning vector 
quantitization, or classification tree–based methods, such as Random Forests analysis, which 
can identify which features are most useful in classifying different groups. The use of such 
approaches may be informative in defining which cytokines, or combinations of cytokines, 
may distinguish different patient groups. In addition, it would be important to repeat the 
experiment in an independent cohort and use the data as a test set to verify the findings made 
in this study which would serve as a training set; this would verify the significance of the 
findings made in the present study. 
 
In summary, we have identified cytokine genes which are differentially expressed in the 
synovial tissue and synovial fluid of patients with early self-limiting synovitis, early RA and 
established RA. However the majority of cytokines investigated showed similar levels of 
expression in the different patient groups. The differences in mRNA expression reported 
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between early RA and self-limiting synovitis, and between early and established RA will be 
interesting to follow up in the future.  
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5 RANKL EXPRESSION BY B CELLS IN RA 
5.1 Introduction 
One of the hallmarks of RA is bone destruction mediated by the action of osteoclasts, a 
population of large, multinucleated cells derived from myeloid lineage precursor cells. The 
process of osteoclast differentiation is dependent on the TNF family member RANKL in 
addition to the growth factor, M-CSF, and as recently described, IL-34 (Chen et al. 2011). 
Binding of RANKL to its cell-bound receptor molecule RANK, triggers differentiation and 
activation of osteoclasts (Kong et al. 1999b; Lacey et al. 1998). The importance of RANKL-
driven osteoclast-mediated bone destruction in RA is demonstrated by the effectiveness of 
denosumab, an anti-RANKL antibody, to suppress erosive progress in RA (Cohen et al. 
2008). In a study of cytokine mRNA expression in RA synovial fluid cells we found that 
RANKL is expressed predominantly by the B cell population. Previous studies have reported 
expression of RANKL by T cells, fibroblasts and chondrocytes in RA, but this is the first 
report of RANKL production by RA B cells. The importance of the B cell lineage in RA 
pathogenesis is highlighted by the effectiveness of rituximab in suppressing the progression of 
joint damage in RA. Our observation of high mRNA levels of RANKL in B cells in RA raises 
the possibility that expression of this cytokine by B cells could contribute directly or 
indirectly to promoting bone erosion in RA. However, from our RANKL mRNA expression 
data from sorted synovial fluid cell populations, it is not clear whether a small proportion of B 
cells express high levels of RANKL, or whether RANKL is expressed equally among the 
whole B cell population.  Due to its potential clinical relevance, this observation warranted 
further investigation.  
 
125 
 
RANKL mRNA expression has been described in B cells as part of an expression profile 
defining a subset of memory B cells that normally reside in epithelial tissue-based niches 
(Ehrhardt et al. 2008). The relevance of this RANKL-expressing B cell subset has yet to be 
explored in the context of RA. Classification of B cell developmental stages is commonly 
based on the expression of three surface markers. In humans, B cells are generated in the bone 
marrow, where they mature from stem cells to naïve B cells. Naïve B cells leave the bone 
marrow and migrate via the circulation to secondary lymphoid tissues where further 
development takes place. In secondary lymphoid tissues, antigen-specific memory B cells or 
plasma cells are formed. Plasma cells, or “effector B cells”, are responsible for the production 
of antibody. Memory B cells are precursors capable of generating and replenishing the plasma 
cell compartment, and may also be responsible for the generation of distinct subsets of 
effector B cells. In addition, memory B cells also have important roles in antigen presentation, 
T cell and dendritic cell regulation, and cytokine production. 
 
B cells can be classified based on relative expression of IgD and CD38; this so-called Bm1-
Bm5 classification system can be used to identify the following subsets in the human tonsil: 
virgin naïve cells (Bm1: IgD+CD38-), activated naïve cells (Bm2: IgD+CD38+), pre-GC cells 
(Bm2'; IgD+CD38++), GC cells (Bm3-centroblasts and Bm4-centrocytes: both 
IgD−CD38++), and memory cells (Bm5: IgD−CD38+/−). The Bm1-Bm5 classification 
system recognizes similar subsets in the peripheral blood. However, this classification, 
although a useful point of reference, has significant limitations, for example Bm1 and Bm2 
cells also contain unswitched memory cells and Bm2' also contains transitional cells. B cells 
are also commonly classified based on their expression of the surface markers IgD and CD27 
as naïve (IgD+CD27-), pre-switch memory (IgD+CD27+) or post-switch memory (IgD-
CD27+), and “double-negative” (IgD-CD27-) B cells. CD27 is a marker of activation which 
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was initially regarded as a universal marker of human memory cells. However, it now 
recognised that there are some memory B cells which do not express CD27. This CD27- 
population carries somatically mutated immunoglobulin genes, has a CD24/CD37 expression 
profile characteristic of memory cells, and can produce antibodies specific for previously 
encountered antigens (Fecteau et al. 2006; Wirths and Lanzavecchia 2005). It is thought that 
CD27- memory B cells are likely to derive from extra-follicular responses or incomplete 
germinal centre reactions. Alternatively, they may be derived from activated CD27+ B 
memory cells that have lost their CD27 expression (Sanz et al. 2008). 
 
In the RA synovium there are increased numbers of CD27+ memory B cells compared to 
peripheral blood (Souto-Carneiro et al. 2009). In RA synovial fluid there are increased 
frequencies of IgD-CD27+ and IgD-CD27- B cells, and a reduced frequency of IgD+CD27- B 
cells compared to peripheral blood (Michelutti et al. 2011). Abnormalities in B cell subsets 
have also been reported in the peripheral blood of RA patients compared to healthy 
individuals. Studies have reported an increased frequency of IgD-CD27+ and a reduced 
frequency of IgD+CD27+ peripheral blood B cells in RA compared to healthy donors (Fekete 
et al. 2007; Souto-Carneiro et al. 2009). 
 
The use of B cell depletion therapy in patients with RA has provided a useful tool for 
elucidating the role of B cells in RA pathogenesis. Rituximab is a chimaeric monoclonal 
antibody directed at CD20, a transmembrane protein expressed exclusively on B cells, 
including pre-B cells, naïve, mature, and activated B cells, B cell blasts, but not on early B 
cell progenitors or plasma cells. Rituximab is used for TNF blockade-refractory disease and is 
effective in improving disease symptoms and reducing radiographic progression in RA 
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(Cohen et al. 2006; Keystone et al. 2009). Treatment with rituximab significantly reduces 
levels of anti-CCP, IgA-RF, IgG-RF, and IgG antibodies compared to their corresponding 
total serum immunoglobulin classes (Cambridge et al. 2003). A reduction in CRP levels also 
parallels the decreases in autoantibody levels, whereas levels of antimicrobial antibodies do 
not change significantly (Cambridge et al. 2003). The mechanism by which rituximab 
produces its clinical effect is not well understood at present. Interference with B cell functions 
such as antigen presentation and cytokine production may be involved. 
 
Rituximab is usually effective in inducing a near complete depletion of CD20+ B cells from 
peripheral blood, whereas B cell depletion in the synovial tissue is highly variable between 
patients (Boumans et al. 2011). Rituximab induces a transient depletion of B cells in the 
peripheral blood within a few hours (Leandro et al. 2006). The mean time frame of B cell 
return is 8 months, but this is highly variable between patients (Leandro et al. 2006). 
Repopulation occurs firstly by immature B cells, followed by naïve B cells. There is delayed 
recovery of memory B cells, and these cells may remain at reduced levels for over two years 
(Moller et al. 2009; Roll et al. 2008; Roll et al. 2006). Interestingly, the extent of memory B 
cell repletion is associated with clinical response: early clinical relapse is associated with a 
higher proportion of CD27+ memory B cells before therapy, and is also associated with 
repopulation with a higher proportion of IgD+CD27+ or IgD-CD27+ memory B cells 
(Leandro et al. 2006; Moller et al. 2009; Roll et al. 2008). As the expression of RANKL by B 
cells in RA is a novel observation which remains to be further investigated, we sought to 
determine protein expression of RANKL in B cells in synovial fluid and tissue and to 
investigate the differentiation and activation status of B cell subsets responsible for producing 
RANKL. 
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5.2 Identification and characterisation of RANKL-producing B cells in 
synovial fluid 
In sorted cell populations from RA synovial fluid, high expression of RANKL mRNA was 
detected in the B cell population (see Figure 3.3). In this initial study, mRNA gene expression 
data were normalised to levels of 18S rRNA. In following up this observation, to exclude 
potential bias which may have arisen from normalisation to 18S as a result of varying levels 
of rRNA in different cell types, the mRNA data for RANKL was normalised to the number of 
cells in each sorted cell sample, as shown in Figure 5.1. Confirming our original observation, 
PCR data normalised to cell numbers identified synovial fluid B cells as the dominant 
producers of RANKL mRNA, while a smaller proportion of CD4 T cells also showed 
RANKL mRNA expression.  
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Figure 5.1 mRNA expression of RANKL in SF and PB cell populations. (A) RANKL 
expression normalised to 18S in CD4 and CD8 T cells, B cells, macrophages and neutrophils 
from PB (open circles) and SF (closed circles). (B) RANKL expression normalised to cell 
number in each cell population sorted using FACS. Kruskal-Wallis test; *** p<0.005. CD4: 
CD3+CD4+CD45RO+ T cells; CD8: CD3+CD8+CD45RO+ T cells; B: CD19+ B cells; M: 
CD14+ macrophages; N: CD15+ neutrophils. 
 
 
130 
 
The observation of RANKL expression in B cells was subsequently extended to the protein 
level in synovial fluid and peripheral blood of RA patients. Matched synovial fluid and 
peripheral blood samples were taken from eleven patients with RA. The clinical details are 
shown in Appendix Table 8.6. Surface expression of RANKL on CD19+ B cells in synovial 
fluid and peripheral blood was determined by flow cytometry. In synovial fluid the B cell 
population represented a smaller proportion of mononuclear cells compared with the 
peripheral blood (median 3.41% synovial fluid vs 9.05% peripheral blood) (Figure 5.2). The 
surface markers IgD and CD27 were used to divide CD19+ synovial fluid and peripheral 
blood B cells into naïve (IgD+CD27-), pre-switch memory (IgD+CD27+), and post-switch 
memory (IgD-CD27+ and IgD-CD27-) B cell subpopulations. As shown in Figure 5.2, the 
majority of B cells in synovial fluid were IgD-CD27+ (median 33%) or IgD-CD27- (median 
28%). The relative proportions of IgD-CD27- and IgD-CD27+ B cell subsets in the synovial 
fluid were significantly higher than in peripheral blood (p=0.03 and p=0.04 respectively). The 
predominant B cell subset in peripheral blood was IgD+CD27- (median 54%) and the relative 
size of this population was significantly larger in peripheral blood than in synovial fluid 
(p=0.03). 
 
RANKL expression was detected in a significantly higher proportion of B cells in synovial 
fluid compared to peripheral blood (median 14.0 vs 1.89, p=0.009) (Figure 5.3). Synovial 
fluid B cells expressing RANKL were further characterised by their expression of IgD and 
CD27 in seven samples which had a sufficient cell number for analysis. As the frequency of 
RANKL-expressing B cells in peripheral blood was very low, their phenotype was not 
characterised due to low cell numbers. In the synovial fluid, RANKL-producing B cells were 
mainly IgD-CD27- (median 64%) and a smaller proportion was IgD-CD27+ (median 19%) 
(Figure 5.3). The relative frequency of the IgD-CD27- population was significantly higher in 
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the RANKL-expressing B cell population compared to the RANKL-negative fraction of B 
cells, whereas the relative IgD-CD27+ population was significantly higher in the RANKL-
negative B cell population compared to the RANKL-positive fraction of B cells  (Figure 5.3). 
However, there was considerable variation between the patients studied. The percentage of 
RANKL+ B cells in all of the subsets defined by expression of IgD and CD27 was higher in 
the synovial fluid compared to the corresponding population in the peripheral blood (Figure 
5.3C). 
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Figure 5.2 Distribution of B cell populations in RA peripheral blood and synovial fluid. 
(A) Percentage of CD19+ B cells in mononuclear cell fractions of peripheral blood and 
synovial fluid; n=11. Wilcoxon matched pairs test; ns = non-significant. (B) Representative 
image showing staining of B cell subsets based on expression of IgD and CD27 by CD19+ 
cells in peripheral blood and synovial fluid. (C) Frequency of B cell subsets gated on CD19 
present in peripheral blood (open circles) and synovial fluid (closed circles); n=7. Wilcoxon 
matched pairs test; * p<0.05. 
 
30 0.8
60 10
10 3.2
5.1 81
Gated on CD19
IgD IgD
PB                                SF
C
D
27
C
D
27
C
D
27
C
D
27
133 
 
 
0
10
20
30
40
* *
IgD-CD27+      IgD+CD27+      IgD-CD27-        IgD+CD27-
* *
C PB CD19+
SF CD19+
%
 R
AN
K
L+
 B
 c
el
ls
 
Figure 5.3 RANKL production by B cells in peripheral blood and synovial fluid. (A)  
Representative flow cytometry plot showing RANKL-expressing CD19+ B cells in peripheral 
blood and synovial fluid. IgD and CD27 expression of RANKL+ and RANKL- B cells in 
synovial fluid. (B) Percentage of RANKL+ B cells in mononuclear cell fraction of peripheral 
blood and synovial fluid (n=11) (left). B cell subsets based on IgD and CD27 expression 
within RANKL- (open circles) and RANKL+ (closed cells) B cell populations in synovial 
fluid. (C) Percentage of RANKL+ B cells in B cell subsets defined by IgD/CD27 expression 
in peripheral blood (open circles) and synovial fluid (closed circles). Wilcoxon matched pairs 
test; *p<0.05, **p<0.001. 
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5.3 RANKL production by B cells in synovial tissue and the effect of B 
cell depletion therapy 
As the synovium is the primary site of inflammation in RA, we investigated protein 
expression of RANKL by B cells in the synovial tissue. Biopsies from four RA patients were 
stained for RANKL and CD19 and assessed using immunofluorescence microscopy. As 
shown in Figure 5.4, RANKL expression was found in CD19+ B cells in the synovium.  
 
In light of the observation that B cell depletion is effective in reducing synovial inflammation 
and progression of joint destruction in RA, we wished to investigate whether there was an 
association between the presence of B cells in the synovium and expression of RANKL and if 
depletion of synovial B cells correlated with a reduction in RANKL. Synovial tissue biopsies 
from RA patients taken at baseline and 4 and 16 weeks after rituximab treatment were 
provided by Professor Paul Peter Tak, Academic Medical Centre/University of Amsterdam. 
Clinical details of the patients studied are shown in Appendix Table 8.7. Synovial tissue was 
stained for RANKL and the B cell marker CD22. Sections were analysed by 
immunofluorescence microscopy and the expression of both markers was quantified using 
digital image analysis. 13 patients from whom biopsies were available from all three time 
points were included in the study. Following staining, two patients were excluded from 
analysis due to poor quality of the tissue. 
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Figure 5.4 RANKL expression by synovial tissue B cells. Synovial tissue sections from RA 
patients were stained for CD19 and RANKL (left) or matched negative control antibodies 
(right). RANKL is shown in red; CD19 is shown in green. Expression of the B cell antigen 
CD19 was detected on the cell surface. RANKL expression was localised predominantly 
beneath the cell membrane, indicating intracellular expression of RANKL by B cells 
(indicated by arrow). Co-expression of CD19 and RANKL, indicated by yellow staining, 
shows membrane expression of RANKL by B cells. Immunofluorescence staining was 
visualised using a confocal microscope and viewed at a final magnification of X400. Images 
are representative of five samples. 
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RANKL and CD22 expression was quantified in the whole synovial biopsy section at the 
three time points for each patient. This approach was taken in order to exclude bias which 
may arise if specific areas of synovial tissue to be quantified are selected by the assessor. The 
synovial tissue sections assessed were comprised of at least six biopsies taken from different 
areas of the joint to reduce sampling variation. Representative images of stained sections are 
shown in Figure 5.5. There was a significant reduction in RANKL at 4 weeks and 16 weeks 
after rituximab compared to baseline (p=0.01 and p=0.03 respectively) (Figure 5.6A). There 
was no statistically significant decrease in CD22 at 4 or 16 weeks compared to baseline 
(Figure 5.6A). Since the clinical response to rituximab treatment is variable, we determined if 
changes in RANKL and CD22 were related to clinical improvement. Patients were grouped as 
responders (n=6) and non-responders (n=5). Patients were classed as responders if they 
showed a decrease in DAS28 of ≥1.2 at 24 weeks (Smolen et al. 2007), and had a good or 
moderate response according to the EULAR response criteria (van Gestel et al. 1998). One 
patient did not have a decrease in DAS28 of at least 1.2 at 24 weeks but had a moderate 
response according to the EULAR response criteria, and in this study this patient was 
classified as a non-responder. As reported previously in this patient cohort, clinical response 
was not predicted by the baseline number of B cells, and the decrease in synovial B cells 
between baseline and 4 weeks or between 4 and 16 weeks was not significantly different 
between the responders and non-responders (Thurlings et al. 2008). We did not observe a 
significant reduction in CD22 at 16 weeks compared to baseline in either group (Figure 5.6B 
and C). However, in the group of responders but not non-responders, total RANKL was 
significantly reduced at 16 weeks post-treatment compared to baseline (Figure 5.6B and C).  
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Figure 5.5 RANKL and CD22 synovial tissue expression before and after rituximab. 
Representative images of synovial tissue obtained at baseline (t1), 4 weeks post-infusion (t2) 
and 16 weeks post-infusion (t3) stained for RANKL (red) and CD22 (green) from patients 
classified by DAS28 improvement as a responder (left) or non-responder (right). 
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Figure 5.6 Changes in the B cell marker CD22 and RANKL expression in the synovium 
after rituximab treatment. Synovial tissue sections taken at baseline and 4 and 16 weeks 
after rituximab were stained for CD22 and RANKL by immunofluorescence. Expression of 
each marker in the whole section was quantified by digital image analysis and expressed as 
pixels per unit area. (A) Synovial CD22 and RANKL expression at baseline (t1), 4 weeks 
post-treatment (t2) and 16 weeks post-treatment (t3) in all patients. Patients were classified as 
responders or non-responders based on their DAS28 score at week 24. (B) Synovial CD22 
and RANKL expression at each time point in responding patients. (C) Synovial CD22 and 
RANKL expression at each time point in non-responding patients. Friedman repeated-
measures non-parametric tests with Dunn’s post-tests; *p<0.05, **p<0.001. 
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5.4 Discussion 
The aim of these experiments was to investigate RANKL protein expression by B cells in RA. 
We have shown that RANKL is expressed by B cells in synovial fluid and synovial tissue. 
Furthermore we observed that synovial RANKL levels decrease after B cell depletion therapy. 
The identification and characterisation of RANKL-producing B cells in RA is important as 
RANKL expression by B cells has not been previously reported in RA and implicates new 
potential roles for this cell type in RA pathogenesis.  
 
We observed increased frequencies of IgD-CD27- and IgD-CD27+ B cell subsets in synovial 
fluid compared to peripheral blood in agreement with findings from a recent study (Michelutti 
et al. 2011). RANKL production by B cells was ascribed predominantly to the IgD-CD27- 
subset, and to a lesser extent, the IgD-CD27+ subset. It is of interest that both of these 
populations are expanded in the synovial fluid. In addition, it has been reported that CD27+ 
memory B cells are increased in the RA synovium (Souto-Carneiro et al. 2009). The IgD-
CD27+ B cell subset represents a population of switched B cells which have undergone 
somatic hypermutation, and the IgD-CD27- population is also thought to represent a memory 
B cell subset. In addition to being expanded in the synovial fluid in RA, the population of 
IgD-CD27- B cells is significantly expanded in the peripheral blood of patients with SLE 
(Anolik et al. 2004; Rodriguez-Bayona et al. 2010; Wei et al. 2007), and the appearance of 
this subset correlated with disease activity. The IgD-CD27- memory population is also 
expanded in healthy subjects exposed to respiratory syncytial virus (RSV) (Sanz et al. 2008). 
The functional relevance of the expansion of this population in RA and SLE has yet to be 
investigated. Our observation that RANKL is mainly produced by memory B cells is of 
interest in light of the observation that a higher fraction of memory B cells and lower fraction 
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of immature transitional B cells during reconstitution after B cell depletion therapy correlates 
with earlier relapse of disease (Leandro et al. 2006; Palanichamy et al. 2008). 
 
We have identified RANKL-expressing B cells in the synovium, the primary site of 
inflammation in RA. In light of this observation, the ability of RANKL to mediate bone 
erosion implicates a role for B cells in joint destruction. Although not previously described in 
RA, RANKL expression by B cells associated with bone destruction has been reported in 
other diseases. In periodontal disease, B cells have been found to constitute the major source 
of RANKL in the gingival tissue, and this expression by B cells is associated with osteoclast-
mediated bone resorption (Kawai et al. 2006). RANKL production has been described in 
plasma cells in osteolytic myeloma bone disease (Heider et al. 2003), indicating a role for 
terminally differentiated B cells in bone degradation via RANKL. In addition, B cell 
lymphomas can also produce RANKL where B cell expression of RANKL is associated with 
bone loss and hypercalcemia (Shibata et al. 2005). It remains to be determined whether B 
cells have a similar role in mediating bone destruction in RA. 
 
In addition to its role in mediating bone resorption, studies using RANKL-deficient mice have 
suggested that RANKL also has a critical role in the differentiation of T and B cells and is 
required for development of lymph nodes (Kong et al. 1999a). The role of RANKL in 
lymphocyte development and its production by B cells may be relevant to the development of 
ectopic lymphoid structures in RA. Germinal centre-like structures can be found in the 
inflamed RA synovium where they can participate in the local immune response and maintain 
autoreactive lymphocytes. It has been shown that B cells in synovial lymphoid aggregates 
undergo affinity maturation and somatic hypermutation (Gause et al. 1995; Randen et al. 
1992). B cells are recognised as having an important role in the development of these ectopic 
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lymphoid structures due to their surface expression of LT-α. In a study using synovial 
biopsies it was demonstrated that activation of CD4 T cells is dependent on the presence of B 
cell follicles (Takemura et al. 2001b). It is possible that synovial B cells could also contribute 
to lymphocyte development in the RA synovium via production of RANKL. Lymphoid 
neogenesis has also been described in subchondral bone marrow adjacent to the joint in RA 
(Jimenez-Boj et al. 2007; Jimenez-Boj et al. 2005). Lymphoid aggregates were predominantly 
composed of CD27+ B cells, and B cells expressed bone morphogenic protein BMP-6 and 
BMP-7 which stimulate formation of new bone. An accumulation of osteoblasts and osteoid 
deposition in the endosteal bone next to the subcortical bone marrow aggregates implied a 
protective role for B cells. Animal models of arthritis have also postulated a protective role 
for B cell bone marrow infiltrates (Gortz et al. 2004; Hayer et al. 2008), although a study by 
Bugatti and colleagues described bone marrow lymphoid neogenesis associated with bone 
erosion (Bugatti et al. 2005). It remains unclear whether B cells present in bone marrow 
aggregates contribute to or protect against bone erosion, but may depend on the 
developmental stage and activation state of the B cell subset. For example, RANKL 
expression has been described in memory B cell subsets, whereas B cell precursors can 
produce OPG (Ehrhardt et al. 2008; Li et al. 2007). The potential for RANKL-producing B 
cells in bone marrow aggregates to promote bone erosion remains an interesting possibility. 
 
We observed that levels of RANKL in the synovium decrease after B cell depletion therapy. 
In addition, baseline expression of RANKL was found to correlate with bone erosion and 
joint space narrowing as measured by the Sharpe/van der Heijde score (SHS) (Boumans et al., 
2011). This observation supports the notion that RANKL production by synovial B cells 
could have a direct role in promoting joint destruction. However, since we have not looked at 
the impact of rituximab on RANKL in B cells specifically, it remains possible that the 
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decrease in RANKL observed may be due to effects of rituximab on other cell types. We did 
not observe a significant reduction in synovial B cells, which is in keeping with previous 
reports that B cell depletion in the synovium is highly variable between patients (Thurlings et 
al. 2008). Immunohistochemical analysis of biopsies from the same cohort as examined in the 
present study showed that rituximab treatment resulted in a decrease in synovial T cells, 
lymphocyte aggregates, germinal centres and macrophages, and plasma cell depletion in 
responding patients (Thurlings et al. 2008). This indicates that B cells have an important role 
in maintaining inflammatory cells in the synovium. B cells could potentially contribute via 
production of RANKL which prolongs the survival of dendritic cells. Dendritic cells are 
present in the RA synovium and could have a role in perpetuating synovial inflammation by 
presenting autoantigens to T cells. Immature dendritic cells express both RANK and RANKL 
and are thus able to provide an autocrine survival signal; however, peripheral maturation leads 
to down-regulation of RANKL, suggesting that an independent source of RANKL may be 
required for dendritic activation (Cremer et al. 2002). 
 
RANKL is produced in membrane-bound and soluble forms, both of which are capable of 
stimulating osteoclast differentiation in vitro. The soluble form can be generated by 
proteolytic cleavage of the membrane-bound protein, or by alternative splicing. It is thought 
that transcription of a RANKL gene that does not encode a trans-membrane domain may be 
preferentially produced in malignant cell types. It would be interesting to determine 
intracellular expression of RANKL in B cell subsets, and soluble expression of RANKL by B 
cells in addition to the membrane expression that we have previously detected. Future 
experiments include detection of intracellular RANKL expression in synovial fluid B cells by 
flow cytometry, following fixing and permeabilisation of the cell membrane, or using 
immunofluorescence microscopy to detect intracellular vs surface expression of RANKL by 
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sorted synovial fluid B cells. It would also be important to determine whether RANKL is 
released from the cell surface, which could be addressed by stimulating synovial fluid B cells 
then using ELISA to detect soluble RANKL in the supernatant. 
 
In summary, the identification of RANKL-producing B cells in the RA synovium and 
characterisation of the memory B cell subsets expressing RANKL is of importance due to the 
functional relevance of this cytokine in the pathogenesis of RA. These experiments thus 
provide an important basis for determining the functional role of RANKL expression by B 
cells in RA. 
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6 GENERAL DISCUSSION 
6.1 Cytokine production in RA 
Cytokines play a critical role in influencing the immune response, being involved in almost 
every aspect of immunity and inflammation, from the induction of an innate immune response 
to the generation of cytotoxic T cells and the production of antibodies by the adaptive immune 
system. Many cytokines are found in the chronically inflamed synovium of patients with 
rheumatoid arthritis, and over the years there have been many studies undertaken to address 
the roles of cytokines in the disease processes. In the literature there is much evidence to 
suggest that cytokines play a central role in RA pathogenesis, and this concept is supported by 
the demonstration that cytokines are effective therapeutic targets in current clinical practice. 
Despite the large number of studies investigating the expression and functions of many 
cytokines in RA, there has been no attempt made to systematically determine the expression 
of multiple cytokines in the predominant cell populations present in the inflamed RA 
synovium. In this thesis I have presented data showing cytokine expression profiles 
determined directly ex vivo in the major cell populations isolated from RA synovial fluid. 
This work provides important confirmation of cytokine expression data from studies which 
were performed using ex vivo stimulation or in vitro culture of RA synovial cells, and has also 
resulted in several novel observations which will be discussed further in this chapter. 
 
Chronic inflammation of the synovium in RA is characterised by interactions between cells of 
the adaptive immune system, the innate immune system, and resident stromal cells. 
Characterising cytokine production by these cell types can provide insight into disease 
processes. Indeed, efforts have been made to determine cytokine production in the RA 
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synovium and synovial fluid since the necessary molecular techniques became available in the 
late 1980s. At the time of these studies, the prevailing hypothesis implicated Th1 cells as the 
cell type responsible for driving RA, and the detection of relatively low concentrations of 
IFN-γ was an unexpected observation. In recent years, Th17 cells have been proposed as 
central mediators of RA pathology, although their role in RA is still a matter of debate. IL-17 
synergises with IL-1β by inducing RANKL and its receptor, RANK, which induces osteoclast 
differentiation (Lubberts et al. 2003). IL-17 also synergises with TNF-α to induce pro-
inflammatory cytokines and chemokines from monocytes and synovial fibroblasts (Chabaud 
et al. 1998; Jovanovic et al. 1998; Katz et al. 2001). In this work, both IFN-γ and IL-17 were 
found to be expressed by established RA synovial fluid CD4 T cells. It remains to be 
determined whether these CD4 T cells represent Th1 and Th17 cell subsets as have been 
previously reported in RA (Chabaud et al. 1999; Kotake et al. 1999; Raza et al. 2005; 
Yamada et al. 2011; Ziolkowska et al. 2000), or whether these cells express both IFN-γ and 
IL-17 as has been described in a Th17/1 subset of T cells (Annunziato et al. 2007). The 
concept that T cells have a remarkable degree of plasticity has revolutionised our 
understanding of cell lineages, which were originally ascribed a unique transcription factor 
and a terminally differentiated effector phenotype. Cells with an intermediate phenotype 
sharing master transcription factors from apparently distinct cell types such as Th17/1 cells 
are detectable in humans, and regulatory T cells can convert to Th17 cells (Koenen et al. 
2008; Lee et al. 2009; Manel et al. 2008). Therefore it would be of interest to further 
characterise the T cell subsets we have identified as producing IL-17 and IFN-γ in RA 
synovial fluid, although many of the recently-described subsets are defined by their effector 
function, i.e. cytokine production or suppression, and very few surface markers are defined 
that would allow us to safely distinguish these subsets without ex vivo stimulation. 
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B cells are regarded as an important cell type in RA due to their ability to produce antibody 
and present antigen, but little is known about direct cytokine production by B cells in RA. In 
this study, RA synovial fluid B cells were found to express high levels of mRNA for pro-
inflammatory cytokines including IL-12 and IL-23, indicating a potential role in promoting 
the differentiation of Th1 and Th17 cell subsets in the RA synovium, which as discussed may 
have important roles in promoting inflammation and joint destruction. We also observed high 
levels of RANKL expression in RA B synovial fluid cells (Yeo et al. 2011), suggesting a role 
in promoting osteoclast-mediated bone erosion, and this finding is discussed in further detail 
in 7.2. 
 
In the first studies of cytokine expression in RA, a striking observation was that macrophage 
and fibroblast products were abundant in the RA synovium. In this study RA synovial fluid 
macrophages were found to express high levels of pro-inflammatory cytokines TNF-α, IL-6 
and IL-1α, in addition to other synovial fluid populations. Importantly, this work has 
highlighted neutrophils as a prominent source of the type II IFNs, IFN-α1 and IFN-β1, 
suggesting a role in activating and maintaining inflammatory cell populations in the RA 
synovium. We observed that RA synovial fluid neutrophils also express high levels of mRNA 
for IL-1β, CCL3 and CXCL8, indicating a direct pro-inflammatory role for this cell type in 
RA and indicating their ability to attract other leukocytes to the synovial fluid, thus 
perpetuating the cycle of inflammation. 
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6.2 B cells as a source of RANKL in RA 
Destruction of bone, manifesting as erosions on radiographs, is a major effect of RA, and joint 
destruction may occur very early in the disease course (Plant et al. 1998). RA causes local 
erosions and juxta-articular and general osteopenia. In this thesis I have presented evidence 
that B cells in the synovial fluid and synovial tissue of patients with RA produce RANKL, a 
critical factor for osteoclast differentiation. Expression of RANKL implies a direct role for B 
cells in promoting osteoclastogenesis leading to joint destruction, a concept supported by 
previous reports of bone destruction driven by B-cell RANKL production in periodontitis, and 
in transformed B cells and plasma cells of B cell lymphomas and multiple myeloma 
respectively. Several cell populations have previously been reported to produce RANKL in 
the RA synovium, including T cells, chondrocytes, and synovial fibroblasts which are present 
at the site at which the pannus tissue invades the bone (Crotti et al. 2002; Gravallese et al. 
2000; Shigeyama et al. 2000; Skoumal et al. 2005). The functional relevance of the B cell 
population contribution to RANKL expression in the RA synovium has yet to be explored. A 
growing body of evidence suggests an important role for B cells in regulating 
osteoclastogenesis through their ability to produce RANKL, (Choi et al. 2001; Manabe et al. 
2001), OPG (Li et al. 2007), and TGFβ (Weitzmann et al. 2000). 
 
RANKL was found to be expressed by B cells in the synovial fluid of patients with 
established RA and early RA but not with resolving synovitis, indicating that RANKL 
expression may be specific for RA. This observation requires further analysis as we have only 
investigated a small number of patients with resolving disease so far. However, other studies 
have reported expression of RANKL by activated B cells (Choi et al. 2001), and mRNA 
expression of RANKL has been reported in memory B cells from healthy individuals 
(Ehrhardt et al. 2008). It would be of interest to investigate whether RANKL expression by B 
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cells plays a role in other autoimmune pathologies associated with osteopenia and 
osteoporosis such as SLE, type I diabetes, autoimmune thyroid disease and celiac disease, in 
which bone impairment may occur as a consequence of immunoregulatory imbalance. 
Interestingly, RANKL is upregulated in B cells and T cells isolated from the bone marrow of 
post-menopausal women compared with pre-menopausal women or post-menopausal women 
treated with estrogen (Eghbali-Fatourechi et al. 2003), and it has been suggested that 
lymphocyte expression of RANKL could play a role in the elevated bone resorption 
associated with loss of sex steroids. This may be pertinent to the pathogenesis of RA which is 
2-3 times more prevalent in women than men and is most common in those aged 40 to 60, an 
age range which coincides with that during which women commonly enter menopause. 
Hormone replacement therapy administered to post-menopausal women with RA has been 
found to increase and maintain bone mineral density, indicating a protective role of estrogens 
against bone loss. In addition, studies have shown that B cell precursors are able to 
differentiate into osteoclasts in vitro (Sato et al. 2001). It has been suggested that by 
stimulating B cell lymphopoiesis, estrogen deficiency could enhance osteoclastogenesis by 
increasing the number of B cell precursors with the potential to differentiate into osteoclasts 
(Li et al. 2007). It would be interesting to explore a potential association between the 
influence of estrogens and RANKL expression by lymphocytes, including B cells, in patients 
with RA. Another aspect which would be interesting to investigate is whether RANKL is 
expressed by B cells in the B cell aggregates which are found at erosive sites at the interphase 
between synovial tissue and bone marrow in RA (Bugatti et al. 2005). While the authors 
suggest an erosive role for B cells in RA, other studies have proposed that B cells in the bone 
marrow in animal models of RA may have a protective effect: B cell infiltration in the bone 
marrow in RA has been linked to a shift in bone homeostasis toward osteoblasts and new 
bone formation (Gortz et al. 2004; Jimenez-Boj et al. 2005), and in an experimental model of 
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arthritis using TNF-transgenic mice lacking an essential molecule for B cell development, 
Btk, bone marrow infiltration by B cells was significantly diminished (Hayer et al. 2008). It 
would be interesting to investigate whether RANKL-expressing B cells are found in the bone 
marrow in RA in relation to the hypothesis that RA starts in the bone marrow and migrates to 
the synovium (the so-called “inside-out” hypothesis) rather than originating in the synovial 
membrane and promoting invasion into cartilage, bone and bone marrow space (the “outside-
in” hypothesis) (Schett and Firestein 2010). 
 
RANKL was found to be produced predominantly by IgD-CD27- and IgD-CD27+  memory B 
cell subsets in RA synovial fluid. Memory B cell subsets are expanded in the RA synovium 
compared to peripheral blood (Michelutti et al. 2011; Souto-Carneiro et al. 2009), supporting 
the concept of RANKL produced by B cells mediating local joint destruction.  Our 
observation that B cells produce RANKL in RA is important in the context of understanding 
current therapies used in RA, rituximab and denosumab, which target B cells and RANKL 
respectively. Interestingly, the presence of IgD-CD27- memory B cells correlates with disease 
activity in SLE (Wei et al. 2007), highlighting a potential pathogenic role for this B cell 
compartment. Furthermore, levels of RANKL in the RA synovium were found to decrease 
following treatment with rituximab, suggesting that B cell depletion at least has an indirect 
effect, if not direct, in inhibiting bone erosion by osteoclasts. The memory B cell 
compartment is considered important in mediating chronic autoimmunity due to its properties 
of long lifespan, prompt and enhanced responses to activation, and ability to stimulate T cells. 
Thus, once tolerance is broken in the B cell compartment, memory responses would continue 
to persist, being easily reactivated in the presence of self-antigen, and could serve to further 
diversify and amplify the autoimmunity. RANKL was mostly expressed by the IgD-CD27- 
memory B cell subset, a population suggested to derive from extra-follicular responses or 
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incomplete germinal centre reactions (Sanz et al. 2008). This is interesting in light of the 
observation that the ACPA have a significantly lower avidity than antibodies to the recall 
antigens tetanus toxoid and diphtheria toxoid, suggesting that avidity maturation in germinal 
centres in the ACPA response differs from that which occurs in conventional B cell responses 
(Suwannalai et al. 2010). Evidence of lymphoid aggregation and germinal centre-like 
structures has been observed in the RA synovium, suggesting that the memory cells which 
produce RANKL may be produced locally in the synovium. Recent unpublished evidence 
from studies in mice suggests that RANKL is expressed by long-lived plasma cells in T cell-
dependent responses and has a role in inducing and maintaining long-lived plasma cells (M. 
Cancro, presented at 17th Germinal Centre Conference 2011). These data may fit with our 
observation in that memory B cells found to be expressing RANKL in our study may 
represent B cells differentiating towards a long-lived plasma cell fate. A further avenue to be 
explored concerns the putative role of RANKL in lymphocyte differentiation and lymph node 
development (Kong et al. 1999b). Interpretation of results from studies using RANKL-
deficient mice needs to take into account the fact that these mice lack a bone marrow 
compartment. Nevertheless, it would be interesting to investigate in the context of human RA 
whether RANKL expression by B cells has a role in maintaining lymphocytes and lymphoid 
aggregates in the RA synovium, especially in light of the observation that B cells appear to 
have a role, which may be indirect, in maintaining inflammatory cell populations in the RA 
synovium (Thurlings et al. 2008). RANKL has been reported to be involved in activating 
dendritic cells (Cremer et al. 2002), a population which is present in the RA synovium and 
may thus have a role in activating T cells in the RA synovium.  
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6.3 Cytokine expression in early synovitis: early RA vs self-resolving 
disease 
The potential outcomes of patients with early synovitis vary from self-limiting inflammation 
to severe destructive RA. We hypothesised that early synovitis patients with resolving disease 
vs early RA would differ in cytokine expression in synovial fluid cell populations and in the 
synovium. Chronic inflammatory diseases such RA can be considered to have both “public” 
features of inflammation that are common to a generic inflammatory response, and “private” 
features of inflammation that are specific for the site of inflammation and development of 
chronicity. By comparing cytokine profiles of the synovium of patients with different 
outcomes, we sought to determine whether particular cytokines would identify those 
pathological features that are unique to RA. Cytokine profiling of synovial fluid populations 
showed that IFN-β1 expression in CD8 T cells was higher in patients with early synovitis 
with resolving disease than synovitis patients who develop RA, suggesting a heightened anti-
viral response in resolving synovitis patients. In synovial tissue, perhaps partly due to the 
large variation within patient groups, cytokine levels were not significantly different between 
early synovitis patients with resolving disease and those destined to develop RA. These 
results indicate that the same type of inflammatory response may be present in synovitis 
patients irrespective of their final outcome. This would be consistent with histological data 
from a previous study (Schumacher and Kitridou 1972) and our own preliminary histological 
observations. We did not detect differences in expression of cytokines which have been 
previously reported as upregulated in the synovial fluid of early RA compared to resolving 
synovitis patients (Raza et al. 2005), which may be due to different methods such as 
measurement of mRNA rather than protein expression, the site of sample collection, and 
measurement of cytokine expression in isolated synovial fluid populations rather than in the 
whole synovial fluid. Evidence suggests that treatment of RA within the first 3 months is 
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more effective than when commenced later in the disease, highlighting the need for the early 
identification of patients destined to develop RA. Our results suggest that it is not possible to 
distinguish by their synovial cytokine profile those early synovitis patients who will develop 
RA from those with resolving synovitis, and that other parameters need to be assessed to 
predict the outcome of synovitis patients at presentation. At present, treatment protocols are 
guided by prognostic algorithms that include clinical parameters and positivity for 
autoantibodies. Current research efforts aimed at predicting the fate of early synovitis patients 
include the assessment of clinical, radiological, genetic and biological data collated from 
multiple centres within the Pathobiology of Early Arthritis Cohort (PEAC) consortium. Data 
derived from studies using gene expression profiling, proteomics, metabonomics, genotyping, 
serum and synovial fluid cytokine and chemokine analysis, synovial tissue characterisation, 
ultrasound imaging and clinical phenotyping may provide predictors of disease evolution that 
will be useful in future clinical practice, and shed light on the underlying disease processes 
involved in perpetuation or resolution of inflammation in patients with diverging clinical 
outcomes. 
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6.4 Synovial cytokine expression in different phases of RA and patient 
subsets 
Evidence suggests that different disease mechanisms may operate during the early and 
established phases of RA. In this work, higher levels of IFN-β were found in established RA 
patients, which may reflect a mechanism that sustains the survival of inflammatory cells in the 
synovium. Apart from this difference, cytokine expression was similar in the early and 
established phases of RA, indicating that in patients destined to develop RA, inflammation is 
already established within the first 3 months of symptom onset. These findings support the 
notion that intervention before onset of clinical signs and symptoms may be beneficial, as it 
may provide an opportunity to prevent synovial inflammation from becoming established. 
The inability of currently used therapies, such as anti-TNF therapy, to induce permanent 
remission that is maintained following drug withdrawal, may be explained if the arbiters of 
persistent inflammation have already been established at the time treatment is initiated and are 
not modulated by this treatment; in this situation, therapy is only able to suppress 
inflammation rather than cure the disease. 
 
The presence of ACPA in a large proportion of patients with RA and the specificity of ACPA 
for RA implicates an autoimmune component at least in a proportion of patients with RA. It is 
still debated whether autoimmunity may arise as an inevitable consequence of a highly 
sensitive amplificatory immune system or if it only occurs as a result of an external stimulus. 
The striking similarities observed between ACPA-positive and ACPA-negative RA suggests 
that although the aetiology of disease may be different in these patient subsets, pathogenic 
mechanisms converge on a final common pathway resulting in the clinical entity we define as 
“RA”. Similarities between ACPA-positive and ACPA-negative patients with early RA fits 
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with the observation that at presentation, there are no apparent clinical phenotypic differences 
according to ACPA status (Cader et al. 2010; van der Helm-van Mil et al. 2005). However, 
similarities observed between ACPA-positive and ACPA-negative patients with established 
RA does not reflect the observation that ACPA-positive patients have a more erosive disease 
course, although cytokine expression reflecting these differences may be more apparent at the 
site of bone and cartilage destruction, i.e. the cartilage-pannus junction, rather than the sites 
biopsied from the synovium in this study. 
 
Several pieces of evidence support the importance of pre-clinical abnormalities which precede 
development of RA. The presence of ACPA predicts development of RA, and there is 
evidence for epitope spreading prior to disease onset, with the extent of the repertoire being 
associated with development of arthritis in patients with arthralgia (van de Stadt et al. 2010). 
Positivity for rheumatoid factor is also strongly associated with the development of RA. 
mRNA expression profiling of peripheral blood cells from ACPA- and/or rheumatoid factor-
positive patients with arthralgia found that signatures associated with development of arthritis 
were involved in IFN-mediated immunity, haematopoiesis, and chemokine/cytokine activity 
(van Baarsen et al. 2010). In addition, the upregulation of serum cytokines at the protein level 
(IL-1, TNF-α, IL-6, IL-2, IL-12, IFN-γ, IL-4, IL-10, CCL2, CCL3, GM-CSF and G-CSF) has 
been reported in another study which examined ACPA-positive individuals who went on to 
develop RA (Kokkonen et al., 2010). Some studies have also reported increased levels of 
CRP prior to onset of RA (Aho et al. 2000; Nielen et al. 2004). Despite increasing insight into 
the pre-clinical phase of RA, the natural history of the disease remains unknown. Evidence 
supports an initial phase in which genetic and environmental interactions lead to a period of 
asymptomatic autoimmunity which later develops into clinically-apparent disease. However, 
the physical location where genetic and environmental factors interact leading to a break in 
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tolerance remains unknown. Due to the link between RA and smoking it has been suggested 
that this may occur at periodontal surfaces or the lung. Furthermore, the stimuli responsible 
for mediating the transition from a systemic immune disturbance into a joint-centric 
pathology are not clear at present. Studying disease processes in non-articular tissue such as 
the bone marrow and lymph nodes, and systems such as the neuroendocrine system, may be 
informative in furthering our understanding of the development of RA. Some of these issues 
are being addressed by collaborative efforts such as those within the EULAR study group on 
the pre-clinical and earliest clinically-apparent phases of RA. Ultimately, research into these 
areas may lead to the development of pharmacological or non-pharmacological interventions 
that could be used in the pre-clinical and earliest clinically-apparent phases of RA. For 
example, risk-factor modification in certain individuals such as cessation of smoking could 
prevent clinical development of the disease. 
 
6.5 Future work 
In this work I have described novel cytokine mRNA expression patterns in cell populations 
isolated from the synovial fluid of RA patients. For example, several pro-inflammatory 
cytokines were found to be expressed by synovial fluid B cells and neutrophils. These 
observations, made on the level of mRNA expression, need to be verified on the protein level, 
since mRNA expression may not be representative of protein production due to post-
transcriptional and post-translational regulation of gene expression. To follow up the findings 
reported here, it would also be interesting to sort these populations from synovial tissue and 
confirm cytokine expression in cells present within the RA synovium itself. This could be 
achieved by digestion of synovial tissue, isolation of mononuclear cell populations on a Ficoll 
gradient, and sorting stained cell populations by FACS as I have done for synovial fluid 
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populations. In this study I have identified genes as being differentially expressed between 
different patient groups (early resolving synovitis, early RA and established RA). These 
observations also need to be confirmed on the protein level, for example by 
immunofluorescence staining of synovial tissue sections.  
 
The cytokine expression profiling study of RA synovial fluid populations has enabled us to 
characterise sources of several cytokines. Using the data generated in this study, it would be 
of interest to employ bioinformatic strategies to propose a model of cell-cell interactions 
mediated by cytokines between the five largest populations in the synovial fluid in RA. 
 
Further work remains to be done to characterise the B cell subsets producing RANKL in RA 
synovial fluid, and to extend this work to synovial tissue B cells. We are planning to use an 
extended panel of antibodies including RANKL, CD19, IgD, IgM, CD27, CD38, CD20, 
CD21, CD95, CD11c and CD138 to identify subsets of B cells and plasma cells in the 
synovial fluid and peripheral blood and to assess their level of RANKL expression. 
Immunofluorescence staining could also be used to distinguish these B cell and plasma cell 
populations in RA synovial tissue. RANKL-expressing B cell subsets could then be sorted 
from synovial tissue and synovial fluid to assess mRNA levels of RANKL expression. An 
aspect that remains to be addressed concerns the regulation of the expression and release of 
RANKL which is produced in both membrane-bound and soluble forms. This may be 
investigated by stimulating sorted B cells in vitro using anti-CD40 or anti-IgG, and assessing 
the effects of B cell stimulating cytokines such as BAFF, APRIL, IL-5, IL-6 and IL-10. In 
addition, functional assays need to be carried out to assess whether RANKL-producing B 
cells from patients with RA are capable of mediating bone-resorption by osteoclasts in vitro.  
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8 APPENDIX 
8.1 Custom gene sets 
Table 8.1 Custom gene set for real-time PCR assays used to detect mRNA expression in 
synovial fluid and peripheral blood cell populations 
 
No. Assay ID No.  Assay ID 
1 IL1A-Hs00174092_m1 25 CCL5-Hs00174575_m1 
2 IL1B-Hs00174097_m1 26 MIF-Hs00236988_g1 
3 IL2-Hs00174114_m1 27 CCL11-Hs00237013_m1 
4 IL4-Hs00174122_m1 28 TNF-Hs00174128_m1 
5 IL5-Hs00174200_m1 29 LTB-Hs00242739_m1 
6 IL6-Hs00174131_m1 30 TGFB1-Hs99999918_m1 
7 IL7-Hs00174202_m1 31 TNFSF11-Hs00243522_m1 
8 IL8-Hs00174103_m1 32 TNFSF13B-Hs00198106_m1 
9 IL10-Hs00174086_m1 33 
TNFSF13;TNFSF12-TNFSF13-
Hs00182565_m1 
10 IL11-Hs00174148_m1 34 IFNA1-Hs00256882_s1 
11 18S-Hs99999901_s1 35 IFNG-Hs99999041_m1 
12 IL12A-Hs00168405_m1 36 IFNB1-Hs00277188_s1 
13 IL12B-Hs00233688_m1 37 CSF2-Hs00171266_m1 
14 IL13-Hs00174379_m1 38 CSF3-Hs00236884_m1 
15 IL15-Hs00174106_m1 39 CXCL12-Hs00171022_m1 
16 IL17A-Hs00174383_m1 40 EGF-Hs01099999_m1 
17 IL18-Hs00155517_m1 41 FGF2-Hs00266645_m1 
18 IL21-Hs00222327_m1 42 VEGFA-Hs00173626_m1 
19 IL22-Hs00220924_m1 43 LGALS3-Hs00173587_m1 
20 IL23A-Hs00413259_m1 44 LGALS9-Hs00371321_m1 
21 IL27-Hs00377366_m1 45 HSD11B1-Hs01547870_m1 
22 CCL3-Hs00234142_m1 46 HSD11B2-Hs00388669_m1 
23 
CCL4;CCL4L1;CCL4L2-
Hs00237011_m1 47 GAPDH-Hs99999905_m1 
24 CCL2-Hs00234140_m1 48 IL6ST-Hs00174360_m1 
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Table 8.2 Custom gene set 1 for real-time PCR assays used to detect mRNA 
expression in synovial tissue  
 
No. Assay ID No.  Assay ID 
1 CSF3-Hs00236884_m1 25 
TXLNA-
Hs00233304_m1 
2 CSF2-Hs00171266_m1 26 IL15-Hs00542562_m1 
3 CSF1-Hs00174164_m1 27 IL16-Hs00189606_m1 
4 IFNA1-Hs00256882_s1 28 IL17A-Hs00174383_m1 
5 IFNA2-Hs00265051_s1 29 IL17F-Hs00369400_m1 
6 IFNB1-Hs00277188_s1 30 IL18-Hs00155517_m1 
7 IFNG-Hs00174143_m1 31 IL19-Hs00203540_m1 
8 IL1A-Hs00174092_m1 32 IL20-Hs00218888_m1 
9 IL1B-Hs00174097_m1 33 IL22-Hs00220924_m1 
10 IL1RN-Hs00277299_m1 34 IL23A-Hs00372324_m1 
11 18S-Hs99999901_s1 35 IL24-Hs01114274_m1 
12 IL2-Hs00174114_m1 36 IL25-Hs00224471_m1 
13 IL3-Hs00174117_m1 37 IL26-Hs00218189_m1 
14 IL4-Hs00174122_m1 38 IL27-Hs00377366_m1 
15 IL5-Hs00174200_m1 39 IL28A-Hs00820125_g1 
16 IL6-Hs00985639_m1 40 IL29-Hs00601677_g1 
17 IL7-Hs00174202_m1 41 IL32-Hs00992441_m1 
18 IL8-Hs00174103_m1 42 IL33-Hs00369211_m1 
19 IL9-Hs00174125_m1 43 LIF-Hs00171455_m1 
20 IL10-Hs00174086_m1 44 OSM-Hs00171165_m1 
21 IL11-Hs00174148_m1 45 LTA-Hs00236874_m1 
22 IL12A-Hs00168405_m1 46 TNF-Hs00174128_m1 
23 IL12B-Hs00233688_m1 47 LTB-Hs00242739_m1 
24 IL13-Hs00174379_m1 48 
TNFSF4-
Hs00182411_m1 
 
continued 
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No. Assay ID No.  Assay ID 
49 CD40LG-Hs00163934_m1 73 CXCL5-Hs00171085_m1 
50 FASLG-Hs00181225_m1 74 CXCL6-Hs00237017_m1 
51 CD70-Hs00174297_m1 75 PPBP-Hs00234077_m1 
52 TNFSF8-Hs00174286_m1 76 CXCL9-Hs00171065_m1 
53 TNFSF9-Hs00169409_m1 77 CXCL10-Hs00171042_m1 
54 TNFSF10-Hs00234356_m1 78 CXCL11-Hs00171138_m1 
55 TNFSF11-Hs00243522_m1 79 CXCL12-Hs00171022_m1 
56 TNFSF12-Hs00611242_m1 80 CXCL13-Hs00757930_m1 
57 
TNFSF13;TNFSF12-TNFSF13-
Hs00182565_m1 81 CXCL14-Hs00171135_m1 
58 TNFSF13B-Hs00198106_m1 82 CXCL16-Hs00222859_m1 
59 TNFSF14-Hs00542477_m1 83 CCL1-Hs00171072_m1 
60 TNFSF15-Hs00353710_s1 84 CCL2-Hs00234140_m1 
61 TNFSF18-Hs00183225_m1 85 CCL3-Hs00234142_m1 
62 CD40-Hs00386848_m1 86 
CCL4;CCL4L1;CCL4L2-
Hs00237011_m1 
63 FAS-Hs00531110_m1 87 CCL5-Hs00174575_m1 
64 TNFRSF18-Hs00188346_m1 88 CCL7-Hs00171147_m1 
65 TGFB1-Hs00998133_m1 89 CCL8-Hs00271615_m1 
66 TGFB2-Hs00234244_m1 90 CCL11-Hs00237013_m1 
67 TGFB3-Hs00234245_m1 91 CCL13-Hs00234646_m1 
68 MIF-Hs00236988_g1 92 CCL15;CCL14-Hs00234981_m1 
69 CXCL1-Hs00236937_m1 93 CCL16-Hs00171123_m1 
70 CXCL2-Hs00236966_m1 94 CCL17-Hs00171074_m1 
71 CXCL3-Hs00171061_m1 95 CCL18-Hs00268113_m1 
72 PF4-Hs00427220_g1 96 GAPDH-Hs99999905_m1 
 
197 
 
Table 8.3 Custom gene set 2 for real-time PCR assays used to detect mRNA 
expression in synovial tissue  
No. Assay ID No.  Assay ID 
1 IFNA1-Hs00256882_s1 25 IL20-Hs00218888_m1 
2 IFNA2-Hs00265051_s1 26 IL22-Hs00220924_m1 
3 IFNB1-Hs00277188_s1 27 IL24-Hs01114274_m1 
4 KITLG-Hs00295067_s1 28 IL25-Hs00224471_m1 
5 ADIPOQ-Hs02564413_s1 29 CCL1-Hs00171072_m1 
6 TNFSF15-Hs00353710_s1 30 CCL7-Hs00171147_m1 
7 CD248-Hs00535586_s1 31 CSF3-Hs99999083_m1 
8 SOCS3-Hs00269575_s1 32 18S-Hs99999901_s1 
9 IL28A-Hs00820125_g1 33 B2M-Hs00187842_m1 
10 IL29-Hs00601677_g1 34 IFNG-Hs00174143_m1 
11 GAPDH-Hs99999905_m1 35 IL2-Hs00174114_m1 
12 MIF-Hs00236988_g1 36 IL23A-Hs00372324_m1 
13 SUMO1-Hs02339312_g1 37 IL11-Hs00174148_m1 
14 SRD5A1-Hs00971643_g1 38 IL12A-Hs00168405_m1 
15 IL21-Hs00222327_m1 39 IL12B-Hs00233688_m1 
16 IL1A-Hs00174092_m1 40 LTA-Hs00236874_m1 
17 IL3-Hs00174117_m1 41 CSF2-Hs00171266_m1 
18 IL4-Hs00174122_m1 42 CCL11-Hs00237013_m1 
19 IL5-Hs00174200_m1 43 CCL25-Hs00171144_m1 
20 IL9-Hs00174125_m1 44 PADI4-Hs00202612_m1 
21 IL13-Hs00174379_m1 45 PADI2-Hs00247108_m1 
22 IL17A-Hs00174383_m1 46 AOC3-Hs00186647_m1 
23 IL17F-Hs00369400_m1 47 FAP-Hs00990806_m1 
24 IL19-Hs00203540_m1 48 IL1F7-Hs00367199_m1 
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8.2 Patient clinical data 
Table 8.4 Clinical data for established RA, early RA and early resolving synovitis patients. Synovial fluid and peripheral blood 
samples from these patients were used for experiments described in Chapter 3 and Chapter 4.  
Outcome Age Gender 
Symptom 
duration ESR  CRP RF CCP Treatment  TJC28 SJC28 
DAS28 
ESR 
Early RA 66 M 6 weeks 25 83 positive negative nsaid 3 24 4.7 
Early RA 48 F 2 weeks 4 102 negative negative diclofenac 8 6 3.5 
Early RA 75 M 5 weeks 40 40 negative negative nil 27 26 8.3 
Early RA NA F 7 weeks 60 40 negative negative nsaid 11 16 6.7 
Early RA 41 F 6 weeks 54 40 positive positive diclofenac 28 18 8.3 
Early 
Resolving 32 M 7 weeks 10 10 negative negative nsaid 1 1 2.9 
Early 
Resolving 35 M 1 week 2 9 negative negative nil 1 3 1.6 
Early 
Resolving 34 M 2 weeks 51 7 negative NA ibuprofen 1 1 NA 
Est RA 66 F 6 yrs 81 92 negative negative hydroxychloroquine 1 3 4.4 
Est RA 79 M 1 yr 17 16 positive positive prednisolone, methotrexate 5 5 4.5 
Est RA 67 F 30 yrs 66 89 positive positive hydroxycholorquine, sulfasalazine 13 10 7.2 
Est RA 59 F 1 yr 27 19 positive positive ibuprofen, prednisolone 3 3 5 
Est RA 41 M 6 yrs 32 54 positive positive prednisolone, methotrexate, etanercept 3 8 5.1 
Est RA 79 M 1 yr 48 119 positive positive nil 28 26 8.4 
Est RA 75 F 40 yrs 55 49 positive positive methotrexate, sulphasalazine 2 3 4.9 
Est RA 41 M 6 yrs 32 44 positive positive methotrexate, prednisolone, adalimumab 3 5 5.3 
Est RA 55 F 5 yrs 124 221 positive positive methotrexate 14 8 7.5 
Est RA 52 M 2 yrs 7 9 positive negative diclofenac 2 8 3.2 
Est RA 73 F 18 yrs 7 7 positive NA meloxicam, methotrexate 9 10 4.6 
Est RA 58 F 6 yrs 22 18 positive positive nabumetone, prednisolone 7 6 5.6  
Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), Rheumatoid Factor (RF), Cyclic Citrullinated Peptide Antibody (CCP), Tender Joint Count 28 (TJC), 
Swollen Joint Count 28 (SJC), Disease Activity Score 28 (DAS28), Established RA (Est RA), non-steroidal anti-inflammatory drug (NSAID), data not available (NA). 
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Table 8.5 Clinical data for established RA, early RA and early resolving synovitis patients. Synovial tissue samples from these patients 
were used for experiments described in Chapter 4.  
Outcome Age Gender 
Symptom 
duration 
(weeks) ESR  CRP RF CCP 
Treatment 
NSAID 
Treatment 
Prednisolone TJC28 SJC28 
DAS28 
ESR 
Est RA 46 M 150 34 7 p p y n 13 16 6.7 
Est RA 61 F 30 8 9 n n n n 15 6 4.9 
Est RA 69 F 52 11 0 n n n n 7 7 4.6 
Est RA 57 M 14 56 16 p p y n 21 14 7.1 
Est RA 58 M 16 7 0 p p y n 7 7 4 
Est RA 56 F 52 10 0 p p y n 12 3 5.5 
Est RA 46 F 30 24 na n p y n 10 4 5.2 
Est RA 64 M 26 13 17 n n y n 14 16 5.4 
Est RA 67 M 38 29 48 p p n n 1 1 4.2 
Est RA 22 F 52 81 79 n n y n 6 6 6.4 
Est RA 72 F 38 53 43 n n y n 21 16 7.4 
Est RA 52 F 38 26 52 p p y n 20 8 6.5 
Est RA 65 M 156 72 81 p p n n 3 12 5.3 
Early RA 70 F 5 68 26 n n y n 4 5 6 
Early RA 49 F 2 12 8 n n n n 9 8 4.7 
Early RA 45 F 10 24 12 n n y n 3 3 3.8 
Early RA 63 F 4 104 9 n n n n 1 5 5.1 
Early RA 48 F 2 4 102 n n y n 8 6 3.5 
Early RA 59 M 6 14 22 n n n y 4 20 5 
Early RA 44 F 5 18 10 n n y n 3 2 3.8 
Early RA 43 M 9 58 0 n n y n 19 4 6.9 
Early RA 56 M 10 5 0 p n n n 14 21 5.2 
Early RA 55 M 4 58 45 n p n n 0 4 3.5 
Early RA 42 F 2 54 40 p p y n 28 18 8.3 
Early RA 53 F 12 11 0 n n y n 7 2 4.2 
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Outcome Age Gender 
Symptom 
duration 
(weeks) ESR  CRP RF CCP 
Treatment 
NSAID 
Treatment 
Prednisolone TJC28 SJC28 
DAS28 
ESR 
Early RA 62 F 12 40 5 p p y n 4 2 4.3 
Early RA 74 F 9 20 32 n p n n 3 3 4.4 
Early RA 58 F 7 27 0 p p y n 5 9 4.5 
Early RA 49 F 6 25 18 p p y n 17 12 6.8 
Early RA 48 M 4 63 38 p p y n 8 9 6 
Early Resolving  64 M 6 24 15 n n y n 5 2 4.5 
Early Resolving  40 F 4 5 0 n n y n 7 7 3.9 
Early Resolving  32 M 7 10 10 n n y n 1 1 2.9 
Early Resolving  33 M 4 51 14 n n y n 12 9 6.7 
Early Resolving  74 M 5 45 13 n n y n 0 23 4.8 
Early Resolving  72 M 8 5 0 n n n n 7 4 3.6 
Early Resolving  81 F 7 60 52 n n y n 16 11 6.7 
Early Resolving  45 F 1 4 0 n n n n 5 5 4 
Early Resolving  35 M 2 51 7 n n y n 1 1 4.1 
Early Resolving  35 M 1 2 9 n n n n 1 3 1.6 
Early Resolving  41 F 4 5 9 n n y n 0 2 1.7 
Early Resolving  28 M 6 18 8 n n y n 2 1 4.5 
Early Resolving  27 M 4 37 28 n n y n 2 2 3.8 
 
Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), Rheumatoid Factor (RF), Cyclic Citrullinated Peptide Antibody (CCP), Tender Joint Count 28 (TJC), 
Swollen Joint Count 28 (SJC), Disease Activity Score 28 (DAS28), Established RA (Est RA), non-steroidal anti-inflammatory drug (NSAID), data not available (NA). 
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Table 8.6 Clinical data for RA patients. Synovial fluid and peripheral blood samples from these patients were used for experiments 
described in Chapter 5. 
Outcome Age Gender 
Symptom 
duration ESR  CRP RF CCP Treatment nsaid TJC28 SJC28 
DAS28 
ESR 
Est RA 41 M 6 yrs 26 37 positive positive 
prednisolone, methotrexate, 
adalimumab 2 6 4.2 
Est RA 81 M < 1 yr 21 9 positive positive nil 12 15 6.2 
Est RA 67 F 6 yrs 86 84 negative negative methotrexate, hydroxychloroqine 5 8 5.8 
Est RA 55 F 5 yrs 124 221 positive positive methotrexate 14 8 7.5 
Est RA 82 M 1 yr 77 54 positive positive adalimumab (first injection 1/7 ago) 14 6 6.7 
Est RA 52 M 2 yrs 7 9 positive negative diclofenac 2 8 3.2 
Est RA 74 F 2 yrs 2 0 negative positive prednisolone, methotrexate 2 1 1.8 
Early RA 73 f 9 weeks 20 32 negative positive nil 4 5 4.7 
Est RA 66 F 10 yrs 45 32 positive positive nil 8 7 6.3 
Est RA 47 M 9 yrs 41 26 positive positive nil 11 23 6.9 
Est RA 82 M 1 yr 76 31 positive positive prednisolone, adalimumab 21 12 7.9 
 
Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), Rheumatoid Factor (RF), Cyclic Citrullinated Peptide Antibody (CCP), Tender Joint Count 28 (TJC), 
Swollen Joint Count 28 (SJC), Disease Activity Score 28 (DAS28), Established RA (Est RA). 
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Table 8.7 Clinical data for established RA patients treated with rituximab. Synovial tissue samples from these patients were used for 
experiments described in Chapter 5. 
Age Gender Disease duration ESR CRP SHS RF  CCP 
No. of failed 
DMARDs 
No. of failed 
biologicals 
MTX use 
(mg/week) 
Prednisolone use 
(mg/day) 
43 F 2 50 37.2 29 38 26 3 1 25 10 
42 F 20 47 40.5 33 9 240 5 2 10 10 
55 M 17 49 83 10 46 24 2 2 15 0 
63 F 6 37 87 63 50 208 2 1 10 5 
67 F 29 37 9.4 247 247 37 3 0 10 0 
75 F 29 59 92.7 NA 117 1332 3 4 15 5 
46 F 13 66 111.8 43 55 2370 8 4 15 10 
60 M 14 57 15 80 417 126 4 1 10 0 
64 F 6 11 7.4 29 8 68 2 3 30 10 
61 F 8 16 5.2 0 3 1268 2 2 15 0 
53 F 14 27 12.7 81 26 15 9 3 5 5 
49 F 9 47 33.5 0 15 2709 6 2 10 8 
65 F 7 45 58.6 169 26 516 4 1 20 0 
 
Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), Sharpe/van der Heijde score (SHS), Rheumatoid Factor (RF), Cyclic Citrullinated Peptide Antibody 
(CCP), disease-modifying anti-rheumatic drug (DMARD), methotrexate (MTX).
  
 
8.3 Cytokine mRNA expression data 
8.3.1 Cytokine mRNA expression in synovial tissue from patients with resolving 
synovitis, early RA, established RA and 
controls
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Established RA (circles), early RA (squares), early resolving synovitis (upward triangles) and 
controls (downward triangles). Kruskal-Wallis test with Dunn’s post-hoc test for multiple 
comparisons; p*<0.05. 
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8.3.2 Cytokine expression in ACPA-positive and ACPA-positive early RA and 
established RA 
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ACPA-negative patients (closed symbols) and ACPA-positive patients (open symbols) with 
established RA (circles) or early RA (squares). Expression quantified relative to GAPDH. 
Mann-Whitney unpaired t-test; p*<0.05. 
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8.3.3  Cytokine mRNA expression in populations sorted from synovial fluid of 
patients with resolving synovitis, early RA and established RA 
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Established RA (circles), early RA (squares), early resolving synovitis (upward triangles). 
CD3+CD45RO+CD4+ T cells (CD4), CD3+CD45RO+CD8+ T cells (CD8), CD19+ B cells 
(CD19), CD14+ macrophages (CD14) and CD15+ neutrophils (CD15) sorted from synovial 
fluid. Kruskal-Wallis test with Dunn’s post-hoc test for multiple comparisons; *p<0.01. 
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8.3.4  Cytokine mRNA expression in peripheral blood cell populations of patients 
with resolving synovitis, early RA, established RA, and healthy controls. 
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Established RA (circles), early RA (squares), early resolving synovitis (upward triangles) and 
healthy donors (diamonds) .CD3+CD45RO+CD4+ T cells, CD3+CD45RO+CD8+ T cells, 
CD19+ B cells, CD14+ macrophages and CD15+ neutrophils were sorted from peripheral 
blood . Expression was quantified relative to 18S. Kruskal-Wallis test with Dunn’s post-hoc 
test for multiple comparisons; none of tests performed had a level of significance of p<0.01. 
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8.3.5  Cytokine mRNA expression in populations sorted from synovial fluid and 
peripheral blood of patients established RA. 
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CD3+CD45RO+CD4+ T cells (CD4), CD3+CD45RO+CD8+ T cells (CD8), CD19+ B cells (B), CD14+ 
macrophages (M), CD15+ neutrophils (N).  
  
 
Table 8.8 Kruskal-Wallis and Dunn’s post-test analysis of cytokine expression in 
synovial fluid cell populations. Cytokine expression was compared across CD4 T cells 
(CD4), CD8 T cells (CD8), B cells (CD19), macrophages (CD14) and neutrophils (CD15) 
using the Kruskal-Wallis test (K-W); the P value is shown. Paired analysis between cell 
populations was performed using the Dunn’s post-test. ns = non-significant; *P<0.05, 
**P<0.001; ***p<0.0001. 
 
  K-W Dunn's post-test 
  
P 
value 
CD4  
vs  
CD8 
CD4 
vs 
CD19 
CD4 
vs 
CD14 
CD4 
vs 
CD15 
CD8 
vs 
CD19 
CD8 
vs 
CD14 
CD8 
vs 
CD15 
CD19 
vs 
CD14 
CD19 
vs 
CD15 
CD14 
vs 
CD15 
IL1A 0.0050 ns ns ns ns ns * * ns ns ns 
IL1B 0.0001 ns ns * * ns * * ** ** ns 
IL2 0.0003 ns * *** ** ns ns ns ns ns ns 
IL6 0.0018 ns * ns ns * ns ns ns ns ns 
IL7 0.0033 ns ns ns * ns ns ns ns * ns 
IL10 0.0212 ns ns ns ns ns ns ns * ns ns 
IL11 0.0480 ns ns ns ns ns ns ns ns ns ns 
IL12A 0.0038 ns ns ns ns ns ns * ns ** ns 
IL12B <0.0001 ns *** ns * *** ns * ns ns ns 
IL15 0.0196 ns ns ns ns ns ns ns ns ns ** 
IL17A <0.0001 ** *** *** * ns ns ns ns ns ns 
IL18 0.0010 ns ns ** ns ns ** ns ns ns ns 
IL21 0.0161 ns ns * ns ns ns ns ns ns ns 
IL23A <0.0001 ns ns ** *** ns * ** ns ns ns 
IL27 <0.0001 ns ns *** * ns ** ns *** ** ns 
CCL2 0.0002 ns ns ** ns ns ** ns * ns ns 
CCL3 0.0060 ns ns * ns ns ns ns * ns ns 
CCL4 0.1008 ns ns ns ns ns ns ns ns ns ns 
CCL5 0.0002 ns ns ns * ns * *** ns ns ns 
CXCL8 <0.0001 ns ns ** *** ns ns ** ns ** ns 
MIF 0.3684 ns ns ns ns ns ns ns ns ns ns 
TNF 0.0227 ns ns ns ns ns * ns ns ns ns 
LTB 0.0002 ns ns ** ns ns ns ns *** ns ns 
TGFb 0.2789 ns ns ns ns ns ns ns ns ns ns 
RANKL 0.0005 ns ns ns ns *** ns ns ** ** ns 
BAFF <0.0001 ns ns ns ** ns ns ** ** *** ns 
APRIL 0.0074 ns ns * ns ns ** ns ns ns ns 
IFNa 0.0143 ns ns ns ns ns ns ns ns * * 
IFNg 0.0001 ns * ** ns * ** ns ns ns ns 
IFNb 0.0010 ns ns ns * ns ns ** ns ** ** 
CSF2 0.0064 * * ns ns ns ns ns ns ns ns 
FGF2 0.5576 ns ns ns ns ns ns ns ns ns ns 
VEGFA 0.0002 ns ns ** ns ns *** ns ns ns ns 
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